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Summary 
Inhaled medications are the mainstay of therapy in the treatment of chronic 
respiratory diseases like asthma and COPD because they allow delivery of the 
active ingredient directly to the site of action. Poor adherence to inhaled 
controller medications has been estimated to account for up to 60% of 
asthma-related hospitalizations and increased rates of 30- and 60- day 
hospital readmissions in patients with COPD. Numerous electronic monitoring 
devices have been developed over the last four decades to monitor temporal 
non-adherence; however, many of these devices do not monitor all or most 
aspects of inhaler technique. Currently used methods for monitoring inhaler 
technique, including subjective checklists, are suboptimal.  
There is a need to study the frequency of temporal and technique non-
adherence in the Irish population and to investigate the impact of dosing and 
technique errors on drug delivery. Moreover, a comprehensive system of 
tracking the date and time of inhaler use, as well as the presence or absence 
of technique errors, on a daily basis is essential to not only an epidemiological 
understanding of inhaler use but to tailoring of inhaler training and clinical care 
plans to individual patients. This thesis describes the use of the INCATM 
device, a novel acoustic monitor, which provides longitudinal data on the date 
and time of inhaler use, as well as data on inhaler technique.  
Studies showed that inhalation flow rate, exhalation into the inhaler 
mouthpiece prior to inhalation, breath-hold duration and missed doses had a 
significant effect on delivered dose. Data on both temporal and technique 
adherence were combined in an algorithm, which provided a single measure 
of overall adherence, called “actual adherence”. The dose counter rate 
correlated poorly with INCATM derived adherence rates, highlighting the need 
to incorporate technologies, like the INCATM device, into clinical trials and 
patient care. 
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CHAPTER 1 – Introduction 
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1.1. General Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are two common 
types of chronic respiratory disease, characterized by airways obstruction. 
Prevalence of these two respiratory diseases has risen sharply over recent 
decades, creating a large economic burden due to treatment costs.(1, 2) 
Prevalence estimates for COPD range from 7.6% to 34.1% depending on the 
spirometric criteria used for diagnosis and in 2010, COPD became the third 
leading cause of death worldwide.(3, 4) Estimates for asthma prevalence vary 
widely from approximately 1-4% in developing countries to as high as 20% in 
developed countries.(5, 6) Exacerbations of COPD and asthma constitute the 
main component of the burden of disease, often leading to increased 
physician visits, hospitalizations or death. The global burden for patients from 
asthma exacerbations and day-to-day symptoms has increased by almost 
30% in the past 20 years.(7) The total direct costs of respiratory disease in the 
European Union is estimated at more than 6% of the total health care budget, 
with COPD accounting for more than half of this amount.(8) In 2010, the direct 
costs attributable to COPD was estimated at $32.1billion in the United States, 
with hospital admissions being the largest contributor.(9) 
1.1.1. Asthma 
Asthma has traditionally been thought of as a chronic inflammatory disease of 
the airways, characterized by variable and recurring symptoms of wheeze, 
cough, dyspnea and chest tightness, reversible airflow obstruction, airway 
hyper-responsiveness and bronchospasm, and airway inflammation.(10) 
Bronchial hyper-responsiveness is provoked by numerous triggers, including 
exercise, viral upper respiratory tract infections, cigarette smoke and 
respiratory allergens.(11) Hyper-responsiveness is tested clinically by 
monitoring lung function parameters after provocation with methacholine or 
histamine.(12) 
Immunologically, asthma is characterized by a T-helper subclass 2 (Th2) 
response with production of Interleukins (IL) 4, 5 and 13, a switch from 
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immunoglobulin (Ig) M to IgE, mast cell degranulation and recruitment of 
eosinophils to the airways.(11) It is now also recognized that some asthmatic 
inflammation is neutrophilic in nature and controlled by T-helper 17 cells.(13) 
Asthma has now been dichotomized into Th2-high and Th2-low endotypes 
based on the role of type 2 T-helper cells in the pathobiology of the 
disease.(14) 
Chronic inflammation in asthma leads to “airway remodeling” with alterations in 
the airway epithelium, lamina propria and submucosa, leading to airway 
thickening.(15) Grossly, there is lung hyperinflation, smooth muscle 
hypertrophy, mucosal edema, mucus gland hypersecretion, epithelial 
sloughing and ciliary dysfunction.(16) 
Establishing a diagnosis of asthma depends on medical history and physical 
examination to show that symptoms of recurrent episodes of airflow 
obstruction are present. These symptoms include wheeze, cough, chest 
tightness or dyspnea and usually occur or are worsened by triggers such as 
viral infections, allergens like the house dust mite or pollen, irritants like 
tobacco smoke, changes in weather, stress, exercise or strong emotional 
expression.(17) The clinician should also consider and rule out other causes of 
airway obstruction. Confirmation of reversible airflow obstruction is made by 
spirometric or lung function tests in patients older than 5 years of age.(17)  
1.1.2. Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is characterized by 
progressive airflow restriction that is not fully reversible, associated with 
abnormal airway inflammation in response to noxious particles or gases and 
systemic effects, such as ischaemic heart disease, heart failure, diabetes and 
lung cancer.(18) In fact, the major burden of morbidity and mortality in COPD 
is related to the extra-pulmonary effects.  
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Cigarette smoking is the major cause of COPD leading to direct injury of 
airway epithelial cells, release of inflammatory mediators, reactive oxygen 
species and proteolytic enzymes, as well as impaired immune regulation and 
immunological senescence.(18) The chronic airway inflammatory response 
results in emphysema due to parenchymal tissue destruction, loss of alveolar 
attachments and decrease in elastic recoil; and small airways disease due to 
airway fibrosis and luminal plugs, in turn leading to air trapping and 
progressive airflow obstruction.(19) 
The diagnosis of COPD is also based on a thorough clinical history and 
physical examination, including assessing for extrapulmonary disease, but 
spirometry plays a significant role in establishing a diagnosis. 
1.1.3. Spirometric diagnosis of asthma and COPD 
Mechanical respiratory abnormalities can be classified into obstructive or 
restrictive defects based on the presence or absence of flow-related or 
volume-related defects.(20) Asthma and COPD are examples of obstructive 
airways diseases. The diagnosis of COPD must include an FEV1 (forced 
expiratory volume in 1 second) to FVC (forced vital capacity) ratio of less than 
0.70.(21) 
The Global Initiative on Obstructive Lung Disease (GOLD) classifies COPD 
into four stages based on post-bronchodilator FEV1% predicted (22): 
Stage 1: Mild, FEV1>=80% predicted 
Stage 2: Moderate, FEV1 50-80% predicted 
Stage 3: Severe, FEV1 30-50% predicted 
Stage 4: Very severe, FEV1 <30% predicted 
Asthmatic patients may or may not exhibit an FEV1/FVC ratio less than 0.70 
but should demonstrate evidence of reversibility, that is, an increase of at 
least 12% or 200ml in FEV1 after administration of a bronchodilator.(21) 
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It is now recognized that there may be some spirometric overlap between 
asthma and COPD, since some COPD patients may show a degree of 
reversibility in FEV1 after bronchodilator therapy, although the FEV1/FVC ratio 
usually remains less than 0.70 in this group.(23) Hence, clinical history and 
physical examination remain the key to distinguishing between COPD and 
asthma. 
1.1.4. Management of asthma 
In recent years, the foundation of asthma management was based on 
determining the degree of severity or intrinsic intensity of the disease process 
and level of control.(17) Asthma has been classified into and managed in a 
stepwise fashion based on the following categories(10): 
1) Intermittent:
- Symptoms ≤ 2 days/ week
- Night-time awakenings ≤ 2nights/ month
- Use of Short acting beta agonist (SABA) ≤ 2 days/ week
- No interference with normal activity
- Lung function: Normal FEV1 (> 80% predicted) and normal FEV1/FVC
ratio
- Treatment with as needed SABA
2) Mild Persistent:
- Symptoms > 2 days / week but not daily
- Night-time awakenings ~ 3-4 nights/ month
- Use of short acting beta agonist (SABA) > 2 days / week but not daily
- Minor limitation on normal activity
- Lung function: Normal FEV1 (> 80% predicted) and normal FEV1/FVC
ratio
- Treatment with low dose inhaled corticosteroids (ICS) and as needed
SABA
37 
3) Moderate Persistent:
- Symptoms daily
- Night-time awakenings > 1/ week but not nightly
- Use of short acting beta agonist (SABA) daily
- Some limitation on normal activity
- Lung function: FEV1 > 60% but <80% predicted and FEV1/FVC ratio <
0.7
- Treatment with low dose ICS + long acting beta agonist (LABA) and as
needed SABA
4) Severe Persistent:
- Symptoms throughout the day
- Night-time awakenings nightly
- Use of Short acting beta agonist (SABA) several times daily
- Extreme limitation on normal activity
- Lung function: FEV1 < 60% predicted and FEV1/FVC ratio < 0.7
- Treatment with medium-high dose ICS + LABA and as needed SABA
with consideration of Omalizumab and oral corticosteroids
The new definition of asthma according to the revised Global Initiative for 
Asthma (GINA) guidelines describes asthma as a “heterogeneous disease, 
usually characterized by chronic airway inflammation…defined by the history 
of respiratory symptoms such as wheeze, shortness of breath, chest tightness 
and cough that vary over time and in intensity…with variable expiratory airflow 
limitation.”(24) The new GINA guidelines also stress the need to individualize 
patient management, by considering behavioural, social and cultural 
factors.(24, 25)  
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Figure 1.1: Steps involved in asthma diagnosis, management and treatment. 
Reproduced from (26). ICS: inhaled corticosteroids. 
Figure 1.1, taken from the GINA 2015 report, highlights a new control-based 
care system for treatment of asthma. One key point stressed in the “Assess” 
portion is inhaler technique, adherence and patient preference to ensure that 
treatment is tailored to the individual patient. Traditionally, asthma has been 
managed pharmacologically and by avoidance of triggers, with a seemingly 
“one size fits all” approach.(24)  
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1.1.5. Management of COPD 
The cornerstone of management of stable COPD is risk factor reduction, 
including smoking cessation. All COPD patients should be encouraged to stop 
smoking at every opportunity.(27)  
Bronchodilator therapy is the main symptomatic therapy for patients with 
stable COPD. Beneficial effects include reductions in shortness of breath and 
improved exercise capacity and quality of life.(28) Short-acting beta-agonists 
(SABAs), mainly salbutamol and terbutaline, are the first-line therapy for 
symptomatic relief. When disease is no longer controlled with a SABA, a long-
acting beta-agonist (LABA) like salmeterol or formoterol or an anti-muscarinic 
agent like tiotropium should be added.(28) While beta-agonist therapy has 
been shown to improve exercise capacity, reduce exacerbation rate and 
improve quality of life, there is no evidence that they prevent lung function 
decline or improve survival in COPD patients.(29) 
Combination therapy with an ICS and LABA (fluticasone/ salmeterol or 
budesonide/ formoterol) has been shown to reduce exacerbation rates, 
hospital admissions and all-cause mortality, and to improve lung function.(28) 
Most patients with moderate to severe COPD are now maintained on a 
combination ICS/ LABA inhaler. 
Other therapeutic options in stable COPD include pulmonary rehabilitation, 
long term oxygen therapy, immunization and management of extrapulmonary 
disease.(30) 
An exacerbation of COPD is characterized by an acute worsening of a 
patient’s symptoms, which is acute in onset and necessitates a change in 
regular medication.(31) Management of an acute exacerbation depends on 
severity. Outpatient management consists of increased bronchodilators, 
antibiotics and oral corticosteroid therapy.(28) Severe exacerbations are 
usually managed in the hospital setting with the addition of non-invasive 
ventilation for symptoms or signs of respiratory failure.(32) 
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1.1.6. Inhaled medications in asthma and COPD 
The following review discusses active drugs, which can be delivered via the 
DiskusTM DPI, the focus of this thesis. These drugs include salbutamol, 
salmeterol and fluticasone. 
1.1.6.1. Beta-agonists 
Inhaled beta-agonists are sympathomimetic agents, which selectively bind to 
and stimulate beta-2 receptors in the bronchial walls leading to smooth muscle 
relaxation and bronchodilation.(33) The mechanism of action is via a G-protein 
coupled second messenger system with subsequent activation of adenylate 
cyclase and an increase in cyclic AMP (cAMP) levels and protein kinase A 
(PKA) activity. Bronchial smooth muscle relaxation is mediated via PKA 
phosphorylation of myosin light chain kinase and calcium-dependent 
potassium channels.(34)  
Effects of beta-2 receptor stimulation include bronchodilation, fine skeletal 
muscle tremor, skeletal muscle vasodilation, glycogenolysis, myometrial 
relaxation and mast cell mobilization.(34) Effects of beta-1 receptor stimulation 
include tachycardia and increased stroke volume, lipolysis, reduced gut 
motility and secretions and hyper-reninism.(34) The beneficial effects of beta-
agonists in respiratory diseases are mediated via beta-2 receptor agonism, 
whereas the main side effects are mediated via beta-1 receptor agonism. 
Inhaled beta-agonists can be divided into short-acting (SABA) and long-acting 
(LABA) agents based on the half-life of the drug.  
Examples of short-acting beta-agonists include salbutamol, levosalbutamol, 
terbutaline, pirbuterol and metaproterenol. Salbutamol is the most widely used 
short-acting beta-agonist due to its good safety profile owing to predominant 
beta-2 receptor binding. It is administered via pMDI, DiskusTM and nebulizer. 
Salbutamol has an onset of action between 5 and 20 minutes, an elimination 
half-life of 6.1 ± 2.1 hours and a duration of action of 3 to 6 hours.(34, 35) 
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Elers et al. showed that median urinary concentrations of salbutamol after 
inhalation of 0.8 mg of salbutamol ranged from 129.2 to 260.9 ng/ml with the 
maximal median concentration in samples collected 0-4 hours after 
administration.(36) Fast absorption was observed after inhaled salbutamol 
with the time of maximal median serum concentration (Tmax) being 30-60 
minutes and the median serum Cmax of 1.75 ng/ml and maximum individual 
serum concentration being 2.74 ng/ml. Other pharmacokinetic studies have 
shown a Tmax of 20-25 minutes.(37) Salbutamol is metabolized almost 
exclusively hepatically, being converted to salbutamol 4'-O-sulfate, which is 
subsequently excreted in faeces (10%) and urine (90%).(38-40)  
The two widely used LABAs are salmeterol and formoterol. Both have a 
duration of action greater than 12 hours.(41) Salmeterol is usually 
administered via the DiskusTM DPI or pMDI and formoterol via the 
TurbuhalerTM DPI.  
Plasma salmeterol concentrations of 0.1 to 0.2 and 1 to 2 mcg/L have been 
attained in healthy volunteers about 5 to 15 minutes after inhalation of a single 
dose of 50 and 400 mcg, respectively.(42) Salmeterol is available 
commercially bound to the xinafoate moiety, which has no pharmacologic 
activity of its own. Both salmeterol and xinafoate are more than 95% protein 
bound. Salmeterol base is metabolized by cytochrome P450 (CYP) 3A4 to 
alpha-hydroxy salmeterol, which is subsequently eliminated in the faeces 
(60%) and urine (25%).(42) At the recommended doses of salmeterol, 
systemic concentrations are low or even undetectable. Although the half-life of 
the drug is only 5.5 hours, the duration of action is 12 hours and salmeterol 
has an effective pulmonary half-life of 12 hours based on pharmacodynamic 
effect and receptor binding kinetics.(43) Based on a population 
pharmacokinetic study, salmeterol metabolism fits to a two-compartment 
model with first-order elimination.(44) 
A novel group of ultra-long-acting beta-agonists (ultra-LABA) has been 
marketed recently. These include drugs such as indacaterol, olodaterol, 
carmoterol, miveterol and vilanterol, which have a duration of action exceeding 
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20 hours, allowing once daily dosing.(45) Table 1.1 shows properties of a 
number of ultra-LABAs. 
Table 1.1: Pharmacologic properties of ultra-LABA in current clinical use. 
Reproduced from (45). 
Drug Onset of 
action 
(min) 
Duration 
of action 
(h) 
Systemic 
exposure 
(% of 
dose) 
Volume of 
distribution 
(L) 
Protein 
binding 
(%) 
Metabolism Elimination 
Indacaterol 5 24 44 2361 - 2557 95 Hepatic (CYP 
3A4, 2D6, 1A1) 
Faeces 
(>90%) 
Vilanterol 5 21.3 27.3 165 93.9 Hepatic (CYP 
3A4) 
Urine (70%) 
and faeces 
(30%) 
Olodaterol 5 >24 30 1110 60 Hepatic (CYP 
2C9, 2C8, 
glucuronidation, 
O-methylation)
Urine and 
faeces 
1.1.6.2. Anticholinergics 
Inhaled anticholinergics act by inhibiting muscarinic acetylcholine receptors in 
the bronchial wall. They can be divided into short-acting agents, such as 
ipratropium bromide, and long-acting agents, such as tiotropium. 
Parasympathetic activity is mediated via M1 and M3 muscarinic receptors and 
results in smooth muscle contraction and mucous secretion.(46) M2 receptors 
inhibit acetylcholine release from nerve terminals.(47)  
Ipratropium inhibits all three muscarinic receptors thus inhibiting the cyclic 
guanosine 3',5'-monophosphate system at parasympathetic nerve endings. It 
has a delayed onset of action (45 minutes), elimination half-life of 3.2-3.8 
hours and a duration of action of 3-5 hours.(48) Ipratropium has a good side 
effect profile due to very low systemic concentrations (6.9% systemic 
bioavailability) and the lack of penetration of the blood-brain barrier.(49) 
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Tiotropium has higher affinity for the M1 to M3 receptors, but it dissociates 
rapidly from the M2 receptor and is considered a functionally selective 
agent.(50, 51) Tiotropium has approximately 2% oral bioavailability and about 
20% of an inhaled dose reaches the smaller airways. Clearance is primarily 
renal.(52) Tiotropium has a prolonged duration of action (functional half-life of 
35 hours at the M3 receptor) allowing once daily dosing.(50, 53) 
1.1.6.3. Inhaled corticosteroids 
Inhaled corticosteroids (ICS) are the mainstay of treatment in COPD and 
persistent asthma due to their anti-inflammatory effects. ICS reduce airway 
inflammation and hyper-responsiveness, improve lung function, decrease 
symptom severity, and reduce the incidence of acute exacerbations.(54) ICS 
bind to glucocorticoid receptors in the cell cytoplasm; the steroid-receptor 
complex then translocates to the nucleus, where they regulate the 
transcription and synthesis of many inflammatory mediators, including 
cytokines, in eosinophils, monocytes, basophils, lymphocytes and mast 
cells.(55-57) In patients with persistent asthma, ICS inhibit the late response 
and bronchial hyper-responsiveness that follows allergen exposure, whereas 
chronic administration may also reduce the number of mast cells, which may 
also ameliorate the immediate allergic response.(57) 
Systemic exposure to corticosteroids can cause a number of side effects 
including hypertension, insulin resistance, obesity, easy bruising, poor wound 
healing, adrenal insufficiency, cataracts, glaucoma, osteopaenia, osteoporosis 
and suppressed growth velocity in children.(58) Due to the low bioavailability 
of ICS, inhalation has become the preferred route of delivery in the 
maintenance therapy of asthma and COPD. Nonetheless, ICS therapy can 
have local side effects including reflex cough or bronchospasm, dysphonia, 
oral candidiasis, pharyngitis and sore throat.(59) It is therefore important to 
monitor for both under-dosing and over-dosing. 
The two most commonly prescribed ICS in DPI devices are fluticasone 
(DiskusTM) and budesonide (TurbuhalerTM). Other available ICS include 
44 
beclometasone, ciclesonide, flunisolide, mometasone and triamcinolone.(60) 
Table 1.2 shows the common pharmacokinetic parameters of these ICS.(59) 
Table 1.2: Pharmacokinetic parameters of inhaled corticosteroids. Reproduced 
from (59). 
Drug Oral 
bioavailability 
Protein-
binding (%) 
Clearance 
(L/h) 
Volume of 
distribution (L) 
Half-
life (h) 
Beclometasone 
dipropionate 
15 87 230 20 0.1 
Beclometasone 
monopropionate 
26 - 120 424 2.7 
Budesonide 11 88 84 183 2.8 
Ciclesonide <1 99 152 207 0.4 
Flunisolide <1 99 396 1190 3.6-5.1 
Fluticasone 
propionate 
7 80 58 96 1.6 
Mometasone 
furoate 
<1 98 53.5 332 4.5 
Triamcinolone 
acetonide 
23 71 37 103 2.0 
1.1.7. Inhaler devices 
The two main categories of inhaler devices used are pressurized metered 
dose inhalers (pMDIs) and dry powder inhalers (DPIs). pMDIs utilize a 
pressurized canister with the drug emitted in a fine spray or mist (see Figure 
1.2). Patients must coordinate inhalation with actuation of pMDIs to deliver the 
maximum dose to the small airways. SABAs like salbutamol are commonly 
delivered via pMDIs. 
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Figure 1.2: Components of a pMDI showing canister, plastic sleeve and 
mouthpiece cap. 
DPIs are considered advantageous over pMDIs since they avoid the use of 
propellants, and are instead actuated during the inhalation.(61) The 
elimination of propellants allows patient coordination issues to be overcome. 
DPIs use a dry powder formulation of the drug with an inert carrier such as 
lactose.(62) Based on the inhaler design and intrinsic resistance, generation of 
a certain peak inspiratory flow causes de-agglomeration of drug particles to a 
particle size sufficiently small to reach the smaller airways.(62) 
Despite the benefits of DPIs, pMDIs remain very popular. Lavorini et al 
evaluated retail sales of inhalation devices in European countries and found 
that average inhaler retail sales (expressed as percentages of total sales) 
were 47.5% for pMDIs, 39.5% for DPIs and 13% for nebulisers.(63)  
Different DPIs require different user techniques for opening, blistering or 
activation of the dosing chamber and inspiratory flow for optimal drug delivery. 
The ideal DPI should be effective at reproducibly delivering particles ≤ 6um in 
size to the patient’s smaller airways relatively independent of flow rate, should 
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be precise in terms of knowing the delivered dose based on the user 
technique, should have a stable drug formulation, should be user-friendly and 
should be affordable.(62) Based on the drug half-lives, DPIs also require 
different dosing frequency, commonly ranging from once daily for newer 
formulations such as indacaterol/ fluticasone to twice daily for the commonest 
formulations, salmeterol/ fluticasone and formoterol/ budesonide.(64) 
The two most frequently prescribed ICS/ LABA combinations are delivered via 
the DiskusTM inhaler (for salmeterol/ fluticasone) and the TurbuhalerTM 
(formoterol/ budesonide).(65) The TurbuhalerTM is an example of a multi-dose 
reservoir device, which contains a bulk supply of drug from which individual 
doses are released with each actuation.(66) The DiskusTM inhaler is an 
example of a multi-unit dose device, which utilizes individually prepared and 
sealed doses of drug.(66) Tiotropium, used in the treatment of COPD, is 
usually delivered via the HandiHalerTM, which is an example of a single-unit 
dose device.(66) The new ELLIPTATM inhaler has been designed to contain 
two separate blister strips from which inhalation powder can be delivered, and 
to be simple to use with a large, easy-to-read dose counter.(64) Figure 1.3 
shows the design of these four DPI devices. While there are more than 20 
other DPI devices currently on the market, these make up a small market 
share and will not be further discussed.(67) The Seretide or Advair DiskusTM
accounts for the largest market share in DPI devices, as evident by IMS Health 
data in the United States (Figure 1.4).(68) For this reason, the focus of the 
remainder of this work will be the DiskusTM inhaler. 
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Figure 1.3: Commonly prescribed inhaler devices: (a) TurbuhalerTM 
[AstraZeneca], (b) DiskusTM [GlaxoSmithKline], (c) HandiHalerTM [Boehringer 
Ingelheim], and (d) ELLIPTATM [GlaxoSmithKline]. 
Figure 1.4: Combination inhaler total prescription trends. Reproduced from 
(68). 
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1.1.8. Adherence to inhaled therapy 
The major benefit of inhaled therapy is direct application of the active drug to 
the site of action with reduced systemic effects. However, poor adherence to 
inhaled medications remains one of the main reasons for a suboptimal 
therapeutic response.  
Adherence is defined as the “active, voluntary, and collaborative involvement 
of the patient in a mutually acceptable course of behavior to produce a 
therapeutic result”.(69) Non-adherence to inhaled controller medication in 
asthma and COPD have been recognized as a major problem affecting drug 
efficacy.  
Causes of non-adherence include inadequate health literacy, a lack of 
understanding about medication efficacy and misunderstanding of directions 
for use. Poor adherence has also been associated with older age, physical 
and cognitive function, different types of inhaler devices, design, and 
technique, patient education and other social factors.(70) There are many 
different factors that can influence the effectiveness and adherence to 
medication such as age, physical and cognitive function, different types of 
inhalers, inhaler design or technique, patient education, provider skills 
(clinician), society and lifelong therapy.(71) Elderly patients tend to have 
impairments such as weakness or poor vision and decline in cognitive skills, 
which make it difficult for them to master the inhaler techniques. Using 
different types of inhaler with different techniques may lead to incorrect use of 
the devices. Clinicians should be aware of the guidelines on COPD 
management to avoid insufficient amount of information received by the 
patient.(72, 73) Other than that, language barriers and cultural differences 
could also be an obstacle in explaining the technique of using the device. 
Adherence to inhaled medications can be divided into temporal adherence 
(sometimes simply referred to as adherence) and technique adherence 
(sometimes referred to as competence). Poor temporal adherence can take 
the form of underuse, overuse and haphazard use. Technique adherence 
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assesses proper use of the inhaler device as laid out in the manufacturer’s 
recommendations for use.  
1.1.8.1. Methods of assessing inhaler adherence 
Adherence to inhaled therapy has traditionally been assessed by using patient 
questionnaires or diaries, dose counters integrated into DPIs or pMDIs, 
canister weights in pMDIs, biochemical monitoring or pharmacy registers.(74) 
Table 1.3 shows the advantages and disadvantages of these traditional 
methods. 
These methods are all very crude measures, which provide an average of 
adherence usually over a period of 1 to 3 months. Day-to-day or periodic 
trends in overuse, underuse or haphazard use cannot be objectively 
measured. 
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Table 1.3: Advantages and disadvantages of methods for assessing inhaler 
adherence. 
Category Method Advantages Disadvantages 
Subjective Patient self-
report 
questionnaire/ 
diary 
Simple 
Low cost 
Questions can be adapted 
to patient population 
Inaccurate 
Overestimates adherence 
Patients do not accurately 
assess their own 
competence 
Clinician 
assessment 
Simple 
Low cost 
Can assess technique 
and combine outcome 
measures to assess 
temporal adherence 
Inaccurate 
Adherence may not correlate 
with outcome measures in all 
groups 
Time-consuming 
Many clinicians have poor 
inhaler technique themselves 
Objective Canister 
weight 
Simple 
Low cost 
Incapable of detecting 
dose dumping or medication 
sharing 
Does not assess technique 
Averages adherence over a 
period of time 
Pharmacy 
registers 
Simple 
Moderate cost 
Requires proper 
infrastructure 
Incapable of detecting dose 
dumping or medication 
sharing 
Averages adherence over a 
period of time 
Limits patient choice 
regarding pharmacy 
Biochemical 
monitoring 
Direct 
Accurate 
Costly 
Invasive 
Requires expertise and 
equipment 
Depends on half-life of drug 
Cannot distinguish 
adherence from technique 
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1.1.8.3. Methods of assessing inhaler technique 
Mechanisms of deposition of aerosol particles can be categorized into inertial 
impaction at airway bifurcations, sedimentation due to gravity and diffusion 
due to Brownian motion (Figure 1.5).(75) Recommendations for inhaler 
technique are devised to minimize deposition in the oropharynx and trachea 
and maximize deposition in the small airways and alveoli.  
Inhaler technique is assessed using standardized checklists and subjective 
clinician observation, as shown in Table 1.4.(76) Unfortunately, many different 
checklists exist for individual devices, with 16 in the literature for the DiskusTM
device ranging from 3 to 13 steps.(76) Scoring systems also varied with the 
most common system being assigning a score of 0 for an incorrect step or a 
score of 1 for a correct step and summing the score from all steps.(77-79)  
Figure 1.5: Schematic of deposition mechanisms of inertial impaction at airway 
bifurcations, sedimentation due to gravity, and diffusion due to random 
Brownian motion. Reproduced from (75). 
1.1.9. DiskusTM inhaler technique 
The 13 steps for proper use of the DiskusTM inhaler are outlined below.(80) 
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Table 1.4: Standardized checklist used for evaluation of DiskusTM inhaler 
technique. 
Step Correct step Possible technique errors Is error critical? 
1 Push the outer cover as far 
as possible before the 
inhalation 
Failure to open the outer 
cover 
Incomplete opening of outer 
cover 
Yes 
2 Slide the lever until the 
”click” sound to actuate 
dose 
Failure to slide the lever until 
the “click” sound 
Yes 
3 Keep the mouthpiece 
horizontal or in upward 
position 
Holding the DiskusTM 
inhaler with the mouthpiece 
facing downward 
Likely significant 
4 Exhale into the room and 
away from the mouthpiece 
after loading 
Exhalation into the device 
mouthpiece 
Likely significant 
5 Slowly and completely 
exhale out to residual 
volume (to empty the lungs) 
(1) No exhalation or
insufficient exhalation
(2) Forced and fast
exhalation
Probable 
6 Tilt head back (hyperextend) 
slightly and keep the device 
horizontal during inhalation 
Lowering one’s head or 
holding the mouthpiece 
upward during inhalation 
Possible 
7 Place teeth over the 
mouthpiece with lips 
positioned around it deeply 
(over tongue) and securely 
(sealing lip) 
(1) Lips surround the
mouthpiece shallowly
against teeth or tongue
(2) Lips are not sealed
around the mouthpiece
during inhalation
Possible 
8 Inhale forcefully from the 
beginning, slowly (for > 2–3 
sec), deeply, uniformly, and 
continuously inhale during 
the inspiratory phase until 
the lungs are full 
(1) Gradual increase in the
speed of inhalation
(2) Fast and extremely
forceful inhalation
(3) Prematurely stop inhaling
(not inhaling to total lung
capacity) or inhaling twice or
more during the inspiratory
phase of the breathing cycle
Likely significant 
9 At the end of inhalation 
remove the inhaler from the 
mouth and close the lips 
Not removing the inhaler 
from the mouth at the end of 
inhalation 
Unlikely 
10 Hold breath for > 5 sec 
(optimally for 10 sec) after 
inhalation (an objective 
measurement performed 
using a stopwatch) 
Not holding breath or holding 
breath for 
< 5 sec 
Likely significant 
11 Exhale slowly through the 
nose and away from 
mouthpiece 
(1) Breathing out rapidly
from the mouth after holding
breath
(2) Exhaling into the
mouthpiece
Possible 
12 Recover the lever and the 
outer cover 
Not closing the lever and the 
outer cover 
Unlikely 
13 Rinse one’s mouth out after 
inhaling and do not swallow 
the rinsing water 
(1) Failure to rinse one’s
mouth
(2) Swallowing the rinsing
water
Likely significant for 
adverse events 
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The evidence for the significance of errors in each of these steps is reviewed 
below. 
1.1.9.1. Failure to open the outer cover 
Failure to open the outer cover of the inhaler means that the dose cannot be 
actuated and the mouthpiece and air inlet are not accessible for dose 
inhalation. Zero percent of the drug is available for delivery and this is 
considered a critical error. 
1.1.9.2. Failure to slide the lever until the “click” sound 
Failure to slide the lever causes failure to actuate or blister a dose, that is, the 
dose remains sealed in the blister pack and is not available for delivery. This is 
a critical error since 0% of the dose is available. 
1.1.9.3. Failure to hold the device in the horizontal or up position after 
dose actuation 
Figure 1.6: Internal components of the DiskusTM inhaler and direction of airflow 
and air entrainment during inhalation. Reproduced from (66). 
Figure 1.6 above shows the major components of the DiskusTM inhaler. The 
arrows show the direction of airflow during an inhalation. The drug is kept in a 
pocket in front of the drug exit port and is susceptible to being displaced from 
this pocket if the inhaler is not held in a horizontal or upward position after the 
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sealed pocket is opened. Although the manufacturer recommends holding the 
inhaler in a horizontal or upward position, the effect on drug delivery or 
available dose of holding the inhaler in other positions has never been formally 
studied. 
1.1.9.4. Exhalation away from the mouthpiece 
For DPIs, one frequently observed error is that patients exhale into the device 
mouthpiece after loading or blistering the dose.(71, 76, 81, 82) Correct DPI 
inhaler technique involves exhaling away from the inhaler mouthpiece to 
functional residual capacity or residual volume before the inhalation 
manoeuvre. Exhaling into a DPI mouthpiece, however, can cause medication 
to become dispersed or altered, which in turn leads to a reduced quantity of 
medication available for pulmonary drug delivery. A previous study carried out 
by Engel et al. first demonstrated this finding using a TurbuhalerTM DPI. They 
reported that inhalations which were preceded by exhalations into the 
TurbuhalerTM’s mouthpiece resulted in poor bronchodilatation for patients.(83) 
It was also hypothesized that the introduction of humidity from exhaled air can 
potentially cause powder to agglomerate, which subsequently reduces the 
intended deaggregation properties of the inhalation. 
It is reported in literature that between 14-22% of patients exhale into their DPI 
mouthpiece, depending on the type of DPI used.(82) The actual figure may be 
significantly higher because checklist methods for detecting this error only 
capture a snapshot of a patient’s behaviour at one point in time. The inability
of many patients to correctly use their inhaler device may be a direct 
consequence of insufficient or poor inhaler technique instruction.(71) In a 
study on pharmacists’ knowledge of correct DPI technique, it was reported that 
the vast majority were unaware of the requirement to exhale away from the 
device mouthpiece prior to inhalation.(81) Regardless of the causes of this 
error in technique, the outcomes include a lack of improvement in respiratory 
symptoms leading to a perceived lack of effectiveness of the medication. This 
causes clinicians to prescribe higher doses of medication to patients, who may 
then suffer from adverse reactions and incur higher medication costs.      
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1.1.9.5. Exhalation to residual volume 
A systematic review of inhaler technique found that the most frequent DPI 
technique error was failure to exhale prior to inhalation (12-77% of errors).(71) 
Most DPIs require rapid, forceful inhalation to achieve drug de-agglomeration. 
Manufacturers recommend an exhalation to residual volume or functional 
residual capacity to facilitate the subsequent deep inspiratory effort required. 
While many in vivo studies have been done to investigate the impact of 
exhalation to different lung volumes on pMDI drug delivery,(84) no similar 
studies exist for DPI devices and the recommendations are based on 
consensus. 
1.1.9.6. Tilt head back (hyperextend) slightly and keep the device 
horizontal during inhalation 
Neck extension is recommended to reduce the angle aerosolized particles 
must travel to enter the larynx from the oropharynx. Again, it is recommended 
that the inhaler be held in the horizontal position during inhalation to minimize 
displacement of the drug from its pocket. There is no data on the in vitro or in 
vivo effects of this technique error. 
1.1.9.7. Place teeth over the mouthpiece with lips positioned around it 
deeply (over tongue) and securely (sealing lip) 
A tight mouthseal is required to ensure that all inspiratory force generated is 
transferred to the inhaler device. No experimental data exists on the 
importance of this factor. 
1.1.9.8. Inhale forcefully from the beginning, slowly (for > 2–3 sec), 
deeply, uniformly, and continuously inhale during the inspiratory phase until 
the lungs are full 
For greatest benefit, the maximum amount of drug needs to reach the site of 
action, that is, the airways. This depends on the patient’s inspiratory flow, 
56 
inhaled volume, ramp rate of inhalation and degree of airways obstruction.(85, 
86) Findings from previous studies using the Electronic Lung Model showed
that in a large subgroup of patients, only 15-30% of the inhaler dose was 
deposited in the small airways and alveoli of the lung.(10, 66) 
For patients using a dry powder inhaler (DPI), de-agglomeration of the active 
drug from its carrier (typically lactose monohydrate) depends on a combination 
of factors: turbulence, mechanical impaction, particle uptake and mechanical 
vibration.(87, 88) One study using a Ventolin DiskhalerTM showed that 
mechanical impaction was not an effective mechanism for powder de-
agglomeration, whereas turbulence was found to have a definite effect.(89) 
Turbulence leads to aerodynamic lift, drag and shear, as well as separation 
forces. The turbulent energy generated depends on the intrinsic resistance of 
the inhaler and the flow rate generated by the patient. Some DPIs have high 
internal resistance, for example the TurbuhalerTM, while some have relatively 
low resistance, like the DiskusTM, as shown in Table 1.5.(90) There is a direct 
relationship between the intrinsic resistance of a DPI and the peak inspiratory 
flow rate (PIFR)-dependence for drug delivery (Figure 1.7). There is some in 
vitro evidence that the DiskusTM device is less effort-dependent than other high 
resistance inhalers (91); however, there is consensus that PIFR is an 
important factor for all current DPIs. Regardless, it is recommended that 
optimal drug delivery is achieved with a flow rate of greater than 30 l/min and 
ideally, greater than 60 l/min.(92) 
For traditional DPIs, insufficient PIFR can lead to ineffective drug delivery 
resulting in unintentional non-adherence and poor clinical outcomes. 
Conversely, some authors have advised that very high inhalation flow rates 
can lead to increased throat deposition and exhalation of particles that are less 
than 1 µm in aerodynamic particle size.(93, 94) While modern, sophistically 
engineered powders and inhaler devices are less flow-rate dependent, or even 
flow-rate independent (95), it is our experience that the majority of patients 
with obstructive airways disease are currently prescribed traditional DPIs like 
the Seretide DiskusTM or Symbicort TurbuhalerTM. 
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Table 1.5: Internal resistance of common dry powder inhaler devices. 
Adapted from (91). Resistance is given by the ratio of the square root of 
pressure drop to airflow rate. A ‘medium’ resistance (0.033 kPa0.5.min/L) 
inhaler device requires a pressure drop of 4 kPa to draw an airflow rate of 60 
L/min through it. 
Inhaler Resistance (kPa0.5.min/L) 
Diskhaler (GlaxoSmithKline) 0.032 
Diskus (GlaxoSmithKline) 0.034 
Handihaler (Boehringer Ingelheim 
Pharmaceuticals) 
0.042 
Inhalator (Boehringer Ingelheim 
Pharmaceuticals) 
0.051 – 0.062 
ISF inhaler (Cyclohaler, 
Pharmachemie) 
0.019 
Rotahaler (GlaxoSmithKline) 0.015 
Ratiopharm Jethaler (Ratiopharm) 0.036 
Spinhaler (Aventis) 0.016 
Turbuhaler (AstraZeneca) 0.043 
Figure 1.7: Relationship between peak inspiratory flow rate and fine particle 
fraction emitted for five common dry powder inhalers. Reproduced from (91). 
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1.1.9.9. At the end of inhalation remove the inhaler from the mouth and 
close the lips 
Closing the lips after exhalation is related to the next step of breath holding. 
1.1.9.10. Hold breath for > 5 sec (optimally for 10 sec) after inhalation (an 
objective measurement performed using a stopwatch) 
The effect of breath holding duration on drug delivery has been well-studied in 
pMDI devices. Breath holding after inhalation enables particles delivered to the 
smaller airways to be deposited in that region, instead of being exhaled.(96) 
The breath hold increases particle residence time and increasing the breath 
hold duration from 0 seconds to 10 seconds leads to an 8-fold increase in 
particle (< 1um) deposition in the smaller airways.(91) An in silico study of 
aerosol deposition using the Electronic Lung Model showed that breath hold 
duration has minimal effect on tracheobronchial deposition but is positively 
correlated with pulmonary deposition.(86) Similar in silico studies using 
aerosolized insulin have shown that breath holding allows the mechanisms of 
sedimentation and diffusion more time to act, thus increasing particle 
deposition in the smaller airways, as shown in Figure 1.8.(75) 
1.1.9.11. Exhale slowly through the nose and away from mouthpiece 
This step prevents humidified air from entering the device and is likely less 
important for a multi-unit dose device like the DiskusTM inhaler compared to 
bulk storage devices like the TurbuhalerTM. There is no data on the effect of 
forceful exhalation or exhalation through the mouth on subsequent drug 
efficacy. These effects may be more dependent on the duration of the prior 
breath hold. 
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Figure 1.8: Relationship between breath hold duration, particle diameter and 
pulmonary deposition. Higher breath hold durations are associated with 
increased pulmonary deposition. Reproduced from (75). 
1.1.9.12. Recover the lever and the outer cover 
This step relates to device storage. Recovering the outer cover automatically 
resets the dosing lever, making the device ready for the next actuation. It also 
closes the drug exit port, reducing exposure of the internal components to the 
elements. Again, with a multi-unit dose device where all doses are contained 
in sealed pockets, the effect of not recovering the outer cover is likely 
insignificant but has never been formally studied. 
1.1.9.13. Rinse one’s mouth out after inhaling and do not swallow the 
rinsing water 
Mouth rinsing is important with steroid inhalers to reduce the risk of oral 
candidiasis. This step will not be discussed further since it is related to 
adverse effects and not to drug delivery or efficacy. 
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1.1.10. Estimates of temporal and technique adherence 
Feehan et al. studied the dispensing records of 2193 patients who received 
controller medications for asthma in a 12-month period and found that only 
14-16% of patients had ‘satisfactory’ adherence (adherence ≥ 80%).(97)
Numerous other studies have found that adherence to inhaled controller 
medications is generally poor with temporal adherence estimates ranging from 
14 to 40%.(98, 99) Non-adherence to controller therapy leads to poor asthma 
control, higher rates of exacerbations and increased healthcare utilization in 
both adult and paediatric populations.(100) Compared to other chronic 
diseases, patients with COPD have a lower mean adherence rate of 68.8% to 
medical treatments.(101) In a study of adherence of COPD patients with 
inhaler therapy for 5 years, it was found that inhaler compliance had declined 
over the 5 year period from more than 60% to less than 50%.(102) Poor 
adherence in COPD has also been associated with increased hospital 
admissions, length of hospital stay and reduced quality of life.(103) 
While the majority of adherence studies in chronic diseases assess mainly 
temporal adherence, several studies have highlighted that errors in inhaler 
technique may be as detrimental as the lack of temporal adherence.(104-106) 
In 2000, Cochrane et al. summarized all papers describing inhaler technique 
and concluded that the frequency of efficient inhalation technique ranged from 
46–59%.(107) Hesselink et al. showed that about 24% of patients using DPIs 
made at least one critical error causing detrimental effects on drug delivery 
and efficacy.(108) Table 1.6 shows the breakdown of technique errors in 
DiskusTM inhaler use in the published literature. The most common technique 
errors when using the DiskusTM inhaler are errors in exhalation prior to 
inhalation, breath holding, incorrect mouthpiece positioning and incorrect dose 
metering. However, the study by Li et al. in a Chinese population found that 
errors in inhalation were most common (109). 
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Table 1.6: Breakdown of technique errors in DiskusTM inhaler use in 
the published literature. For each considered study, values represent 
the percentage of patients showing speciﬁc errors in the use of the dry 
powder inhaler (DPI).
Study Incorrect 
dose 
metering 
Incorrect 
inhaler 
positioning 
No 
exhalation 
before 
activation 
Incorrect 
mouthpiece 
positioning 
No 
forceful 
and deep 
inhalation 
No 
breath 
hold 
Failure 
to 
breathe 
out 
slowly 
Molimard
et al. 
(110) 
(n=3811) 
- - 30 - - 26 - 
Van der 
Palen et 
al. (111) 
(n=50) 
8 - 40 - - 6 2 
Girodet 
et al. 
(112) 
(n=984) 
- - 40 9 - 36 - 
De 
Angelis 
et al. 
(113) 
(n=358) 
- - 18 - - - - 
Li et al. 
(109) 
(n=384) 
30 25 48 65 94 90 23 
 1.1.11. Improved methods for monitoring adherence and technique 
Electronic monitors, developed over the last two decades, have become the 
gold standard for measuring adherence.(114) These methods are objective 
and allow more accurate comparison of changes in adherence from a 
patient’s baseline. The majority of electronic monitors were developed for the 
pMDI and monitor temporal adherence only.  
The Smartinhaler and Doser CT devices record the date, time and number of 
actuations of a pMDI using a pressure sensor, which detects actuations.
(115-117) The SmartTrak inhaler is a newer monitoring device for the pMDI, 
which allows remote upload and ringtone reminder capabilities and generates 
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a graphical display of medication use for patient- and physician-feedback.(118) 
The Spiroscout system uses Global Positioning System (GPS) technology to 
track both when and where a patient uses his/ her inhaler.(74) Newer devices, 
such as the AdHaler and I-neb Adaptive Aerosol Delivery System utilize 
mobile telecommunications networks to transmit data wirelessly to clinicians or 
other healthcare professionals who can provide feedback to the patient.(74) 
The DiskusTM Adherence Logger was developed specifically for the DiskusTM
DPI; a magnetic sensor is used to detect motion of the drug delivery 
lever.(119) The device also features software, which allows the adherence 
data to be uploaded to a computer for display and analysis. 
Although some of the above devices allow a graphical display of both date and 
time of inhaler use, most studies using electronic recording devices have 
reported adherence as the mean daily dose, or mean dose over the study 
period.(120-122) There are limitations to this method; for example, the mean 
rate of adherence is the same whether an individual took the medication 
according to the prescribed schedule or one who took all the doses in the first 
half of a dosing period, leaving none in the second half.  
Inhaled medications add a further challenge because electronic recording 
devices usually do not assess if the inhaler was taken correctly.(71, 76, 82, 
123-126) An individual may take their inhaler according to the dosing schedule
but with incorrect technique leading to minimal or no clinical benefit. In this 
case the average use over time is meaningless unless data on the technique of 
use is also incorporated into the calculation of adherence. Hence, there is a 
need to develop a method to quantify adherence that accounts for variations in 
dosing schedules and inhaler user technique as these features influence the 
pharmacokinetic profile of the medication. 
There have been increased attempts recently to develop electronic monitors 
for both temporal and technique adherence. The MDILog monitors the shaking 
of the pMDI canister and the timing of actuation.(127) The SmartMist 
microprocessor-assisted system, now discontinued, analyses the inspiratory 
flow profile and automatically actuates the MDI when predefined conditions of 
flow rate and cumulative inspired volume coincide.(128) There has also been 
a push towards tele-health monitoring systems, such as the I-neb Insight 
Online, where adherence data is pushed to a secure server, which can be 
accessed by patients and clinicians.(129) A competence monitor for the 
DiskusTM, called the DPILog, has also been developed but it does not assess 
all aspects in DiskusTM technique. 
Apart from longitudinal monitors, two technologies allow estimation of the peak 
inspiratory flow rate generated by a patient when an inhaler’s intrinsic 
resistance is simulated. One such device is the Clement-Clarke In-Check Dial, 
which uses apertures of different sizes to simulate an inhaler’s resistance to 
airflow. The device can be used to measure the inhalation rate of a patient 
when they use each of the commonly prescribed inhalers that are currently 
available and also to select an appropriate inhaler.(130) An accuracy study 
showed that there was a constant bias of 3.9 l/min for the DiskusTM and 3.5 
l/min for the TurbuhalerTM when the In-Check Dial was compared to an inhaler 
profile recorder.(131) Mahler et al. showed that approximately 20% of COPD 
patients greater than 60 years of age had a subotimal PIFR, when measured 
using the In-Check Dial.(132) Melani and colleagues reported that 24% of 
TurbuhalerTM users had suboptimal PIFR (< 60 l/min), of which 77% had a 
PIFR < 30 l/min, and 12% of DiskusTM users had suboptimal PIFR, of which 
60% had a PIFR < 30 l/min.(133) The downside of using the In-Check Dial for 
longitudinal monitoring relates to the fact that patients must use a separate 
device and there may be natural variation in the PIFR achieved with the DPI 
and with the In-Check Dial even when used consecutively within a short 
period of time. 
The Vitalograph Aerosol Inhalation Monitor uses a hygienic single-use 
disposable inhaler simulator to provide information regarding inspiratory 
acceleration at start of inspiration, timing of firing of MDI / activation of DPI, 
inspiratory flow rate throughout inspiration, inhalation time within target flow 
range and breath hold time at end of inhalation.(134)  
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1.1.12. Impact of feedback and training on adherence 
There is overwhelming evidence that feedback and training improve both 
temporal and technique adherence. Jolly et al. studied the effect of 
educational training on MDI technique and found that the median inhaler 
proficiency score (based on the number of correct steps executed) increased 
from 3 to 6 after one education session and to 8 after three sessions. Scores 
decreased one month after training and again increased with further 
training.(135) In one randomized controlled trial, MDI technique training lead to 
improvements of proficiency scores from 6.2 to 10.7.(136) Another RCT in 
hospitalized patients found that 62% and 78% misused their MDI and DiskusTM
inhalers, respectively.(137)  
Electronic monitors also assist in improving adherence. Nides et al. showed 
that participants that received feedback based on an electronic monitor at the 
4-month follow-up stage adhered more closely to the prescribed three sets per
day (mean 1.95 versus 1.65) and used the prescribed two actuations in a 
greater percentage of sets (80% versus 60.3%).(138) Another study 
investigated whether direct clinician-to-patient feedback discussion on their 
inhaled steroid and beta-agonist use on all visits influenced adherence and 
reported that adherence increased form 61% to 81% by week two and 
remained above 71% for the entire study compared to the control group, for 
which adherence steadily decreased from 51%.(139) Charles et al. also 
showed that an audiovisual reminder device lead to a 26% higher adherence 
rate in the treatment group compared to the control group.(140) 
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1.2. Rationale 
There is a need to develop a comprehensive system for monitoring patient 
inhaler temporal and technique adherence in order to tailor and personalize 
training and feedback. While current electronic monitors are able to accurately 
log the date and time of inhaler use, they have fallen short of capturing all 
aspects of inhaler technique. The majority of monitors have also been 
produced for the MDI inhaler and there is a clinical need for advanced DPI 
monitors. 
Although checklists are the current “gold standard” for assessing inhaler 
technique, there is also a lack of data in the literature and general consensus 
on the significance of all of the errors assessed by these checklists. 
This thesis builds on the work done by a team of biomedical engineers and 
physicians in conjunction with Vitalograph [Ennis, Ireland] to develop an 
acoustic method of monitoring temporal and technique adherence using the 
DiskusTM DPI, the most commonly used DPI device. 
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1.3. The Inhaler Compliance Assessment (INCATM) device 
The INCATM device consists of a microphone, a battery, a memory card and a 
microprocessor for recording audio and carrying out other processes required 
for its operation (Figure 1.9). The main criteria for each of these components 
are small physical size and low power battery consumption in order that the 
INCATM device is small enough to be attached to an inhaler and so that it can 
record for at least one month. The prototype device was attached to a 
DiskusTM inhaler.  
To minimise battery use and to record the time of inhaler use, recording was 
initiated by the rotation of the inhaler, this is the initial stage in the use of a 
DiskusTM inhaler.  The recording finishes when the device is closed by the 
user. Each time a recording begins the time from an electronic real time clock 
is stored as part of the recording’s metadata.  When the inhaler is returned to 
the clinic, the data is downloaded onto a desktop PC for analysis.  The audio 
is recorded at a sampling rate of 8 kHz with an 8 bit sampling resolution.  
The package instructions accompanying a DiskusTM inhaler describes the 
steps required for its correct use. Six critical phases were identified by acoustic 
analysis; opening the device, exhalation, drug release, inhalation, >5 second 
pause of breath holding and exhalation. Figure 1.10 demonstrates how each 
of these phases can be identified visually from a display of an acoustic 
recording created by the INCATM device.  
The steps in inhaler use have distinct acoustic characteristics, these 
characteristics can be used to identify technique errors in inhaler use. For 
example, the lever movement and blistering of the drug during priming is 
characterized by a short burst of energy lasting approximately 20-30 ms with a 
high frequency content (~2 kHz) preceded by a short burst of lower frequency 
noise (~1 kHz). An exhalation has a sharp increase in amplitude that tapers off 
with time and the power of exhalation decreases exponentially from 2 kHz to 
500 Hz while the spectral power for inhalations are higher and they have a low 
increase in amplitude compared to that of exhalations, which is maintained for 
an average duration of 1.8 seconds. These characteristics enabled 
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identification of each step required for drug delivery.  Visual and aural 
analysis was carried out using a commercially available audio processing 
software package Audacity®.  
Figure 1.9: INCATM -enabled DiskusTM inhaler showing profile and internal 
components of the device.   
Figure 1.10: A visual display of correct inhaler use: important steps in 
correct inhaler use are presented in both the time and frequency domain.  
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1.4. Aims and objectives 
1.4.1. Aim 1 (Chapter 3) 
- To determine temporal adherence rates, the patterns
of adherence and the frequency of DiskusTM DPI
technique errors in a community care setting.
1.4.2. Aim 2 (Chapter 4) 
- To determine the relationship between underlying
disease, age, gender and baseline spirometric
parameters on the peak inspiratory flow rate and
inspiratory volume from a DiskusTM DPI.
- To measure the effect of the peak inspiratory flow rate
and inspiratory volume on the delivered dose from a
DiskusTM DPI.
- To develop and validate an acoustic method of
estimating the peak inspiratory flow rate and
inspiratory volume from a DiskusTM DPI.
1.4.3. Aim 3 (Chapter 5) 
- To assess the effect of exhalation into the DiskusTM
DPI after blistering on the dose available for
subsequent delivery.
- To develop and validate an acoustic method of
estimating the direction, distance and flow rate of an
exhalation directed at the DiskusTM DPI.
1.4.4. Aim 4 (Chapter 6) 
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- To determine the effect of spatial orientation of the
DiskusTM DPI after dose blistering on the available
dose for subsequent delivery.
1.4.5. Aim 5 (Chapter 7) 
- To investigate whether the duration of the breath hold
after dose inhalation affects the delivered dose from
the DiskusTM DPI.
1.4.6. Aim 6 (Chapter 8) 
- To assess the contribution of missed doses to
pharmacokinetic trough and peak levels achieved after
repeated dosing.
1.4.7. Aim 7 (Chapter 9) 
- To develop an algorithm for combining data on
temporal adherence and technique errors derived from
the INCATM device into a single “actual adherence”
metric.
- To compare dose counter, INCATM dose and actual
adherence rates in a cohort of asthmatic patients
monitored longitudinally.
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CHAPTER 2 - Methods 
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2.1. How common are DiskusTM inhaler temporal and technique errors in 
a community care setting? 
2.1.1. INCATM device 
The recording device selected to obtain the acoustic signals of inhaler use was 
the INCATM  (Inhaler Compliance Assessment) device, described above.  
2.1.2. Study design 
This was a prospective observational cohort study. Patients were recruited 
from six general practice (GP) clinics and twelve community pharmacies 
based in Ireland.  Over a 2-4 week period, consecutive patients with a history 
of respiratory illness and already prescribed a salmeterol/fluticasone DiskusTM
inhaler were asked to participate. Patients gave informed consent to 
participate in this study of adherence.  Both clinicians and patients were fully 
aware that the device was an acoustic recording device and that both time of 
use and inhaler technique were being assessed.  Once consented, patients 
were given an INCATM enabled inhaler for 1 month and were asked to use it as 
they normally would and return it at the end of one month.   
Demographic data on age, sex, clinical diagnosis, smoking history, education 
level, socio-economic class, number of exacerbations, hospital admissions 
and GP/healthcare use in the last year were also recorded.  
2.1.2. Ethical and consent considerations 
This study was approved by the ethics committee of the Irish College of 
General Practitioners and the Royal College of Surgeons in Ireland 
(NCT02552472).  Unless participants specifically requested to be shown how 
to use their inhaler, inhaler technique training was not performed, since the 
purpose of the study was to assess inhaler adherence in a real world setting.  
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2.1.3. INCATM data processing 
Each audio file, representing each time the inhaler was used, was assessed 
by two separate trained raters who used a commercial software analysis 
program, Audacity® version 2.04 [http://audacity.sourceforge.net/], to visualize 
and listen to inhaler sounds in order to classify inhaler events.  Agreement 
between the two raters was 83% and disagreements were reconciled by 
consensus agreement.  Most of the differences observed between the raters 
were due to the classification decision of poor inspiratory flow. 
2.1.4. Statistical analysis 
Data was analyzed using Stata version 13 [Statacorp, TX, USA]. Descriptive 
statistics were used to describe the patient characteristics and the errors in 
inhaler use. The INCATM adherence rates were calculated as the area under 
the curve (AUC), using the trapezoid formula:
Where 𝑓(𝑎) is the length of the first wall of the trapezoid and 𝑓(𝑏) is the length 
of the second wall of the trapezoid and (𝑏 − 𝑎)is the width of the trapezoid. 
The adherence rates calculated included the attempted rate (how frequently 
the participant tried to take their medication, i.e. evidence of drug priming in 
audio analysis), the technique rate (how frequently the participant made 
critical technique errors) and the actual rate (incorporating time of use, 
interval between doses and critical technique errors).  A negative binomial 
regression model was used to determine trends in technique errors.  The 
number of attempted doses was used as the offset term and age, gender, 
smoking history, education (primary/secondary), GP use, diagnosis, socio-
economic class, exacerbations and hospitalizations were included as fixed 
effects in the model.  An ordinary linear regression model was used to 
determine trends in the actual adherence rate and technique errors to identify 
possible correlations with demographic and clinical features of the patients.  
P-values <0.05 were deemed statistically significant.
∫ 𝑓(𝑥) ≈ (𝑏 − 𝑎) [
𝑓(𝑎) + 𝑓(𝑏)
2
𝑏
𝑎
] 
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2.2. The effect of inhalation parameters on delivered dose and an 
acoustic method to quantify this effect 
2.2.1. The relationship between baseline spirometric PIFR and DiskusTM
inhalation parameters: Is baseline spirometry sufficient for estimating peak 
flow from a DiskusTM DPI? 
2.2.1.1. Participants 
Eighty-five subjects older than 18 years of age from a population of healthy 
volunteers and patients with asthma, COPD, neuromuscular disease and non-
respiratory disorders were recruited by clustered and stratified sampling. 
Patients were recruited from different clinics in Beaumont Hospital in Dublin, 
Ireland. There were no specific exclusion criteria for this study apart from 
capacity to comply with instructions. Informed consent was obtained for the 
study with explanations of the study protocol.  
2.2.1.2. Ethics 
This study was approved by the local Hospital Ethics Committee (ERC/ IRB 
13/36) and was performed in accordance with the ethical standards laid down 
in the 2000 Declaration of Helsinki.(141)  
2.2.1.3. Flow experimental design 
Flow and volume readings were taken while patients used a DiskusTM DPI. 
Several studies have previously employed an airtight container to connect an 
inhaler to a spirometer in order to obtain flow measurements through an 
inhaler device.(142, 143) The construction of the airtight container with the 
DiskusTM inhaler, spirometer connection and Fleish Pneumotachograph 6800 
spirometer used in this study are shown in Figure 2.1.  
The spirometer used was the Vitalograph Pneumotrac (Model 6800) 
[Vitalograph, Ennis, Ireland]. This spirometer uses a Fleisch 
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pneumotachograph for flow/volume readings. The specifications are presented 
below: 
- Flow Detection Principle: Fleisch type pneumotachograph
- Volume Detection: Flow integration sampling @ 100 Hz
- Accuracy when in Operating Range:
Volumes: Better than ± 3% (Max 8 L / Min 0.05 L) 
Flows: Better than ± 5% (Max 16 L/s / Min 0.02 L/s) 
Linearity: ± 1% in range 0.1 L/s to 16 L/s 
- Resistance: <1.2 cmH2O.s/L at 14 L/s
- Performance Standards: ISO 26782:2009, ISO 23747:2007, ATS/ERS
2005
Briefly, the airtight container ensured that all inspired air through the 
mouthpiece of the inhaler comes through the spirometer where it can be 
measured. In this study a clear PET (Polyethylene Terephthalate) container 
was used to act as an airtight adaptor between a DiskusTM inhaler and a 
spirometer. An empty DiskusTM inhaler was placed into the container, which 
had a custom aperture cut for the mouthpiece and the spirometer connector. 
The mouthpiece was extended out 1cm in length in order for subjects to get a 
good seal around the mouthpiece. Steinel Hybond 86 adhesive was used to 
seal any gaps and prevent any unintentional air from going in or out of the 
container. The container was submerged in a water bath before each test in 
order to verify that it was airtight.  The end result was that air could only enter 
or exit via the inhaler mouthpiece and through the spirometer connector.  
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Figure 2.1: Experimental setup showing DiskusTM inhaler in airtight container 
with adaptor connector to Fleisch pneumotachograph spirometer and PC. The 
arrow indicates direction of airflow during inhalation. 
2.2.1.4. Study protocol 
Demographics and baseline lung function by spirometry were recorded. 
Baseline lung function was taken as the best of three trials. Documented 
parameters included forced expiratory volume in 1 second (FEV1), forced vital 
capacity (FVC), FEV1/FVC, forced inspiratory vital capacity (FIVC) and peak 
inspiratory flow rate (PIFR).  
Patients were instructed to exhale gently to functional residual capacity and 
then inhale at maximal flow rate and duration. Each patient performed this 
manoeuvre until two consecutive PIFR readings were within 20% of each 
other. Values for Inspiratory vital capacity and peak inspiratory flow rate from 
the DiskusTM were obtained. 
76 
2.2.1.5. Data analysis 
Statistical analysis was done using Audacity version 2.0.5., MATLAB _R2013b 
[Mathworks, Cambridge, UK]  and Stata SE version 12. Ordinary least squares 
regression of spirometric PIFR versus DiskusTM PIFR was performed to 
determine the degree of correlation between baseline spirometry and flow or 
volume inhaled while using the DiskusTM DPI. A stepwise deletion linear 
regression was also performed to determine the relationship between 
DiskusTM PIFR and the independent variables: condition (categorical), age, 
gender (categorical), height, weight, BMI, FEV1, FVC, FEV1/FVC, spirometric 
PIFR and spirometric IC with a significance level for removal from the model of 
0.05. 
Subjects were classified into subgroups of healthy/ non-respiratory condition 
(NRC), asthma, COPD/ alpha-1-antitrypsin deficiency, and neuromuscular 
disease (NMD). Subgroup analyses were performed for baseline spirometry 
and DiskusTM spirometry. Multiple t-tests were done to compare the means for 
spirometric PIFR, DiskusTM PIFR, spirometric IC and DiskusTM IC for each 
group. The proportion of patients in each category with a flow rate < 60 l/min 
and/ or an inspiratory volume < 1 L was also compared. Patients of age 
greater than or equal to fifty years old and less than fifty years were also 
compared in the same way. 
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2.2.2. Developing an acoustic method of estimating inspiratory flow rate and 
volume from an inhaler  
2.2.2.1. Participants 
Fifteen healthy volunteers between the ages of 18-40 years were recruited. 
Subjects were excluded if they had any cardiac, respiratory, hepatic, renal 
dysfunction, recent respiratory tract infection in the last six weeks, a greater 
than ten pack/year smoking history, a history of drug/alcohol abuse or a known 
sensitivity to salmeterol or fluticasone. Baseline spirometry was performed 
according to ATS recommendations to confirm that subjects had normal lung 
function.(144) This study was approved by the local Hospital Ethics Committee 
(ERC/ IRB 13/36). 
2.2.2.2. Acoustic Recording Device 
The INCATM device was used to capture an acoustic profile of inhalation while 
a subject used the DiskusTM inhaler. Acoustic signal processing is outlined 
below. 
2.2.2.3. Flow Experimental Design 
The apparatus used in section 2.2.1.3. above was used to measure flow rates 
and volumes from the DiskusTM inhaler. The INCATM recording device was 
attached to the top of the DiskusTM, as shown in Figures 2.2 and 2.3 below. 
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Figure 2.2. Airtight container with DiskusTM inhaler placed inside and INCATM 
device attached on top used to measure the acoustic profile, the flow rate and 
the volume of an inhalation. 
Figure 2.3. Apparatus used for obtaining flow-volume recordings and acoustic 
measurements from an inhalation maneuver. 
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2.2.2.4. Test Procedure 
The airtight container was connected to the spirometer. Patients were 
instructed to exhale gently (to functional residual capacity) and then inhale at a 
variety of flow rates and volumes. Each patient performed this manoeuvre six 
to eight separate times. The airtight container was sterilized with 100% 
ethanol and tested for air leaks between subjects. A graphical representation 
of the overall test set up can be seen in Figure 2.3. 
2.2.2.5. Inhalation Signal Analysis 
The inhalation audio signals were divided into 1,024 data samples with 50% 
overlap between successive segments. A Hanning window was used to 
analyze each segment, while a fast fourier transform (FFT) was used to 
calculate the power spectral density. Three measures of amplitude were 
employed in this study; median amplitude (MA), mean absolute deviation 
(MAD) of the amplitude and root mean square (RMS) of the amplitude. These 
three measures of amplitude were chosen in order to investigate which had 
the best correlation with PIFR and IC.  
MA was computed using a relative peak detection method. Peaks of the 
inhalation signal were selected that were greater than their nearest neighbor 
by a minimum threshold height difference of 200. MAD is the mean of the 
absolute deviations from the central value. This measure addresses the 
problem of calculating the mean from a sinusoidal measure and was 
calculated using the following equation (2.1): 
𝑀𝐴𝐷 =  
1
𝑛
 ∑ |𝑥𝑖 − 𝑥|
𝑛
𝑖=1   (2.1) 
The RMS or quadratic mean is a statistical measure of the effective value of a 
signal’s amplitude, including the mean value. It takes into account sinusoidal 
waveforms and gives the equivalent non-varying power of a varying waveform. 
It is the square root of the mean of the squares of the values of either a 
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discrete or continuously varying function. RMS has been used in a previous 
study, which investigated the volume-dependent changes in regional lung 
sound amplitudes.(145) It was calculated using the following equation (2.2): 
𝑅𝑀𝑆 = [ 
1
𝑛
(𝑥1
2 +  𝑥2
2 +  𝑥3
2 + ⋯ + 𝑥𝑛
2)]
1
2
 (2.2) 
The average power (Pave) of each inhalation was calculated in the frequency 
bands: 20-40 Hz, 40-70 Hz, 70-150 Hz, 150-300 Hz, and 300-600 Hz, in 
addition to 70-300 Hz, 70-450 Hz, 100-300 Hz, 100-450 Hz and 150-450 Hz. 
These frequency bands were chosen as they were previously used in a study 
by Hossain and Moussavi, which investigated the best frequency band to 
estimate flow rate from respiratory sounds obtained from the chest wall.(146) 
In spirometry, the area under a PIFR – time curve equates to the volume of 
an inhalation or IC. Since acoustic measurements were used to predict the 
PIFR, integration could not be used to determine IC. Instead it was noted that 
the area under the curve of the inhalational sound waveform (inhalation 
volume) approximates that of the area of a semi-ellipse (Figure 2.4), 
described by the following equation (2.3): 
𝐼𝑛ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =
1
2
∗ 𝑝𝑖 ∗
𝐴∗𝐵
2
,  (2.3) 
𝑤ℎ𝑒𝑟𝑒 𝐴 = 𝑃𝐼𝐹𝑅 𝑎𝑛𝑑 𝐵 = 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 
Values for MA, MAD, RMS and Pave for each inhalation were employed to 
obtain predicted values for the mean PIFR. These predicted mean PIFR 
values and the actual duration of the inhalation were used to calculate a 
predicted IC value (Equation 2.3). The predicted values for IC were then 
compared to the actual IC values for each inhalation, as obtained from the 
spirometer.  
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Figure 2.4. Area of semi-ellipse from which the volume or inspiratory capacity 
(IC) of an inhalation can be calculated. 
2.2.2.6. Statistical Analysis 
Analysis was carried out using the statistical software Stata SE Version 12. 
This study was designed as a repeated measures study due to the fact that 
the samples were not independent. A generalized least squares (GLS) 
regression model, which accounts for random effects intercept at the subject 
level, was used to compare the acoustic parameters of MA, MAD, RMS and 
Pave with measured PIFR and IC. The GLS model takes into account the 
correlation between the observations when calculating the regression model 
and was thus deemed appropriate for analysis of the data in this study.  
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2.2.3. Validation of an acoustic method for estimating inspiratory flow rate and 
volume from an inhaler using acoustic measurements in a respiratory disease 
cohort 
2.2.3.1. Participants 
One hundred and ten subjects from a population of patients with asthma, 
COPD, lung cancer, neuromuscular disease, other respiratory disorders and 
non-respiratory disorders were recruited by clustered and stratified sampling. 
All participants were either on inhaled medications as part of their treatment 
regimens or received training on how to use a DiskusTM inhaler. Patients were 
recruited from different clinics in Beaumont Hospital, Dublin, Ireland. There 
were no specific exclusion criteria for this study apart from capacity to comply 
with instructions and age (excluded if less than 18 years). Informed consent 
was obtained for the study with explanations of the study protocol. 
Demographics and baseline lung function by spirometry were recorded.  
2.2.3.2. Ethical approval 
The study was approved by the local Hospital Ethics Committee (ERC/ IRB 
13/36). 
2.2.3.3. Apparatus used 
The construction of the airtight container with the associated DiskusTM inhaler, 
INCATM TM device and spirometer connection used in these studies has been 
described previously in section 2.2.2.3.
2.2.3.4. Study protocol 
Patients were instructed to exhale gently to functional residual capacity and 
then inhale at maximal flow rate and duration. Each patient performed this 
manoeuvre until two consecutive PIFR readings were within 20% of each 
other. 
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2.2.3.5. Data analysis 
The audio files recorded from the subjects were subsequently analysed using 
Audacity version 2.0.5 and MATLAB_R2013b software packages to determine 
the value of amplitude and duration of each inhalation. Regression analysis 
(linear, polynomial and rational) was performed to determine the relationship 
between measured DiskusTM PIFR and each amplitude parameter described in 
the prior section (MA, MAD, RMS and Pave, 300-600 Hz). The parameter with the 
greatest degree of correlation was chosen to calculate acoustic PIFR.  
2.2.3.6. Statistical analysis 
Statistical analysis was done using MATLAB_R2013b and STATA version 13. 
Creating binary dependent variables using threshold values for measured 
PIFR, sensitivity and specificity analysis was done comparing acoustically-
determined PIFRc with spirometrically-determined PIFRm. Receiver operating 
characteristic (ROC) curves were constructed and the value of acoustically-
determined PIFRc at which the maximum number of inhalations was correctly 
classified was determined and presented in tabular form.  
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2.2.4. Correlation of inhalation acoustics from a DiskusTM DPI with in vitro drug 
delivery 
2.2.4.1. Apparatus 
In vitro deposition and aerodynamic particle size of the delivered dose from 
the DiskusTM DPI was characterized using the Next Generation Impactor (US 
Pharmacopoeia 601, Apparatus 5).(147) The NGI was used with a pre-
separator and cups 1-8. A high capacity vacuum pump [HCP4, Copley 
Scientific, UK] and Critical Flow Controller [TPK 2000, Copley Scientific, UK] 
were attached to the air intake port. Impaction cups 1-5 were lined with filter 
papers wetted with 2 ml of a mixture of methanol: acetonitrile: water (25:25:50) 
and cups 6-8 were coated with 2 ml of solvent only to prevent particle bounce 
and re-entrainment.(148)  
Two DiskusTM inhalers were used in this study: salmeterol 50 µg/ fluticasone 
250 µg and salbutamol 200 µg. An INCATM audio recording device was 
attached to each inhaler so that acoustic recordings of each inhalation were 
obtained. 
2.2.4.2. Experimental conditions 
The study variables were flow rate (PIFR) and duration of inhalation. The 
critical flow controller was adjusted to achieve flow rates of 30, 60 and 90 l/min 
at 2, 4 and 6 second durations. Testing was performed in duplicate at each 
study condition for both inhalers. For each determination, 5 individual doses 
were aerosolized into the induction port via a mouthpiece adaptor. The active 
ingredients were quantitatively recovered from the induction port (throat), pre-
separator, and cups 1-8.  
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2.2.4.3. Chromatographic analysis of active ingredients. 
High performance liquid chromatography (HPLC) analysis was performed 
using a Waters Alliance Separations module 2690 [Waters Corporation, MA, 
USA] equipped with a temperature programmable autosampler and Waters 
2996 PDA detector [Waters Corporation, MA, USA]. Chromatographic data 
was recorded and integrated using Waters Empower chromatography 
software [Waters Corporation, MA, USA] and quantified using external 
standards. HPLC conditions for salbutamol sulphate,(149) and fluticasone 
propionate / salmeterol xinafoate are detailed in Table 2.1.  
Analytical method validation was demonstrated for both methods with regard 
to accuracy, precision, specificity and linearity as per International 
Conferences on Harmonisation (ICH) guidelines.(150) The limits of detection 
for salbutamol, fluticasone and salmeterol peaks were 0.045, 0.032 and 0.014 
µg / mL, respectively, while the LOQ values for the same three peaks were 
0.136, 0.101 and 0.042 µg / mL, respectively. 
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Table 2.1: Details of high performance liquid chromatographic techniques 
used for quantification of salbutamol sulphate, fluticasone propionate and 
salmeterol xinafoate. 
Active 
Ingredient 
Mobile Phase 
(per 1 L) 
Flow 
Rate 
(mL / 
min) 
Column 
Details 
Injection 
Volume 
Detection 
Wavelength 
Salbutamol 
sulphate 
600mL - 
methanol 
400mL - 
deionised 
water 
1g - sodium 
dodecyl 
sulphate 
1.5 
Waters 
Nova-
Pak® 
C18 5µm 
3.9×150 
mm, 
100 µL 276nm 
Fluticasone 
propionate / 
salmeterol 
xinafoate 
500mL - 50mM 
ammonium 
phosphate 
pH2.4 
1mL - 
triethylamine  
250mL - 
methanol 
250mL - 
acetonitrile 
1.2 
Varian 
Pursuit 
XRs 
C18 3µm 
4.6 x 150 
mm, 
200 µL 252nm 
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2.2.4.4. Measures and data analysis 
The total emitted dose (TED) was determined as the sum of the total drug 
recovered from the Throat, PS, and cups 1-8. This was averaged for 
each study condition. The fine particle dose (FPD), i.e. cumulative 
dose less than particle size 5 µm, was calculated by interpolation on a 
log-probit plot using pre-specified stage cutoffs at each flow rate. Fine 
particle fraction (FPF) was calculated by expressing the FPD as a 
percentage of the label claim dose. The upper airway dose (UAD) 
corresponded to the cumulative dose above an aerodynamic particle size 
of 5 µm. Flow rate (PIFRc) was calculated from the acoustic parameters 
using Equation 5. Mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) were also calculated at each study 
condition for both formulations using published methods.(151, 152)
2.2.4.5. Statistical analysis 
Statistical analysis was performed using Stata version 13 and 
MATLAB_R2013b. Multivariate regression analysis was performed using TED, 
FPF and UAD as dependent variables and PIFR, Duration, PIFRc and 
acoustic duration as independent variables. Bar graphs of TED, FPF, and 
UAD for both formulations were generated, grouping by PIFR and duration. 
The regression effect size (η2) was calculated for PIFR and duration in each 
model. Coefficients of variation (CVs) were determined for PIFRc at different 
levels of measured PIFR and for acoustic duration at different levels of preset 
inhalation duration to analyze our method precision.
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2.2.5. Correlation of inhalation acoustics from a DiskusTM Dry Powder Inhaler 
with in vivo drug delivery 
2.2.5.1. Participants and ethical approval 
This study was approved by the local Hospital Ethics Committee (ERC/ IRB 
13/53). Ten healthy volunteers were recruited; demographics are shown in 
Table 4.15 on page 170. 
2.2.5.2. Apparatus 
An INCATM acoustic recording device was attached to a 200 µg salbutamol 
DiskusTM with a hot-wire anemometer [FS5, IST, Switzerland] inserted into an 
air intake port of the DiskusTM. The hot-wire anemometer produced a voltage 
output which was calibrated against flow rate using a vacuum pump.  
2.2.5.3. Sample collection and processing 
Blood samples were collected in 7.5 ml serum separator tubes and allowed to 
coagulate for 20 minutes. Tubes were then centrifuged at 5000 g for 15 
minutes and 2-3 ml of serum pipetted into vials for storage at -20 oC. 
2.2.5.4. Enzyme linked immunosorbent assay for determination of serum 
salbutamol concentration 
Serum concentration of salbutamol was determined using a competitive 
Enzyme Linked Immunosorbent Assay [MaxSignal® Salbutamol ELISA Test Kit 
(Reference 1022-01), New Market Scientific, UK]. Limit of detection for serum/ 
plasma was 0.25 ng/ml and the assay was linear in the range of 0.05 ng/ml to 
10.0 ng/ml. Total assay imprecision was determined to be 14% with recoveries 
between 85-115%. To account for interference between protein components in 
the serum and the assay, the baseline sample concentration was subtracted 
from timed samples. 
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2.2.5.5. Study protocol 
Preliminary pharmacokinetic profiling showed serum peaks at 20 min and at 2-
3 hours post-inhalation (Figure 2.5). The sampling time of 20 minutes was 
used for the comparative study below because this has been reported to 
represent pulmonary absorption.(37) 
Figure 2.5: Line graph showing serum drug concentration versus time post-
inhalation of a 200 microgram dose of Salbutamol via DiskusTM inhaler for 
three healthy individuals. Note the two distinct peaks in drug concentration at 
20-25 minutes and at 2-3 hours.
Due to the wide inter-subject variation in metabolism of salbutamol and other 
similar compounds, we used each subject as his/ her own control to determine 
the effect of flow rate and duration of inhalation on peak concentration. Each 
subject was asked to perform a single inhalation at maximal effort [PIFR ≥ 60 
90 
l/min] and duration from the study apparatus. This was followed by a 10 
second breath hold and then a mouth rinse to reduce gastro-intestinal 
absorption of salbutamol. A previous study has shown this to be an effective 
method.(37) Blood samples were collected at time zero and at 20 minutes. 
This was followed by at least a 24-hour washout period. The procedure was 
repeated at a low flow rate [PIFR <60 l/min] and duration (≤ 50% of maximal 
duration) after this washout period.  
2.2.5.6. Statistical analysis 
Statistical analysis was done in STATA version 13. PIFR and inhalation 
duration were determined both from the hot-wire anemometer and from the 
INCATM device and correlated for each inhalation. A line graph was done for 
each subject and an overall regression model was developed using peak 
concentration as the dependent variable and measured PIFR, duration, 
calculated PIFR and acoustic duration as independent variables. 
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2.3. Development and validation of an acoustic method to detect and 
quantify the effect of exhalation into a Dry Powder Inhaler 
2.3.1 Impact of exhalation on delivered dose 
2.3.1.1. Dosage uniformity analysis 
To validate the in vitro method of removing drug from the DiskusTM DPI, the 
Dosage Uniformity Sampling Apparatus (DUSA) was used to determine the 
delivered- dose uniformity from a salmeterol/fluticasone 50 mcg/ 250 mcg 
DiskusTM DPI (US Pharmacopoeia 601).(147) The DiskusTM DPI was not 
subject to any exhalations. Ten replications were performed. The target 
dosage uniformity was 9 of 10 results between 75% and 125% and no more 
than 1 of 10 results between 65% and 135%.(147) 
2.3.1.2. Experimental setup and protocol 
To recreate the effect of an exhalation with dry air, a high capacity airflow 
pump and critical flow controller (air valve) were connected in series to a glass 
adaptor (mouthpiece) that mimicked the oropharynx (Figure 2.6 – Path A). A 
salmeterol/fluticasone 50 mcg/ 250 mcg DiskusTM DPI was also used. Relative 
air humidity was determined using a Testo 410 Humidity Meter [Testo, 
Hampshire, UK]. For Path A relative air humidity was measured as 28%.  
To recreate the effect of an exhalation containing humid air, the high capacity 
airflow pump and critical flow controller were connected in series with a three-
outlet round bottom flask placed in an inductive heater, as shown in Figure 2.6 
- Path B. The outlet of the round bottom flask was attached to the glass
adaptor. Relative air humidity for Path B was measured as 80%, analogous to 
the relative humidity of actual exhaled air.(153) Detailed pictures of the 
equipment used are shown in Figure 2.7.   
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Figure 2.6: Experimental setup used to investigate the impact of exhalations 
on drug delivery in a dry powder inhaler. Air was propelled at various flow 
rates and durations through variable flow paths. Path A represents dry air at a 
relative humidity of 28% and Path B included a round bottom flask filled with 
boiled water to bring the humidity of the air to 80% relative humidity. Finally 
the distance between the artificial mouthpiece and the inhaler mouthpiece was 
also varied.   
Figure 2.7: Images of glassware, heating device and clampstand used to 
simulate humidified exhalations into the DiskusTM inhaler mouthpiece. 
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Dry air (relative humidity of 28%) was blown at the inhaler at flow rates of 30, 
60, 90, 120 l/min, for durations of 2, 4, 6 seconds and at distances of 0, 5, 10 
cm from the inhaler. Each trial was completed three times in total for all of the 
conditions (36 variations x 3 runs). After each trial, the inhaler was connected 
to the DUSA apparatus and the delivered dose was determined. This 
corresponds with Path A as shown in Figure 2.6. 
The round bottom flask was three-quarters filled with distilled water and 
heated to boiling point to obtain humidified air (relative humidity of 80%). Air 
travelled on Path B, as demonstrated in Figure 2.6, for this section of testing. 
The above procedure was repeated at varying flow rates, distances and 
durations and repeated three times for each condition (36 variations x 3 runs). 
Finally the delivered dose was determined post-exhalation using a DUSA.  
The DUSA apparatus was connected to a high capacity vacuum pump [HCP4, 
Copley Scientific, Nottingham, UK] and Critical Flow Controller [TPK 2000, 
Copley Scientific, Nottingham, UK]. The Flow Controller was operated at 60 
l/min at a pressure drop of 4 kPa for a duration of 4 seconds 
2.3.1.3. Data Analyses 
Data Analysis was carried out in Stata version 13. Multivariate regression 
analysis was performed to investigate what exhalation factors had a significant 
effect on drug delivery. Eta squared and partial eta squared values were 
calculated to interpret the individual effect size for the four exhalation factors. 
Eta squared measures the proportion of the total variance in a dependent 
variable that is accounted for by variation in the independent variable. It is the 
ratio of the between groups sum of squares to the total sum of squares. Partial 
eta squared measures the proportion of variance accounted for by an effect to 
the proportion of variance accounted for by the same effect plus its associated 
error variance (i.e., the effects of other independent variables and interactions 
are partialled out). 
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2.3.1.4. Particle size distribution of emitted dose 
Testing was carried out to investigate the effect of humid air exhalations on the 
particle size distribution of the total emitted dose (TED) for the DiskusTM DPI. 
To investigate this, the TED and fine particle fraction (FPF) from a DiskusTM 
that had previously been subjected to an exhalation were compared to TED 
and FPF obtained from a DiskusTM that was not subject to an exhalation.  
In vitro drug deposition and aerodynamic particle size of the delivered dose 
from the DiskusTM DPI was characterized using a Next Generation Impactor 
(NGI) (US Pharmacopoeia 601, Apparatus 5).(147) The NGI was used with a 
pre-separator and cups 1-8. A high capacity vacuum and critical flow controller 
were attached to the air intake port. Inhalations were performed at a flow rate 
of 60 L/Min, pressure drop of 4 kPa and duration of 4 seconds. NGI impaction 
cups 1-5 were lined with filter papers and with 2 ml of a mixture of methanol: 
acetonitrile: water (25:25:50). Cups 6-8 were coated only with 2 ml of solvent. 
This was to prevent particle bounce and re-entrainment.(148) 
To investigate the effect of exhalations on drug delivery in a DPI, the test 
setup explained previously was employed to exhale air at a flow rate of 60 
l/min, for a duration of 4 seconds and using air with a relative humidity of 80% 
at a DiskusTM DPI. Exhalations were carried out on five separate DiskusTM
DPI’s in order to preserve the possible humidity effect from each trial. A 
regular DiskusTM DPI that was not subjected to any exhalations was used to 
compare the effects of the exhalations. 
The TED was determined as the sum of the total drug recovered from the 
throat, pre-separator, and cups 1-8 of the NGI. This was averaged for each 
study condition. The Fine Particle Dose (FPD), i.e. cumulative drug dose less 
than particle size 5 μm, was calculated by interpolation on a log-probit plot 
using pre-specified stage cutpoints at each flow rate. The Upper Airway Dose 
(UAD) corresponded to the cumulative drug dose above an aerodynamic 
particle size of 5 μm. Mass Median Aerodynamic Diameter (MMAD) and 
Geometric Standard Deviation (GSD) were also calculated at each study 
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condition for both formulations using published methods.(151, 152) The TED, 
FPD and UAD for the standard emitted dose and the post-exhalation emitted 
dose were compared. 
2.3.1.5. Measurement of salmeterol and fluticasone 
The method described in section 2.2.4.3. was used to measure salmeterol and 
fluticasone concentrations using HPLC-UV. 
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2.3.2. Relationship between simulated exhalations and acoustic features 
The INCATM acoustic recording device was attached to the DiskusTM inhaler 
during experimentation to investigate the effect of different exhalation factors 
on delivered dose, and if acoustic features could be used as a means to 
analyse exhalations. Temporal and spectral features of the exhalation signal 
were analysed to investigate the feasibility of using acoustics to analyse 
exhalations during inhaler use. The mean absolute deviation (MAD) and 
average power (Pave) of the exhalation signal were computed and compared to 
the flow rate of the exhalations and to the distance of the exhalations from the 
inhaler mouthpiece. Exhalations were divided into 1024 data samples with 
50% overlap between successive frames. A Hanning window was used to 
analyse each frame, while a Fast Fourier Transform (FFT) was used to 
calculate the power spectral density (PSD). Pave was calculated for 
frequencies between 300 – 600 Hz. Previous studies have reported that this 
frequency band shows the best correlation between airflow rate and sound 
power.(146, 154) MAD is the mean of the absolute deviations from the central 
value. It was calculated using the following equation: 
𝑀𝐴𝐷 =  
1
𝑛
∑ |𝑥𝑖 −  ?̅?|  (2.4)
𝑛
𝑖=1   
Correlations between the simulated expiratory flow rates and distances from 
the inhaler are presented in the results section.   
2.3.2.1. Acoustic method of automatically detecting exhalations 
As previously mentioned, exhalations occurring prior to the inhalation step 
during inhaler use are crucial to detect as they affect pulmonary drug delivery. 
Previous studies have investigated the detection of exhalations during normal 
relaxed breathing, in speech and song signals, however, the detection of 
exhalations recorded during inhaler use have never been investigated in 
detail.(155, 156) In this study a training database of inhaler audio files was 
employed to develop an algorithm to automatically detect exhalation events 
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from non-exhalation events in the audio signals. The algorithm developed was 
then subsequently tested for sensitivity, specificity and accuracy using a 
validation dataset of audio files obtained from separate patients.   
2.3.2.2. Exhalation Detection Algorithm 
Filter-bank energies (FBEs) obtained from calculation of the Mel Frequency 
Cepstral Coefficients (MFCCs) are used as features to detect exhalations in 
the audio signals in this study. FBEs are physically meaningful quantities that 
are known to correlate with human auditory processing.(157) Audio events 
(exhalation and non-exhalation events) were automatically detected using an 
adaptive energy threshold in this study (Figure 2.8). Exhalations were 
segments with higher energy in certain frequency regions compared to other 
background noises in the audio signals. The FBEs are computed using the 
following steps: 
Signal is first epoched into frames of length 25ms (Nw), which overlap every 
10ms. 
Calculation of energy spectrum: 
𝑦(𝑘) = ∑ 𝑥(𝑛)𝑊(𝑛)𝑒
−𝑗
(2𝜋𝑛𝑘)
𝑁𝑤
𝑁𝑤−1
𝑛=0 ;     0 ≤ 𝑘 ≤ 𝑁𝑤  (2.5) 
where x(n) is the input inhaler signal and W(n) is a Hamming window. The 
energy spectrum is subsequently given by: 
𝑋 𝑘 = |𝑦(𝑘)|
2;  0 ≤ 𝑘 ≤ 𝐾  (2.6) 
where 𝐾 is taken equal to Nw/2, as only half the spectrum is considered. 
Using a lower frequency limit of 0 Hz and an upper frequency limit of 4000 
Hz, 20 filter banks were created using the following equation described in 
(158):   
𝑀(𝑓) = 2595𝑙𝑜𝑔10 (1 +
𝑓
700
)  (2.7) 
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The energy in each filter bank is then calculated: 
𝐸𝑗 = ∑ ∅𝑗(𝑘)𝑋𝑘
𝐾−1
𝑘=0 ;   0 ≤ 𝑗 < 𝐽  (2.8) 
where J, which equals 20, is the number of triangular filters (∅𝑗) used. 
FBE channels are then normalized between 0 and 1. To remove short duration 
noise artefacts in the signal, the root mean square (RMS) amplitude of 50 ms 
frames, which overlap every 10ms, are calculated.  
To detect exhalation events the average energy in filter banks 8-10 is 
calculated. It was found from empirical observation in the training dataset that 
the energy in these three filter banks was higher for exhalations in comparison 
to other audio sounds obtained during inhaler use. These filter banks 
correspond with triangular filters starting at 620 Hz and ending at 1197 Hz. 
Comparing the average energy in these three filter banks to the average FBE 
in 20 channels provides a difference waveform (DW) that can be used to 
automatically detect exhalations. 
𝐷𝑊 = 𝐹𝐵𝐸̅̅ ̅̅ ̅̅ 8−10 −  𝐹𝐵𝐸̅̅ ̅̅ ̅̅ 1−20  (2.9) 
An adaptive energy threshold was used to automatically detect and segment 
exhalations events in the DW signal. The mean of all positive values of the 
DW signal was computed and an adaptive threshold was set that was 20% 
higher than this mean value. Potential exhalations less than 200 ms in 
duration were discarded in order to avoid the false detection of sudden 
noise artefacts. This method allowed the successful classification of 
exhalations in the training dataset.     
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Figure  2.8: (a) Inhaler audio signal containing exhalation at 5s and inhalation 
at 9-11s, (b) average FBE for channels 1-20 (red) and channels 8-10 (red), (c) 
difference waveform (FBE8-10 – FBE1-20) and adaptive threshold (dashed red 
line) and (c) inhaler audio signal with automatically detected exhalation 
colored in magenta.    
2.3.2.3. Data and Statistical Analyses 
Acoustic signal processing and statistical analyses were performed using 
MATLAB_R2013b. The training database consisted of 50 audio files obtained 
from 10 patients with asthma and COPD using a DiskusTM DPI in uncontrolled 
real world scenarios. Audio signals were obtained from the INCATM acoustic 
recording device. The training database was employed to decide which 
specific FBE channels contained the largest amount of energy for exhalations 
and in the design of the adaptive energy threshold. The validation dataset 
comprised of a random cross-section of inhaler audio files obtained from 22 
separate asthma and COPD patients. Similar to the training database, the 
audio files were obtained in uncontrolled real world environments using the 
aforementioned INCATM acoustic recording device. Five audio files were 
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randomly selected from each patient to give a total of 110 audio files in the 
validation dataset.     
Two experienced respiratory clinicians independently classified each audio file 
in the validation dataset using visual and aural methods. The classification of 
the audio files by the respiratory clinicians was used as the gold standard 
method of exhalation detection. Exhalation detection performances of the 
algorithm were compared to that of the gold standard method and calculated 
using sensitivity, specificity and accuracy values.  
Cohen’s kappa statistic (k) was used to measure the agreement between the 
two respiratory clinicians. It was also employed to measure the level of 
agreement between the gold standard classification of exhalations and the 
proposed automatic detection method. The guidelines for interpreting k are as 
follows: 
Table 2.2: Interpretation of Cohen’s Kappa statistic (k) 
Cohen’s Kappa 
Statistic (k) 
Interpretation 
<0 Less than chance agreement 
0.01-0.20 Slight agreement 
0.21-0.40 Fair agreement 
0.41-0.60 Moderate agreement 
0.61-0.80 Substantial agreement 
0.81-1 Almost perfect agreement 
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2.3.3. Acoustic method of assessing exhalations during inhaler use 
A DiskusTM inhaler with an INCATM acoustic device attached was clamped to a 
stand. Healthy subjects performed subjectively variable exhalations at 
distances of 0 cm, 5 cm and 10 cm from the mouthpiece of the inhaler in 
locations located above, below and directly into the mouthpiece of the 
DiskusTM inhaler. Exhalations were also performed with a mouth seal at 
subjectively variable high and low flow rates. Forty exhalations from three 
volunteers were analysed (training dataset) to develop an algorithm for 
determining the distance of the exhalation from the inhaler mouthpiece and the 
expiratory flow rate of the exhalation. Exhalations were divided into 1024 data 
samples with 50% overlap between successive frames. A Hanning window 
was used to analyse each frame, while a Fast Fourier Transform (FFT) was 
used to calculate PSD. Pave in the frequency bands 20-40 Hz (P1), 40-70 Hz 
(P2) and 70-150 Hz (P3) was calculated. The MAD of the amplitude of the 
exhalation signals was also calculated using equation 2.1.  
The following three equations were derived from the training dataset to classify 
different aspects of exhalations: 
𝑀𝑜𝑢𝑡ℎ𝑠𝑒𝑎𝑙 𝑇𝑒𝑠𝑡 = 𝑀𝐴𝐷 > 0.002 &
𝑃2
𝑃3
> 0.91 &
𝑃1
𝑃3
> 0.91  (2.10) 
𝑆𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡 𝐸𝑥ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 = 𝑀𝐴𝐷 > 0.003  𝑜𝑟 𝑀𝑜𝑢𝑡ℎ𝑠𝑒𝑎𝑙 𝑡𝑒𝑠𝑡 = 1  (2.11) 
𝐸𝑥ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 5𝑐𝑚 = 𝑀𝐴𝐷 > 0.002 &
𝑃1
𝑃2
< 0.975  (2.12) 
Significant exhalations were classified as any exhalation performed at a 
distance of 0 cm or 5 cm from the inhaler mouthpiece, directly at the inhaler 
mouthpiece or any exhalation performed with a mouthseal. Any exhalation 
directly at the acoustic recording device was also classified as being 
significant. We also tested the sensitivity and specificity of our method for 
distinguishing between an exhalation performed at 0 cm and one performed at 
5 cm. 
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To test the robustness of equations 2.10 - 2.12 in classifying exhalations, 
we obtained a validation dataset of fifty exhalations from 4 healthy subjects. 
Temporal and spectral features of the exhalation signal were extracted and 
employed to classify the exhalations. Classification results were compared 
with documented conditions for the exhalations in the validation dataset to 
obtain sensitivity and specificity values of the method in determining 
significantly detrimental exhalations.  
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2.4. Does orientation of the DiskusTM inhaler affect available dose for
delivery? 
A 200mcg salbutamol DiskusTM inhaler was clamped in a horizontal position 
(designated 0°) and a petri dish was placed directly beneath the mouthpiece of 
the inhaler (Figure 2.9).  
Figure 2.9: Experimental setup to investigate the effect of DiskusTM orientation 
on drug removed from the inhaler. The DiskusTM was position at 0°, 45° and 
90° and the drug removed was collected in the petri dish, dissolved and 
analysed. 
A dose was actuated and the drug released from the inhaler was allowed to 
collect in the petri dish. The contents of the petri dish were dissolved in 5 ml 
of methanol and the sample was analysed by HPLC-UV using the method 
described in 2.2.4.3. above.  
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The DiskusTM inhaler was then held at 45° and 90° and the experiment above 
repeated. The DiskusTM was then clamped at 90°, a dose actuated and the 
inhaler was either tapped or shaken. Five replicates were performed for each 
experimental condition. 
The mean drug lost from the inhaler under each experimental condition was 
calculated and compared with the drug lost in the horizontal position using a t-
test.  
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2.5. The impact of breath holding duration on drug delivery 
2.5.1. Study protocol 
This was a prospective study of seven healthy volunteers using a salbutamol 
200mcg DiskusTM inhaler.  The inclusion criteria allowed for recruitment of 
healthy participants older than 18 years of age and non-frequent users of 
salbutamol.  
Each participant received DiskusTM inhaler technique training and was 
assigned to do a control ‘phase’, consisting of six doses of the drug taken six 
hours apart with correct technique and a breath hold duration of 10 seconds. 
Blood samples were collected before and 25 minutes after doses one and six. 
Blood samples were collected in 7.5 ml serum separator tubes and allowed to 
coagulate for 25 minutes. Tubes were then centrifuged at 5000 g for 15 
minutes and 2-3 ml of serum pipetted into vials for storage at -20 oC. 
This was followed by a washout period of at least 3 days (12 half-lives). The 
volunteers then repeated the above procedure, this time with low breath hold 
duration of approximately 4 seconds. 
The INCATM device was used to monitor time of inhaler use, inhaler technique 
and breath hold duration. The audio signature of each breath was analyzed 
with the software Audacity. At the end of each phase, the inhalers were 
collected and stored at the lab.  
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2.5.2. Measurement of serum salbutamol 
Serum salbutamol concentration was measured using a method adapted from 
Sidler-Moix et al.(159) Salbutamol sulphate was purchased from Sigma Aldrich 
[St. Louis, MO, USA] and salbutamol-d4, the internal standard (IS), was 
purchased from Toronto Research Chemicals [Toronto, Ontario, Canada]. All 
chemicals and solvents were of analytical grade and used as received. 
Protein precipitation was used to prepare samples for subsequent analysis. 
Briefly, a 300 μl aliquot of serum was added to Eppendorf tubes, followed by 
25 μl of internal standard (500 ng/ml of salbutamol-d4 in acetonitrile) and the 
tubes were vortexed for 30 seconds. 0.9 ml of acetonitrile was added to each 
tube and the mixture vortexed for 2 minutes and then centrifuged at 5000g for 
10 minutes. The supernatant was transferred to new tubes and was 
evaporated to dryness under nitrogen gas at room temperature. The residue 
was reconstituted in 150 μl of 0.5% formic acid in water and vortexed for 2 
minutes. The solution was then subjected to further analysis as outlined below. 
The high-performance liquid chromatography system was a Waters Alliance 
2795 separation module with quaternary pump and autosampler, controlled by 
Waters MassLynx software [Waters Corporation, MA, USA]. The separations 
were carried out on a 2.1x50 mm Atlantis T3 3 μm analytical column [Waters 
Corporation, MA, USA]. The chromatographic system was coupled to a Waters 
Quattro Micro triple quadrupole mass analyzer with an Electrospray Ionization 
(ESI) source.  
The mobile phase used consisted of 10 mM ammonium formate in ultrapure 
water containing 0.1% FA (= solution A) and acetonitrile with 1% FA 
(solution B). The following stepwise gradient elution protocol was used: 
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Table 2.3: Gradient elution protocol for measurement of serum salbutamol by 
HPLC-ESI-MS/MS 
Time (min) Flow Rate 
(ml/min) 
Solvent A Solvent B 
0.0 0.3 95 5 
3.0 0.4 95 5 
7.0 0.4 20 80 
8.0 0.4 20 80 
9.0 0.3 95 5 
10.0 0.3 95 5 
Solvent A = 10mM ammonium formate in ultrapure water containing 0.1% FA; 
Solvent B = acetonitrile with 1% FA 
ESI was set in positive ionization mode and operated at a capillary voltage of 
3.5 kV. The source temperature was set at 120°C, the desolvation 
temperature was set at 350°C and the desolvation gas flow was 650 L/h. The 
cone voltage was 30 V, the extractor voltage was 2 V and the RF lens voltage 
was 0.1 V. MS1 and MS2 low and high mass resolutions were set at 15. Ion 
Energy 1 was 1.2 and Ion Energy 2 was 1.0. Entrance potential was -2 V and 
exit potential was 2 V. The multiplier potential was 650 V. Mass spectra were 
acquired in the Multiple Reaction Monitoring mode. The optimal potential 
settings and the MS/MS transitions were determined by direct infusion into the 
MS/MS detector of salbutamol and IS solutions separately at a concentration 
of 10 μg/mL in methanol (Table 2.4). 
Table 2.4: Instrument method for determination of salbutamol and salbutamol-
d4 by ESI-MS/MS. 
Analyte Precursor 
(m/z) 
Product 
(m/z) 
Collision 
Energy (eV) 
Retention 
Time (min) 
Salbutamol 240.1 147.8 25 4.54 
Salbutamol-
d4 
244.1 151.9 23 4.52 
A representative chromatogram is shown in Figure 2.10. 
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Figure 2.10: Sample chromatogram showing salbutamol (labeled Albuterol) 
and salbutamol-d4 (labeled int_std) peaks at a retention time of 4.54 and 4.52 
min, respectively. 
Calibrators were made by spiking blank serum obtained from the blood 
donation center with known amounts of salbutamol standard at the following 
concentrations: 10.00, 5.00, 2.50, 1.25, 0.64, 0.32, 0.16, 0.08, 0.04 ng/ml. 
Quality control samples were also made at the following levels: 7.50, 1.00 and 
0.10 ng/ml. A standard curve was fitted using the internal standard response 
ration method and linear regression with 1/x weighting. 
Method imprecision was determined by performing 5 replicates per day for 5 
days at all 3 levels of QC. Total imprecision was 12% at the LQC, 6% at the 
MQC and 5% at the HQC. Recovery studies were performed by spiking known 
concentrations of salbutamol into the 3 QCs and values were determined to be 
between 85 and 115% at all QC levels. The limit of detection for the assay 
was 0.01 ng/ml and the limit of quantification was 0.04 ng/ml. 
2.5.3. Data analysis 
Statistical analysis was done using Stata version 13. Peak and trough 
salbutamol levels were compared between the 10 second breath hold and the 
4 second breath hold using a box-plot and t-test. 
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2.6. The impact of missed doses on steady state trough and peak levels 
2.6.1. Study protocol 
This was a prospective study of seven healthy volunteers using a salbutamol 
200 mcg DiskusTM inhaler.  The inclusion criteria allowed for recruitment of 
healthy participants older than 18 years of age and non-frequent users of 
salbutamol.  
Each participant received DiskusTM inhaler technique training and was 
assigned to do a control ‘phase’, consisting of six doses of the drug taken six 
hours apart with correct technique. Blood samples were collected before and 
25 minutes after doses one and six. Blood samples were collected in 7.5 ml 
serum separator tubes and allowed to coagulate for 25 minutes. Tubes were 
then centrifuged at 5000 g for 15 minutes and 2-3 ml of serum pipetted into 
vials for storage at -20 oC. 
This was followed by a washout period of at least 3 days (12 half-lives). The 
volunteers then repeated the above procedure, this time missing doses three 
and four, that is, taking doses 1, 2, 5 and 6. Sampling was again done before 
and 25 minutes after doses one and six.  
The INCATM device was used to monitor time of inhaler use and inhaler 
technique. The audio signature of each breath was analyzed with the software 
Audacity. At the end of each phase, the inhalers were collected and stored at 
the lab.  
2.6.2. Measurement of serum salbutamol 
Serum salbutamol concentration was measured using the ESI-LC-MS/MS 
method outlined in section 2.5.2. 
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2.6.3. Data analysis 
Statistical analysis was done using Stata version 13. Peak and trough 
salbutamol levels were compared between the control phase and missed dose 
phase using a connected dot plot and t-test. Results were also compared to 
expected results based on the half-life of salbutamol and a first-order kinetic 
model represented by: 
𝑡
𝑇)  (2.13) 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝐶 = 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝐶0 ∗ 𝑒
−0.673∗
𝑤ℎ𝑒𝑟𝑒 𝑡 = 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 𝑡𝑖𝑚𝑒 𝑎𝑛𝑑 𝑇 = ℎ𝑎𝑙𝑓-𝑙𝑖𝑓𝑒 
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2.7. Development and validation of an algorithm for combining time and 
technique of inhaler use into a single metric 
2.7.1. Algorithm development 
A pharmacokinetic model was developed using features obtained from the 
INCATM device: 
1) Date and time of use
2) Technique errors
a. Failure to actuate dose
b. Exhalation towards the mouthpiece
c. Low peak inspiratory flow rate
d. Short breath hold duration
e. Multiple inhalations (causing short breath hold duration)
The above technique errors were considered significant from the in vitro and in 
vivo experiments outlined in previous sections. 
MATLAB_R2013b and Stata version 13 were used to develop the 
pharmacokinetic model. The model was based on first-order kinetics for 
salmeterol, using an estimated drug half-life of 12 hours. 
2.7.2. Comparison of algorithm adherence rates with dose counter rate in a 
patient cohort 
Audio recordings from 20 patients were drawn from our INCATM asthma 
database in order to compare adherence rates over a period of 1 month 
between the dose counter on the DiskusTM inhaler and those derived from 
analysis of the time-stamped acoustic files. Two independent raters reviewed 
all audio files for the purpose of classification of technique errors. Agreement 
between raters was 90% (Cohen’s kappa). Patients were classified into one of 
three categories based on the combination of temporal and technique 
adherence: 
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Class 0 – Poor overall adherence 
Class 1 – Moderate overall adherence 
Class 2 – Good overall adherence 
Data analysis was done in Stata version 13. Adherence rates were compared 
using a boxplot and a scatterplot matrix to reveal trends, and Spearman’s and 
Pearson’s correlation coefficients with associated p values were determined 
for all pairwise comparisons. Representative scatterplots and bar graphs 
showing the pattern of inhaler use over the course of the month are also 
presented for each subject.  
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CHAPTER 3: How common are DiskusTM inhaler temporal and technique 
errors in a community care setting? 
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3.1. Results 
3.1.1. Patient demographics 
One hundred and twenty three patients were enrolled for an average of 29.6 
days (range: 21-41). After excluding devices that were not returned and 
device failures, acoustic recordings were available from 103 patients, with 
5045 audio files. There were 5228 doses taken according to the dose counter 
(p<0.001 for difference between dose counter and acoustic recordings). 
Table 3.1: Patient demographic data from respiratory cohort given INCATM 
enabled DiskusTM for one month. 
Average Age (range) 57.2 (22-91) 
Gender (M:F) 46:57 (45:55%) 
Diagnosis 65% Asthma 
32% COPD 
3%   Other 
Smoking History 40% Non-Smoker  
40% Current Smoker 
20% Ex-Smoker 
Education Level 42% Primary 
42% Secondary 
15% College 
3.1.2. Errors in inhaler technique 
3823 (76%) acoustic profiles demonstrated good inhaler technique; a 
visual profile of the acoustic signal associated with correct inhaler 
technique is shown in Figure 3.1.  
Parameter Mean or %
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Figure 3.1: Visual representation of acoustic profile showing correct inhaler 
technique. 
Poor peak inspiratory flow rate (PIFR) was the most common inhaler 
technique error identified;  325 (27%) inhalations were performed with a 
PIFR< 35 l/min (shown in Figure 3.2).  
Figure 3.2: Visual representation of acoustic profile showing low inspiratory 
flow. 
116 
Other errors included: dose actuation or blistering with no subsequent 
inhalation - 229 (19%) audio files; exhalation into the inhaler after dose 
actuation and prior to inhalation (Figure 3.3) - 217 (18%) events; multiple 
inhalations (Figure 3.4) - 301 (25%) inhalations; multiple blisters (Figure 3.5) 
- 72 (6%) of audio files; and rarer events, including cough after inhalation
(Figure 3.6), failure to actuate dose (Figure 3.7) and shaking of the inhaler
after dose actuation (Figure 3.8).
Figure 3.3: Visual representation of acoustic profile showing exhalation 
directed towards device prior to inhalation. 
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Figure 3.4: Visual representation of acoustic profile showing multiple 
inhalations. 
Figure 3.5: Visual representation of acoustic profile showing multiple dose 
actuations or blisters. 
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Figure 3.7: Visual representation of acoustic profile showing failure to blister or 
actuate dose. 
Figure 3.6: Visual representation of acoustic profile showing bout of coughing 
after inhalation. 
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Figure 3.8: Visual representation of acoustic profile showing shaking of inhaler 
after blister or dose actuation. 
While errors were common, ranging from 100% (i.e. a patient who made 
persistent technique errors) to 0% it is noteworthy that among the studied 
cohort there was a wide variation in the frequency of inhaler technique user 
errors and the mean number of errors per person was 12 per 60-dose inhaler 
(20%). A breakdown of inhaler technique errors observed is shown in Table 
3.2. 
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Table 3.2: Frequency of errors in inhaler handling among the 103 patients. 
Instruction Audio Error Frequency 
 (% of all 
errors) 
Average per 
patient 
(range) 
Total number 1204 (24%) 12 (0-60) 
Blister 
No Blister, Inhale 
Detected 
24 (2%) 0.23 (0-4) 
Multiple Blisters 72 (6%) 0.68 (0-23) 
Dose Dumping 36 (3%) 0.34 (0-23) 
Breath out deeply 
away from the inhaler 
Exhales into 
inhaler with 
sufficient energy 
to displace >30% 
of dose 
217 (18%) 2.17 (0-46) 
Inhale deeply 
Blister present, 
No Inhale 
229 (19%) 2.28 (0-47) 
Low PIFR (<35 
l/min) 
325 (27%) 3.25 (0-60) 
Hold breath for > 5 sec 
Multiple 
Inhalations 
301 (25%) 3.05 (0-50) 
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3.1.3. Errors in time of use of the inhaler 
Only twenty-one (20%) patients demonstrated correct technique and temporal 
adherence. Twenty (19%) individuals used more than 2 doses in a day for at 
least two consecutive days, with 66 episodes of clustered overdosing, see 
Table 3.3. 
On the other hand, twenty-seven (26%) individuals had at least one incidence 
of a four half-life interval between doses, leading to 56 sub-therapeutic or 
non-therapeutic drug intervals.  Thirty-eight (37%) individuals missed taking 4 
doses over two days, leading to 97 episodes with clustered missed doses.    
Table 3.3:  Breakdown of different measures of adherence, showing the 
number of doses expected to be taken over the time, the number of doses 
actually taken during the study period judged from the dose counter, the 
number of doses attempted based on the number of audio files, number of 
doses successfully taken without technique errors, frequency of missed doses 
and overdoses and the number of technique errors. 
Total Average per 
Patient 
Range 95% 
CI 
Number of doses expected 6180 60 - - 
Number of doses taken (dose counter) 5228 
(85%) 
55 12-60 53-57
Number of doses taken (INCA) 5045 
(82%) 
49 3-67 46-52
Number of doses without technique errors 
(INCA) 
3823 
(76%) 
34 0-60 30-38
Number of episodes of significant clusters 
of missed doses 
97 0-8 0.63-
1.3 
Number of episodes of significant clusters 
of overdoses 
66 0-14 0.24-
1.0 
Number of errors 1204 
(24%) 
12 0-60 9-15
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3.1.4. Variations in inhaler use over time 
The rate of adherence over the 4 weeks of observation were clustered into 
four patterns of adherence. A group of patients started with good adherence 
and ended with poor adherence (slope < - 0.05), Figure 3.9(a).  One group 
demonstrated poor adherence throughout and another group had good 
adherence throughout (slope between -0.05 and 0.05), Figure 3.9(b) and 
3.9(c). The last group had a significant improvement in adherence to 
approximately 80% (slope > 0.05), Figure 3.9(d).  
Figure 3.9: Variation in inhaler use over time. (a) Good initial adherence 
followed by poor adherence; (b) good adherence throughout study; (c) poor 
adherence throughout study; and (d) poor initial adherence followed by good 
adherence. Attempted rate represents the rate determined from the number of 
audio files retrieved from the INCATM device. Actual rate represents the 
attempted rate minus the rate of technique errors. 
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3.1.5. Determinants of adherence 
There were no statistically significant relationships between adherence rates 
and age, gender, smoking history, GP use, diagnosis, exacerbations or 
hospitalizations. Lower technique error rate was associated with higher socio-
economic class and private health insurance (p<0.01), while patients with 
secondary level education demonstrated better combined adherence 
(p=0.015).   
3.2. Discussion 
Practice guidelines suggest addressing aspects of inhaler adherence and 
technique prior to escalation of drug therapy.(13) The INCATM device was 
applied in a community care setting to investigate the prevalence of technique 
and temporal non-adherence to inhaler therapy and to identify the most 
common technique errors. The findings show that errors in both over/under-
use, multiple doses and errors in inhaler handling are equally common.   
Failure to achieve a sufficient inhalation flow rate, drug blistering with no 
subsequent inhalation, exhalation of humid air into the dry powder inhaler and 
rapid exhalation after inhalation constituted 21% of all events and were the 
most common technique errors, often in combination. However, technique 
errors were not present in all inhalations from the same individual and were 
interspersed with events demonstrating correct technique, highlighting the 
day-to-day variation in inhaler use in this setting.  
Temporal adherence was also variable. Only 41 patients had good temporal 
adherence (adherence rate > 80%) throughout the study period. A significant 
proportion (one third) had a decline in their rate of adherence over time, which 
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may have been due to a ‘Hawthorne effect’, that is, as patients received the 
device they were initially adherent to the medication, and this declined over 
time. Another group had improved adherence over the study period over time. 
Finally, two more groups had relatively constant adherence; one group with 
good adherence and one with poor adherence. These variations have been 
difficult to capture with previous measures of adherence since all prior 
methods involve averaging of doses over a period of time. It is clear that 
inhaler adherence changes with time, likely in response to underlying disease 
or social factors. Only by monitoring these trends, can inhaled therapy be 
personalized for individual patients. 
This study has several limitations. The setting in which this study was 
performed (community care) may limit the generalizability of the findings to 
clinical research or secondary/ tertiary care settings.  Nevertheless, we were 
able to describe adherence in a large group of patients, who represent the 
most common users of inhalers. The lack of a significant relationship between 
variables such as age, disease severity or diagnosis and adherence may be 
due to the small sample size and lack of statistical power. Future studies 
should specifically assess adherence in different age groups, different disease 
severities, different socio-economic classes and education histories.  In order 
to explore this, longer, larger and intervention based studies are currently 
underway in both asthma and COPD using the INCATM device. Finally, this 
study did not assess symptoms or measures of disease control, since a 
longer follow-up period exceeding 6 months is required. 
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CHAPTER 4: The effect of inhalation parameters on delivered dose and 
an acoustic method to quantify this effect 
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4.1. The relationship between baseline spirometric PIFR/ IC and DiskusTM 
inhalation parameters: Is baseline spirometry sufficient for estimating 
peak flow from a DiskusTM DPI? 
4.1.1. Results 
Table 4.1 shows the demographics and baseline lung function parameters for 
the study subjects. Approximately two thirds of the recruited patients had a 
diagnosis of obstructive airways disease (32% asthma and 32% COPD). 
Twenty seven percent were either healthy or had a non-respiratory condition 
(healthy/NRC). The asthma and COPD groups were, on average, older than 
the healthy/ NRC group (p=0.001 and p<0.001, respectively). The COPD 
group was also significantly older than the asthma group (p<0.001). Gender 
and BMI differences among groups were not significant.  
Table 4.1: Demographics and baseline lung function tests for patients by 
disease category. 
All Asthma COPD NMD Healthy/ 
NRC 
Number 85 27 27 8 23 
Age 
(years) 
51.8±17.8 
(18-80) 
52.6±15.9 
(18-76) 
66.0±8.4 
(44-80) 
41.9±19.6 
(18-78) 
37.8 ± 14.6 
(20-65) 
Gender 
(M:F%) 
42:58 30:70 37:63 75:25 52:48 
BMI 
(kg/m2) 
27.6±6.8 
(16.7-49.2) 
27.0±6.0 
(16.7-37.8) 
26.2±5.3 
(18.0-38.0) 
29.0±8.6 
(21.3-48.2) 
29.5±8.6 
(19.5-49.2) 
FEV1
(L) 
2.02±1.04 
(0.24-5.07) 
1.74±0.70 
(0.93-3.38) 
1.56±0.75 
(0.24-3.05) 
1.29±1.21 
(0.33-3.06) 
3.13±0.90 
(1.58-5.07) 
FVC 
(L) 
2.75±1.12 
(0.38-5.66) 
2.45±0.78 
(1.23-3.99) 
2.41±0.79 
(0.63-3.60) 
1.69±1.69 
(0.38-4.18) 
3.83±1.02 
(1.89-5.66) 
FEV1/ 
FVC 
0.72±0.16 
(0.35-0.99) 
0.71±0.16 
(0.44-0.94) 
0.62±0.16 
(0.35-0.85) 
0.80±0.09 
(0.71-0.90) 
0.83±0.08 
(0.70-0.99) 
NRC: Non-respiratory condition; NMD: Neuromuscular disease 
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The FEV1 and FVC were significantly lower in the asthma, COPD and 
neuromuscular disease (NMD) groups compared to the healthy/ NRC 
controls (p<0.002 for all comparisons). As expected, asthmatics and COPD 
patients had a lower FEV1/FVC ratio compared to both the NMD and healthy/
NRC groups. 
Figure 4.1: Mean and 95% Confidence Interval plots for (a) spirometric PIFR 
versus patient disease group; (b) DiskusTM PIFR versus patient disease group; 
(c) spirometric IC versus patient disease group; and (d) DiskusTM IC versus
patient disease group. Healthy/ non-respiratory condition (NRC): 
n=23, asthma: n=27, chronic obstructive pulmonary disease (COPD): 
n=27, neuromuscular disease (NMD): n=8. 
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Figure 4.1 shows the mean spirometric PIFR and 95% confidence interval for 
the 4 groups of patients studied. The mean spirometric PIFR was significantly 
lower for the COPD and NMD groups compared to the asthma or healthy/ 
NRC groups (p≤0.001, see Tables 4.2 and 4.3). These trends were also seen 
for mean DiskusTM PIFR values (Figure 4.1(b) and Table 4.2). The mean 
spirometric PIFR for the NMD group was significantly lower than that for the 
COPD group (p=0.005, see Tables 4.2 and 4.3). The DiskusTM PIFR for the 
COPD and NMD groups was more than 10 l/min lower than the healthy or 
asthma groups and was significantly lower than 60 l/min (p<0.05, see Tables 
4.2 and 4.3). The proportions of patients in each group with a DiskusTM PIFR < 
60 l/min (the threshold for optimum drug delivery from the DiskusTM inhaler) 
were significantly different (Table 4.4). 
Table 4.2: Mean values for spirometric and DiskusTM PIFR or IC according to 
patient disease group. 
DiskusTM 
PIFR 
Spirometric 
PIFR 
DiskusTM IC Spirometric 
IC 
Healthy/ NRC 64.57±25.12 
(20-97) 
247.87±104.35 
(59-456) 
2.69±1.24 
(0.27-4.92) 
3.37±1.16 
(1.02-5.42) 
Asthma 61.56±22.15 
(17-102) 
209.41±83.26 
(59-415) 
1.94±0.70 
(0.60-3.37) 
2.42±0.73 
(1.17-3.78) 
COPD 49.37±15.68 
(22-83) 
143.46±62.98 
(55-275) 
1.86±0.80 
(0.36-3.34) 
2.13±0.79 
(0.71-3.59) 
NMD 41.83±24.03 
(10-88) 
97.53±33.54 
(55-153) 
1.24±1.13 
(0.33-3.87) 
1.46±1.19 
(0.42-4.13) 
NRC: Non-respiratory condition; NMD: Neuromuscular disease 
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Table 4.3: p values for one-sided independent samples t-tests for comparisons 
of spirometric and DiskusTM PIFR between patient disease groups.(s) 
represents spirometric values and (d) represents DiskusTM values. 
Peak Inspiratory Flow Rate (PIFR) 
Healthy/ NRC Asthma COPD NMD 
Healthy/ NRC -- NS (d) 0.009 (d) 0.019 (d) 
Asthma NS (s) -- 0.012 (d) 0.030 (d) 
COPD 0.000 (s) 0.001 (s) -- NS (d) 
NMD 0.000 (s) 0.000 (s) 0.005 (s) -- 
NS: not significant at an alpha of 0.05. NRC: Non-respiratory condition; NMD: 
Neuromuscular disease. 
Table 4.4: Number of patients in each disease group with a DiskusTM PIFR 
greater than or equal to 60 l/min and less than 60 l/min. Results from Chi-
squared test are shown. The null hypothesis is that the proportions of patients 
with a DiskusTM PIF value less than or equal to sixty is independent of their 
diagnosis. As the test statistic is greater than the critical value, we can reject 
the null hypothesis. 
PIFR 
(l/min) 
Healthy/ 
NRC 
Asthma COPD NMD Totals 
≥ 60 14 15 8 1 38 
<60 9 12 19 7 47 
Totals 23 27 27 8 85 
Chi-squared Statistic= 8.04; Critical Value= 7.815; df= 3. NRC: Non-respiratory 
condition; NMD: Neuromuscular disease. 
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The mean spirometric and DiskusTM IC values with 95% CIs and the p-values 
for differences between group means are shown in Figures 4.1(c) and 4.1(d) 
and Tables 4.2 and 4.5, respectively. The mean spirometric and DiskusTM IC of 
the healthy/NRC group was significantly (> 0.75 L) higher than the mean for 
the other three groups (p≤0.001 for spirometric PIFR; p=0.004 for DiskusTM 
PIFR). The spirometric IC was also higher for the asthma and COPD groups 
compared to the NMD group; the differences were not statistically significant 
except for the spirometric IC from the asthma group compared to the NMD 
group (p=0.03). 
Table 4.5: p values for one-sided independent samples t-tests for comparisons 
of spirometric and DiskusTM IC between patient disease groups.(s) represents 
spirometric values and (d) represents DiskusTM values. 
Inspiratory Capacity (IC) 
Healthy/ NRC Asthma COPD NMD 
Healthy/ NRC -- 0.004 (d) 0.004 (d) 0.004 (d) 
Asthma 0.001 (s) -- NS (d) NS (d) 
COPD 0.000 (s) NS (s) -- NS (d) 
NMD 0.001 (s) 0.030 (s) NS (s) -- 
NS: not significant at an alpha of 0.05. NRC: Non-respiratory condition; NMD: 
Neuromuscular disease. 
The p-values for two-sided independent samples t-tests for age groups, BMI 
groups and gender groups are shown in Table 4.6. The mean values for all 
four measured flow rate and volume parameters were significantly higher in 
younger patients (age <50 years). There was no difference between the obese 
(BMI >30 kg/m2) versus non-obese groups or the male versus female groups. 
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Table 4.6: Mean differences and p values for two-sided independent samples 
t-tests for comparisons of spirometric or DiskusTM PIFR or IC across age
groups, gender or BMI groups. 
Age  
(<50 vs >=50) 
Male vs Female BMI  
(<30 vs >=30) 
DiskusTM PIFR 9.61 (0.025) -0.429 (NS) 3.609 (NS) 
Baseline PIFR 48.33 (0.017) 23.543 (NS) -2.082 (NS)
DiskusTM IC 0.4803 (0.030) 0.2187 (NS) 0.1492 (NS) 
Baseline IC 0.7755 (0.003) 0.8289 (NS) 0.0646 (NS) 
  (3.1) 
NS: not significant at an alpha of 0.05. 
The stepwise deletion regression showed that gender, height, weight, BMI, 
FEV1, FVC and FEV1/FVC were not significantly correlated with Diskus
TM PIFR 
at a significance level of 0.05. DiskusTM PIFR was moderately correlated with 
spirometric PIFR and age (adjusted R2 = 0.58, p < 0.0001) and the relationship 
is described by the following equation: 
𝑃𝐼𝐹𝑅 𝐷𝑖𝑠𝑘𝑢𝑠= 0.139498* 𝑃𝐼𝐹𝑅𝑆𝑝𝑖𝑟𝑜𝑚𝑒𝑡𝑟𝑖𝑐 - 0.2570845*𝐴𝑔𝑒 + 47.696     
𝑃𝐼𝐹𝑅𝑆𝑝𝑖𝑟𝑜𝑚𝑒𝑡𝑟𝑖𝑐: 𝑝 < 0.0001, 𝜂2 = 0.33661; 𝐴𝑔𝑒: 𝑝 = 0.019, 𝜂2 = 0.03652 
While DiskusTM PIFR from COPD and NMD patients was significantly different 
to that from healthy patients and asthmatics, this effect was modified by both 
age and spirometric PIFR in the stepwise regression and as a result, condition 
was no longer significant in the model.  A scatterplot of DiskusTM PIFR versus 
spirometric PIFR with the line of best fit are shown in Figure 4.2.  
132 
Figure 4.2: Scatterplot of DiskusTM PIFR versus spirometric PIFR showing line 
of best fit. Dashed lines represent DiskusTM PIFR of 30 l/min (minimum 
required) and 60 l/min (optimal PIFR for drug delivery). The DiskusTM dry 
powder inhaler is unsuitable in patients with a DiskusTM PIFR less than 30 
l/min. 
DiskusTM PIFR was binned according to a threshold of 60 l/min and a receiver-
operating characteristic (ROC) curve of Spirometric PIFR versus DiskusTM
PIFR category had an area under the curve of 0.89. At a spirometric PIFR 
cutoff of 196 l/min, 84% of DiskusTM PIFR values were correctly classified as 
either greater than or equal to 60 l/min or less than 60 l/min (sensitivity of 79% 
and specificity of 87%). When the DiskusTM PIFR was binned according to a 
threshold of 30 l/min, a spirometric cutoff of 115 l/min had a sensitivity of 86% 
and a specificity of 83% (86% correctly classified). The ROC Curves for a 
DiskusTM threshold of 60 l/min and 30 l/min are shown in Figures 4.3 and 4.4, 
respectively. 
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Figure 4.3: Receiver operating characteristic curve for spirometric PIFR 
versus binary DiskusTM PIFR based on threshold of 60 l/min. The solid line 
represents an AUC of 0.5. 
Figure 4.4: Receiver operating characteristic curve for spirometric PIFR 
versus binary DiskusTM PIFR based on threshold of 30 l/min. The solid line 
represents an AUC of 0.5. 
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4.1.2. Discussion 
The purpose of this study was to highlight the differences in inspiratory flow 
rates and volumes generated using a DiskusTM DPI based on patient 
demographics and underlying disease. Our results show that patients with 
COPD and neuromuscular disease do not generate as high a PIFR 
(spirometric or through DiskusTM) as healthy subjects, asthmatics or patients 
with non-respiratory conditions. Healthy subjects also have a significantly 
higher spirometric and DiskusTM IC compared to patients with respiratory-
related diseases. Numerous authors have shown that drug delivery from a 
DiskusTM DPI is dependent on the PIFR of inhalation and that ideally, the PIFR 
should be above 60 l/min for optimum fine particle delivery. It is clear that the 
decision to start a patient on an inhaled medication delivered via a DiskusTM 
DPI should take into account the age of the patient and the underlying 
disease. It is likely that the differences seen between the PIFR of asthmatics 
versus COPD patients is explained by the fact that the COPD patients who 
were recruited for this study were older than the patients in the other groups. 
The lower PIFR in the patients with Neuromuscular disease is most likely 
explained by the pathophysiology of their underlying disease process leading 
to poor muscle function and contraction. 
The second aim of our study was to determine whether spirometric PIFR 
measurements could be used to estimate whether patients would be suitable 
for the DiskusTM DPI based on PIFR criteria. There was a moderate correlation 
between spirometric and DiskusTM PIFR and the use of spirometric PIFR was 
very sensitive and specific for categorizing the DiskusTM PIFR as either greater 
than or equal to 60 l/min or less than 60 l/min.  
Based on the stepwise deletion regression, underlying condition was not a 
significant variable in the model but it is likely that the differences in DiskusTM 
PIFR seen among diseases are directly related the differences in mean age 
and spirometric PIFR among groups. As expected, COPD patients were older 
than the other groups and had lower PIFRs than asthmatics and healthy 
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patients. Since these three groups were the largest in this study, it is clear why 
DiskusTM PIFR is also related to age. Age should therefore be taken into 
account when making a decision about suitability for a DiskusTM DPI. 
It is very difficult to subjectively estimate a patient’s inspiratory flow rate 
adequacy when using a checklist to evaluate inhaler technique. In the absence 
of a Clement-Clarke In-Check DialTM for estimating DiskusTM PIFR, we believe 
that our method allows a much better estimation of the flow rate of inhalation 
from the DiskusTM than subjective assessment. Spirometric PIFR cutoffs of 196 
l/min or 115 l/min correlate with a DiskusTM PIFR of 60 l/min (optimal delivery) 
and 30 l/min (minimum required for successful use), respectively. Our study 
showed that no patient with a spirometric PIFR above 196 l/min had a DiskusTM 
PIFR below 30 l/min. The 196 l/min spirometric cutoff is more useful in the 
general practice setting. It will identify all patients who are likely to have the 
minimal required DiskusTM PIFR of 30 l/min. Any patient with a spirometric PIFR 
below 196 l/min should have further testing possibly using the Clement Clark In-
check Dial or consideration of an alternate device. 
The use of spirometric PIFR can direct the clinician to use more sophisticated 
techniques, such as the INCATM device, to train a patient and monitor his/ her 
technique longitudinally. It is noteworthy that our method for estimation of 
DiskusTM PIFR is not perfect (we could not explain about 40% of the variance 
seen in DiskusTM PIFR by using spirometric PIFR). PIFR is a very effort-
dependent measure and variations in effort exerted by the patient could 
explain the differences seen in spirometric and DiskusTM PIFR values. It is also 
likely that a patient’s inspiratory effort changes when they are acutely unwell. 
Therefore, while use of spirometric PIFR is a suitable substitute for the 
Clement Clark In-Check Dial for once off assessments of DiskusTM inhaler 
technique in a clinic setting, a method of longitudinally monitoring DiskusTM 
PIFR will be more beneficial. 
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4.2. Developing an acoustic method of estimating inspiratory flow rate 
and volume from an inhaler  
4.2.1. Results 
Table 4.7 shows the demographics and baseline lung function of the 15 
healthy volunteers enrolled in this study. The ethnic origin of subjects was 
Caucasian for 93.3% (14/15) and Hispanic for the remaining 6.7% (1/15). All 
subjects had an FEV1/FVC ratio >0.7 and a predicted FEV1 > 89%, confirming 
normal baseline lung function according to ATS standards. 
Table 4.7: Summary of demographics and baseline lung function data from all 
subjects (n=15). 
Variable Mean SD Range 
Age (years) 25.9 4.2 22-35
Gender (M:F) (9:6) 
Height (cm) 174.5 6.4 164-185
Weight (kg) 72.8 9.0 56-91
BMIa (kg/m2) 23.86 2.21 20.8-29.7 
FEV1b (L) 3.98 0.58 2.79-4.85 
FEV1b (%) Predicted 99.33 5.33 92-110
FVCc (L) 4.90 0.73 3.41-6.24 
FEV1/FVC Ratio 0.81 0.06 0.70-0.91 
PEFRd (l/min) 547.6 103.7 384-744
FIVCe (L) 4.56 0.67 3.34-5.76 
PIFRf (l/min) 402.1 82.1 276-535
a BMI – Body Mass Index 
b FEV1 – Forced Expiratory Volume in 1 second 
c FVC – Forced Vital Capacity 
d PEFR – Peak Expiratory Flow Rate 
e FIVC – Forced Inspiratory Vital Capacity 
f PIFR – Peak Inspiratory Flow Rate 
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A total of 120 audio files were obtained from the 15 subjects. 17 audio files 
were discarded due to an INCATM device formatting error. In this study the 
PIFR range of interest was between 0-100 L/Min and a subsequent 17 audio 
files were omitted that had PIFR values greater than 100 L/Min, leaving a total 
of 86 observations from the 15 subjects. For each inhalation the spirometer 
provided values for PIFR and IC. PIFR was compared to MA, MAD and RMS 
of the inhalation signal, while Pave at several select frequency bands 
(described earlier) was also compared to PIFR.  
It was found that MA, MAD and RMS were all highly correlated with PIFR 
(p<0.0001) at a significance level of α = 0.05. The coefficients of 
determination were found to be R2 = 0.8386 for MA, R2 = 0.8340 for MAD and 
R2 = 0.8320 for RMS. Pave for a range of select frequency bands was also 
calculated. Using a GLS regression model to compare PIFR to Pave it was 
found that the relationship was also highly correlated for all of the frequency 
bands (p<0.0001, α = 0.05). It is worth noting that at higher powers, the GLS 
regression model will give PIFRs exceeding the maximum possible flow rate 
through the inhaler. The Pave in the frequency band 300-600 Hz had the 
strongest correlation with PIFR, as the GLS regression model for this 
frequency band had an R2 value of 0.9079. A complete analysis of the 
relationship between Pave and PIFR for each of the frequency bands analysed 
is presented in Table 4.8. The overall results demonstrating the relationship 
between MA, MAD, RMS, Pave and PIFR can be seen in Figure 4.5. Individual 
plots of acoustic parameters versus PIFR for each subject are shown in 
Figure 4.6 – 4.9 and the associated GLS regression outputs can be found in 
Figures 4.10 – 4.13. 
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Table 4.8: Correlation scores between Pave and PIFR. 
Frequency Band 
(Hz) 
Coefficient of 
Determination (R2) 
20-40 0.7865 
40-70 0.7018 
70-150 0.8067 
150-300 0.8461 
300-600 0.9079 
70-300 0.8427 
70-450 0.8746 
100-300 0.8431 
100-450 0.7018 
150-450 0.8807 
Figure 4.5: PIFR versus (a) MA, (b) MAD amplitude, (c) RMS amplitude and 
(d) average power (Pave) in the frequency band 300-600Hz. Plotted points are
calculated PIFRs based on regression equation for each subject. Black line
represents overall regression model equation. 
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Figure 4.6: Measured DiskusTM PIFR versus median amplitude for each 
subject with linear trendline. 
Figure 4.7: Measured DiskusTM PIFR versus mean absolute deviation (MAD) 
of amplitude for each subject with linear trendline. 
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Figure 4.8: Measured DiskusTM PIFR versus root mean square (RMS) of 
amplitude for each subject with linear trendline. 
Figure 4.9: Measured DiskusTM PIFR versus average power (Pave) in 300-600 
Hz frequency band for each subject with linear trendline. 
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Figure 4.10: GLS regression results for measured DiskusTM PIFR vs Median 
amplitude. 
Figure 4.11: GLS regression results for measured DiskusTM PIFR vs mean 
absolute deviation (MAD) of amplitude. 
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Figure 4.12: GLS regression results for measured DiskusTM PIFR vs root mean 
square (RMS) of amplitude. 
Figure 4.13: GLS regression results for measured DiskusTM PIFR vs average 
power (Pave) in 300-600 Hz frequency band. 
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With the analysis of MA, MAD, RMS and Pave it is possible to estimate IC. 
Figure 4.5 demonstrates that it is possible to estimate values for PIFR from 
analysis of the inhalation signal. IC can subsequently be calculated by using 
equation 2.3. 
GLS regression demonstrated that IC can be estimated using MA, MAD, 
RMS and Pave (P<0.001, α = 0.05). The coefficients of determination (R2) for 
predicting IC were 0.9020 for MA, 0.9047 for MAD, 0.8989 for RMS and 
0.9245 for Pave in the frequency band 300-600 Hz. Figure 4.13 presents plots 
of measured DiskusTM IC versus IC estimated from MA (IC-MA), MAD (IC-
MAD), RMS (IC-RMS) and Pave (IC-Pave). Individual plots of calculated versus 
measured IC for each subject are shown in Figures 4.14 – 4.17 and GLS 
regression outputs for each acoustic parameter are in Figures 4.18 – 4.21. 
Figure 4.13: Measured IC versus IC calculated from (a) MA, (b) MAD, (c) RMS 
and (d) Pave in 300-600 Hz frequency band. Plotted points are calculated ICs 
based on regression equation for each subject. Black line represents overall 
regression model equation. 
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Figure 4.14: Measured DiskusTM IC versus IC calculated from median 
amplitude (MA) for each subject with linear trendline. 
Figure 4.15: Measured DiskusTM IC versus IC calculated from mean absolute 
deviation (MAD) amplitude for each subject with linear trendline. 
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Figure 4.16: Measured DiskusTM IC versus IC calculated from root mean 
square (RMS) amplitude for each subject with linear trendline. 
Figure 4.17: Measured DiskusTM IC versus IC calculated from average power 
(Pave) in 300-600 Hz frequency band for each subject with linear trendline. 
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Figure 4.18: GLS regression results for measured DiskusTM IC vs IC calculated 
from median amplitude. 
Figure 4.19: GLS regression results for measured DiskusTM IC vs IC calculated 
from mean absolute deviation (MAD) of amplitude. 
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Figure 4.20: GLS regression results for measured DiskusTM IC vs IC calculated 
from root mean square (RMS) of amplitude. 
Figure 4.21: GLS regression results for measured DiskusTM IC vs IC calculated 
from average power (Pave) in 300-600 Hz frequency band. 
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4.2.2. Discussion 
The aim of this study was to investigate whether acoustic features of 
inhalations could be used to estimate PIFR and IC in 15 healthy subjects. The 
main results reveal that MA, MAD and RMS of the amplitude and Pave at a 
range of different frequency bands all provided a robust method of estimating 
PIFR and IC.  The high level of correlation between PIFR and IC from the 
acoustic measurements to the ‘‘gold standard’’ method using spirometry is a 
promising result, suggesting that this approach may be used in future 
validation studies.  
Several previous studies have investigated the relationship between 
respiratory sounds and airflow. Unlike earlier studies, which have investigated 
respiratory sounds recorded on the chest wall and trachea, this study focused 
on sounds generated during inhaler use. Inhaler sounds are a mixture of both 
respiratory sounds and sounds from the inhaler itself. The microphone was 
located in the INCATM device, which was securely bonded to the inhaler in a 
location less than 5cm from the mouth. The results of this study are in 
accordance with previous research which established that variations in flow 
are reflected in the intensity and frequency distribution of the sounds 
generated.(160, 161) A study by Hossain and Moussavi indicated that Pave had 
the strongest correlation with flow rate from respiratory sounds. The results of 
the present study found that Pave had the strongest correlation with flow rate 
from inhaler sounds.(146) The study also reported that the optimum frequency 
band to calculate Pave was 150-450 Hz for healthy subjects, while in the 
present study we found this optimum frequency band to be 300-600 Hz for 
inhaler sounds. It is therefore clear to see that the sounds created by the 
inhaler are different in comparison to normal respiratory sounds. Inhaling 
through the narrow opening of the DiskusTM inhaler has created a shift in 
sound intensity towards higher frequencies. 
The additional dead space volume of the airtight container adds additional 
resistance to the overall pathway of the spirometer. This means that a slightly 
greater patient effort is required in order to obtain PIFR and IC values that 
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would have been reached without the airtight container. This could lead to 
values of MA, MAD, RMS and Pave obtained being slightly higher than they 
should be for the corresponding PIFR and IC values. However, for the 
purposes of this study it was decided that the effects of the container's dead 
space is small enough to be negligible, given that the ranges studied were 
quite large (range of 100 l/min for PIFR and 3.54 L IC). The additional dead 
space of the container also met ATS 2005 requirements for spirometry, in that 
the total dead space of the circuit was less than 350 ml. One point to consider 
in this study also is that if the sound is generated by the flow through the 
inhaler, the frequency content of the sound may be proportionally shifted to 
higher frequencies at higher flows.
The current methods of assessing patients’ inhaler technique are limited. 
At present clinicians make a subjective decision on whether a patient’s 
inhalation is sufficiently adequate for their medication to reach their airways. 
However an effective inhalation is dependent on inspiratory flow rate, which 
cannot be measured subjectively. PIFR can be measured using a Clement 
Clarke In-Check DialTM device,(162, 163) although this device is not widely 
used and when it is used, it is primarily in clinical environments. Additionally, 
the effort patients exert in front of the clinician may not correlate to the effort 
they put into using their inhaler on a day-to-day basis. The method we propose 
in this paper allows PIFR values from real world patient inhaler use to be 
acquired, in addition to IC values.  
The objective of this study was to demonstrate the feasibility of using acoustic 
measurements to estimate PIFR/IC from inhalers. The regression models are 
inherently biased to the dataset used and hence cannot be used to estimate 
the 95% CI for a population of individuals. Nonetheless, the regression outputs 
show that the 95% CIs for the variables are actually relatively small, proving 
the potential of carrying out a validation study on a larger population. There 
are numerous potential clinical applications for a system that can accurately 
predict PIFR and IC from patients’ inhalations during inhaler use. A 
standard threshold could be put in place to inform clinicians whether a patient 
performed an effective or ineffective inhalation. PIFR and IC could also be 
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monitored on a day-to-day basis, providing the opportunity to assess patients’ 
respiratory condition over time. Monitoring PIFR and IC longitudinally may 
provide the opportunity to predict and prevent exacerbations before they take 
place. Analysis of PIFR may also show when narrowing of the airways occurs, 
while analysis of IC variations might be used to study dynamic hyperinflation, 
and monitor the drop in IC associated with exacerbations. Informing patients of 
their day-to-day PIFR and IC values may also encourage them to take better 
control of their respiratory disease, as they may come to realise that a greater 
effort is required on their part, in order to help deliver the medication to their 
airways. Such active feedback may provide the opportunity to improve the 
efficacy of the medication, reduce exacerbations and lower the frequency of 
admittance to hospital emergency departments.  
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4.3. Validation of an acoustic method for estimating inspiratory flow rate 
and volume from an inhaler using acoustic measurements in a 
respiratory disease cohort. 
4.3.1. Results 
Eighteen of the 110 patients recruited had corrupted audio recordings. Table 
4.9 shows the baseline demographics and lung function for the remaining 92 
patients. The majority of the patients had obstructive airways disease, either 
asthma or COPD. Asthmatics, obese patients and patients with non-
respiratory conditions had a significantly higher PIFR than the other patient 
groups. 
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Table 4.9: Demographics and baseline lung function tests for patients by disease category. 
BMI – Body Mass Index, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital Capacity, PEFR – Peak Expiratory Flow Rate, FIVC – Forced Inspiratory Vital 
Capacity, PIFR – Peak Inspiratory Flow Rate, NMD – Neuromuscular disease, ORC – Other respiratory condition, NRC – Non-respiratory condition 
All Asthma COPD NMD Obesity ORC NRC 
Number 92 27 25 9 7 10 14 
Age 
(years) 
53.1±18.0 
(18-84) 
53.1±16.6 
(18-79) 
65.8±6.7 
(52-80) 
39.1±19.0 
(17-78) 
46.4±14.8 
(23-62) 
59.2±23.8 
(23-84) 
38.4±17.4 
(21-77) 
Gender 
(M:F%) 
42:58 30:70 44:56 78:22 86:14 30:70 29:71 
BMI 
(kg/m2) 
27.24±6.35 
(16.65-49.20) 
27.26±6.03 
(16.65-37.80) 
26.51±5.24 
(19.00-38.02) 
26.01±3.80 
(21.3-33.6) 
39.87±6.80 
(30.0-49.2) 
24.70±3.00 
(20.1-28.7) 
24.32±3.96 
(18-31.7) 
FIVC 
(L) 
2.49±1.11 
(0.40-5.42) 
2.38±0.74 
(1.17-3.78) 
2.22±0.81 
(0.71-3.59) 
2.00±1.84 
(0.40-5.42) 
3.49±1.18 
(1.41-4.74) 
2.23±0.93 
(0.87-3.85) 
3.19±1.25 
(1.02-5.25) 
PIFR 
(l/min) 
187.3±93.6 
(28-456) 
205.7±85.4 
(59-415) 
155.5±66.0 
(55-275) 
138.1±105.9 
(28-323) 
233.4±98.0 
(104-389) 
147.0±73.3 
(35-292) 
245.8±114.9 
(59-456) 
FEV1
(L) 
2.17±1.12 
(0.24-5.07) 
1.82±0.92 
(0.82-4.59) 
1.75±0.94 
(0.24-3.80) 
2.65±1.65 
(0.33-5.07) 
2.98±0.84 
(1.58-3.97) 
2.07±1.03 
(0.84-3.97) 
2.93±0.95 
(1.02-5.07) 
FVC 
(L) 
2.88±1.19 
(0.38-5.66) 
2.51±0.96 
(1.23-5.40) 
2.58±0.98 
(0.38-4.30) 
3.09±1.89 
(0.38-5.66) 
3.71±1.05 
(1.89-4.96) 
2.74±1.15 
(1.08-4.96) 
3.65±1.11 
(1.37-5.66) 
FEV1/ 
FVC 
0.74±0.15 
(0.35-0.99) 
0.71±0.16 
(0.44-0.94) 
0.65±0.18 
(0.35-0.89) 
0.87±0.10 
(0.71-0.99) 
0.82±0.06 
(0.71-0.89) 
0.74±0.11 
(0.50-0.87) 
0.80±0.08 
(0.70-0.92) 
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Mean absolute deviation (MAD) amplitude had the strongest correlation with 
measured DiskusTM PIFR in this varied cohort, as shown in Table 4.10. 
Table 4.10: Pearson’s correlation coefficients for comparisons of measured 
DiskusTM PIFR with various amplitude parameters. 
Median 
amplitude (MA) 
MAD 
amplitude 
RMS 
amplitude 
Pave in 300-
600 Hz band 
Correlation 
coefficient, r 
0.836 0.884 0.869 0.808 
Based on the correlation results, PIFRc was calculated using equations 
derived from our previous dataset of 15 healthy volunteers in the method 
development study above using MAD amplitude: 
𝑃𝐼𝐹𝑅𝑐 =
194.7∗𝐴𝑀𝐴𝐷+0.1716
𝐴𝑀𝐴𝐷+0.02621
 (4.1) 
Figure 4.22 shows a scatterplot of acoustically-determined PIFR (test method) 
versus spirometrically-determined PIFR (reference method). Difference and 
relative difference plots are shown in Figure 4.23. Limits for absolute 
difference (+/- 1.96SD) were -11.9 to 19.4. There was a high degree of 
correlation between the values, with an R2 of 0.884. There was a statistically 
significant mean bias of 3.78 and mean relative bias of 6.6% from the 
reference method. 
𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛)  =  1.01 ∗ 𝑃𝐼𝐹𝑅𝑚 (𝑙/𝑚𝑖𝑛)  +  3.18  (4.2)
The results were partitioned by PIFR values of 45, 90 and 120 l/min. There 
was a mean bias of 3.4 between 0-45 l/min and 3.8 between 45-90 l/min. The 
bias above 90 l/min was not significant. 
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Receiver operating characteristic (ROC) curves for various thresholds of 
measured PIFR are shown in Figure 4.24. AUCs are close to 1 for 
classification of PIFR as >= 30, 45, 60 and 90 l/min. We were able to correctly 
classify 95% of inhalations > 30 l/min, 91% > 45 l/min, 93% > 60 l/min and 
92% > 90 l/min. Both sensitivity and specificity were greater than 90% for any 
threshold of measured PIFR (Table 4.11). 
Figure 4.22: Scatter plot of test (acoustically-determined) PIFRc versus 
reference (spirometrically-determined) PIFRm. The equal line represents no 
difference between methods (y =x). The ordinary least squares regression line 
is also shown (R2=0.884, Test PIFR = 1.01*Reference PIFR + 3.18, Mean 
bias = 3.78, Mean relative bias = 6.6%). 
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Figure 4.23: Difference (a) and relative difference (b) plots for test 
(acoustically-determined) PIFRc versus reference (spirometrically-determined) 
PIFRm. 
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Table 4.11: Table showing threshold values of acoustic method for which most 
inhalations are correctly classified, with corresponding sensitivity and 
specificity. Reference method represents spirometric values and test method 
represents acoustic method. 
Reference 
Method 
(l/min) 
Test Method 
(l/min) Sensitivity Specificity Correctly Classified 
≥30 ≥33.55 95.12% 90.00% 94.57% 
≥45 ≥47.91 91.67% 90.62% 91.30% 
≥60 ≥66.27 90.48% 96.00% 93.48% 
≥90 ≥90.57 100.00% 91.86% 92.39% 
Figure 4.24: Receiver operating characteristic (ROC) curves for acoustically-
determined PIFR versus thresholds of measured PIFRm of 30, 45, 60 and 90 
l/min. The equal line represents an Area Under the Curve (AUC) of 0.5. 
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4.3.2. Discussion 
In this study we extended our prior observations, which showed that analysis 
of the acoustics of inhalation from a DiskusTM Dry Powder Inhaler could be 
used to calculate PIFR. Using a large sample of patients with widely varying 
PIFR rates, there was a very strong relationship between measured PIFR and 
calculated PIFR. 
The results reinforced earlier findings that acoustic parameters of inhalation 
are both sensitive and specific for classifying inhalations according to PIFR, 
being able to correctly classify upwards of 89% of all inhalations according to 
preset thresholds of spirometrically-determined PIFR. For these analyses the 
sensitivities and specificities were greater than 90%. Furthermore, we have 
shown that the relationship between flow rate and sound amplitude is 
independent of disease state and is therefore applicable to a large subset of 
the population.  
There are many ways to signal average the inhalation sound; previously, we 
measured the average power in the frequency band 300-600 Hz, root mean 
square of amplitude and mean absolute deviation of the acoustic amplitude 
and found that the first had the best correlation with PIFR. In this study, we 
found that MAD amplitude had the strongest correlation with PIFR. The most 
likely explanation for this is that MAD amplitude is more robust to inter-
individual changes and mean power may shift in different frequency bands 
depending on upper and lower airway anatomy. This is in accordance with 
previous studies, which showed that the optimum frequency band to calculate 
average power is different in healthy subjects compared to asthmatics.(155)
Furthermore, we confirmed our prior findings that patients with Neuromuscular 
Disease and COPD generated lower PIFRs compared to asthmatics, obese 
patients and those with non-respiratory illnesses. This has important 
implications in that different sub-populations may be able to use the DiskusTM
inhaler with different efficacies. Even though their PIFR may be close to their 
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personal best, they may still not be able to generate sufficient turbulent energy 
to benefit from the DPI. 
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4.4. Correlation of inhalation acoustics from a DiskusTM Dry Powder 
Inhaler with in vitro drug delivery 
4.4.1. Results 
There was a high correlation between calculated flow rate (PIFRc) and the 
flow rate at which the Next Generation Impactor was operated (PIFR); overall 
imprecision was less than 10% at all three flow rates (Figure 4.25). Imprecision 
of acoustically-determined duration was approximately 3% (Figure 4.26).  
When regressions through the origin were performed for our data, plots of 
studentized residuals versus the independent variables highlighted non-
horizontal linear trends indicating that a nonzero intercept should be 
suspected. Hence, all our regression models below included a nonzero 
intercept, since it is statistically significant. 
Figure 4.25: Boxplot of calculated flow rate at each preset flow rate for the NGI 
impactor. 
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Figure 4.26: Boxplot of acoustic duration categorized by preset flow controller 
duration for the NGI impactor. 
Fine Particle Fraction (FPF) was directly proportional to inhalation flow rate 
and duration of inhalation for the salmeterol/ fluticasone preparation but FPF 
was proportional to only PIFR for the salbutamol DiskusTM . The relationships 
between FPF, TED, UAD, PIFRc and duration of inhalation for salmeterol, 
fluticasone and salbutamol are given by the following equations: 
 (4.3) 
𝑺𝒂𝒍𝒎𝒆𝒕𝒆𝒓𝒐𝒍 𝑭𝑷𝑭 (%) =  
0.176 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 0.627 ∗ 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑠) + 5.915
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.951  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.000, 𝜂2 = 0.901), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.029, 𝜂2 =  0.050) 
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 (4.4) 
 (4.5) 
 (4.6) 
 (4.7) 
 (4.8) 
 (4.9) 
𝑺𝒂𝒍𝒎𝒆𝒕𝒆𝒓𝒐𝒍 𝑻𝑬𝑫 (%) =
 0.274 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 72.456      
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.858  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.000, 𝜂2 = 0.876), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.139 ∶ 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑) 
𝑺𝒂𝒍𝒎𝒆𝒕𝒆𝒓𝒐𝒍 𝑼𝑨𝑫 (%) =
 0.104 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 64.044      
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.743  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.003, 𝜂2 = 0.775), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.486 ∶ 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑) 
𝑭𝒍𝒖𝒕𝒊𝒄𝒂𝒔𝒐𝒏𝒆 𝑭𝑷𝑭 (%) =   
0.178 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 0.640 ∗ 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑠) + 5.538 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.951  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.000, 𝜂2 = 0.901), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.029, 𝜂2 =  0.050) 
𝑭𝒍𝒖𝒕𝒊𝒄𝒂𝒔𝒐𝒏𝒆 𝑻𝑬𝑫 (%) =
 0.261 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 68.581     
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.891  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.000, 𝜂2 = 0.904), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.151 ∶ 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑) 
𝑭𝒍𝒖𝒕𝒊𝒄𝒂𝒔𝒐𝒏𝒆 𝑼𝑨𝑫 (%) =
 0.046 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 63.450      
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.395  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.041, 𝜂2 = 0.470), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.915 ∶ 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑) 
𝑺𝒂𝒍𝒃𝒖𝒕𝒂m𝒐𝒍 𝑭𝑷𝑭 (%) =
 0.180 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 29.733      
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.7104  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.001, 𝜂2 = 0.747), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.147: 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑) 
𝑺𝒂𝒍𝒃𝒖𝒕𝒂𝒎𝒐𝒍 𝑻𝑬𝑫 (%) =
 0.277 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 79.524 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.725  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.002, 𝜂2 = 0.760), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.124 ∶ 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑 )
 (4.10) 
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𝑺𝒂𝒍𝒃𝒖𝒕𝒂𝒎𝒐𝒍 𝑼𝑨𝑫 (%) =
 0.0970 ∗ 𝑃𝐼𝐹𝑅𝑐 (𝑙/𝑚𝑖𝑛) + 49.790 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑅2 = 0.445  
𝑃𝐼𝐹𝑅𝑐 (𝑝 = 0.031, 𝜂2 = 0.515), 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑝 = 0.253 ∶ 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑) 
 (4.11) 
While both calculated flow rate and acoustic duration are statistically 
significant in the regression models for FPF from the salmeterol/ fluticasone 
inhaler, inhalation duration has a minimal effect compared to PIFR as 
estimated by the η 2. Duration was not a significant variable in the FPF 
model for salbutamol and all of the models for TED and UAD (see equations 
above for p values). The trends for TED were similar to those seen with FPF 
(Figures 4.27 and 4.28). 
Figure 4.27: Bar graph of average total emitted dose (n=2, %RSD < 20%) as 
a % of label claim versus calculated flow rate for salmeterol, fluticasone and 
salbutamol for (a) 2 s inhalation, (b) 4 s inhalation and (c) 6 s inhalation. 
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Figure 4.28: Bar graph of average fine particle fraction (n=2, %RSD < 20%) as 
a % of label claim versus calculated flow rate for salmeterol, fluticasone and 
salbutamol for (a) 2 s inhalation, (b) 4 s inhalation and (c) 6 s inhalation. 
A significant proportion of active drug is of a diameter greater than 5 microns 
and hence, likely to be deposited in the upper airways and throat (Figure 
4.29). PIFRc is only moderately correlated with UAD, with an adjusted R2 of 
0.708 for salmeterol, 0.295 for fluticasone and 0.527 for salbutamol. Inhalation 
duration had no effect on UAD.  
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Figure 4.29: Bar graph of average upper airway deposition (n=2, %RSD < 
20%) as a % of label claim versus calculated flow rate for salmeterol, 
fluticasone and salbutamol for (a) 2 s inhalation, (b) 4 s inhalation and (c) 6 s 
inhalation. 
Tables 4.12, 4.13 and 4.14 present the mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) for salmeterol, fluticasone 
and salbutamol according to flow rate and duration of inhalation. There is a 
clear trend to a lower MMAD at higher flow rates for both DiskusTM 
formulations. However, the GSD or spread of particle diameters increases as 
flow rate increases from 30 l/min to 90 l/min. The MMAD is also consistently 
lower for the salbutamol formulation under all study conditions. 
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Table 4.12: Next Generation Impactor salmeterol deposition by flow rate and 
duration of inhalation. 
Salmeterol 
Flow Rate (l/min) 30 60 90 
Duration (s) 2 4 6 2 4 6 2 4 6 
Throat (µg) 6.66 5.37 5.81 5.96 6.43 4.99 5.36 5.40 4.51 
PSa (µg) 24.60 24.05 24.73 27.81 27.05 28.57 27.36 27.36 29.53 
S1 (µg) 1.03 1.10 1.03 2.01 2.03 2.40 3.87 4.25 4.20 
S2 (µg) 1.72 2.42 2.28 3.37 3.35 3.82 3.85 4.07 4.55 
S3 (µg) 2.50 3.15 2.88 3.30 3.42 3.75 3.36 3.61 3.50 
S4 (µg) 2.05 2.76 2.69 2.32 2.68 2.50 2.37 2.48 2.47 
S5 (µg) BLOQ 0.74 0.65 BLOQ 0.87 BLOQ BLOQ BLOQ BLOQ 
S6 (µg) 
BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 
S7 (µg) 
BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 
MOCb (µg) 
BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 
TEDc (µg) 39.07 39.60 40.23 45.21 45.82 46.60 46.62 47.65 49.32 
FPDd (µg) 5.39 7.13 6.63 9.26 10.15 10.48 11.86 12.67 13.00 
MMADe (µm) 5.18 5.08 4.95 4.26 4.03 4.32 3.83 3.86 3.91 
GSDf 1.77 1.80 1.88 1.81 1.89 1.87 2.23 2.26 2.12 
a PS – Pre-separator, b MOC – Micro-orifice Collector, c TED – Total Emitted Dose, d FPD – 
Fine Particle Dose, e MMAD – Mass Median Aerodynamic  Diameter, f GSD – Geometric 
Standard Deviation, BLOQ – Below Limit of Quantification (0.63 micrograms) 
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Table 4.13: Next Generation Impactor fluticasone deposition by flow rate and 
duration of inhalation. 
Fluticasone 
Flow Rate (l/min) 30 60 90 
Duration (s) 2 4 6 2 4 6 2 4 6 
Throat (µg) 32.72 25.17 28.54 29.77 32.11 23.98 26.64 27.92 23.29 
PSa (µg) 119.13 116.82 118.02 130.41 123.50 131.70 128.31 128.04 137.15 
S1 (µg) 5.13 5.29 5.04 9.74 9.45 11.10 18.12 19.50 19.65 
S2 (µg) 8.58 12.05 11.58 16.69 13.42 19.45 20.25 20.65 24.74 
S3 (µg) 13.05 16.73 15.23 17.92 17.97 21.16 19.60 18.66 20.88 
S4 (µg) 11.22 14.00 15.26 13.77 13.08 13.86 13.91 13.58 14.94 
S5 (µg) 3.38 4.52 3.66 2.98 8.35 3.82 2.84 2.84 2.96 
S6 (µg) BLOQ BLOQ 
BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 
S7 (µg) 
BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 
MOCb (µg) 
BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 
TEDc (µg) 193.22 194.59 197.54 221.28 217.87 225.07 229.68 231.19 243.62 
FPDd (µg) 28.83 36.82 35.48 50.35 52.53 56.93 65.42 65.11 72.64 
MMADe (µm) 4.98 4.98 4.84 4.03 3.63 4.10 3.47 3.65 3.63 
GSDf 1.79 1.78 1.87 1.82 1.86 1.77 2.22 2.23 2.08 
a PS – Pre-separator, b MOC – Micro-orifice Collector, c TED – Total Emitted Dose, d FPD – 
Fine Particle Dose, e MMAD – Mass Median Aerodynamic  Diameter, f GSD – Geometric 
Standard Deviation, BLOQ – Below Limit of Quantification (1.50 micrograms) 
167 
Table 4.14: Next Generation Impactor salbutamol deposition by flow rate and 
duration of inhalation. 
Salbutamol 
Flow Rate (l/min) 30 60 90 
Duration (s) 2 4 6 2 4 6 2 4 6 
Throat (µg) 14.31 14.77 15.38 15.13 15.18 23.15 19.52 21.88 18.61 
PSa (µg) 60.89 62.56 67.96 77.88 79.28 67.38 87.57 73.21 90.58 
S1 (µg) 15.00 15.29 17.45 15.32 15.45 18.97 17.56 17.21 16.40 
S2 (µg) 13.42 15.26 14.29 11.27 11.93 17.26 13.38 13.73 13.05 
S3 (µg) 19.48 20.14 22.03 19.12 16.95 21.78 14.98 16.09 16.33 
S4 (µg) 21.90 24.67 23.16 25.90 24.94 29.68 18.77 22.58 21.30 
S5 (µg) 10.42 11.49 11.68 14.14 12.43 13.74 15.27 18.46 16.13 
S6 (µg) 4.12 3.64 3.87 5.59 3.78 2.45 6.77 6.68 6.90 
S7 (µg) BLOQ 3.66 3.76 3.59 3.81 2.14 6.85 6.30 6.60 
MOCb (µg) BLOQ 5.20 3.69 4.62 4.74 2.04 7.72 6.75 7.47 
TEDc (µg) 160.64 176.68 183.26 192.57 188.49 198.59 208.39 202.90 213.37 
FPDd (µg) 60.52 72.90 72.08 83.29 77.49 85.87 87.66 94.55 91.41 
MMADe (µm) 4.51 4.08 4.32 2.60 2.67 3.06 1.92 1.87 1.88 
GSDf 2.24 2.44 2.29 2.17 2.12 2.42 2.94 2.59 2.66 
a PS – Pre-separator, b MOC – Micro-orifice Collector, c TED – Total Emitted Dose, d FPD – 
Fine Particle Dose, e MMAD – Mass Median Aerodynamic  Diameter, f GSD – Geometric 
Standard Deviation, BLOQ – Below Limit of Quantification (2.00 micrograms) 
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4.4.2. Discussion 
To confirm that drug delivery to the lungs is dependent on flow rate, and hence 
can be estimated from the acoustic sounds of inhalation, we performed in vitro 
and in vivo studies. In vitro, we showed that Fine Particle Dose was dependent 
on both the inhalation flow rate and the duration of inhalation for salmeterol 
and fluticasone; duration was not significant for salbutamol FPF. Using the 
acoustic parameters to determine PIFRc and the duration of inhalation, we 
were able to explain more than 95% of the variance in FPF for salmeterol/ 
fluticasone but only 70% of the variance for salbutamol. In contrast, the Upper 
Airway Deposition was relatively constant regardless of flow rate and duration. 
The implications of this is that patients with poor inhalational technique may 
have all the side effects of thrush and GI absorption with very few beneficial 
effects of the medication. 
Some authors have described the DiskusTM DPI as flow-independent.(91) 
However, on careful review of their results, FPF from the DiskusTM DPI is flow-
dependent, although not to the same degree as that from the TurbuhalerTM 
DPI. There is little published data on the effect of duration or inhaled volume on 
drug delivery. Our data suggest that the effect of inhalation duration is minimal. 
However, duration is still a significant variable in our regression models for 
salmeterol and fluticasone FPF and it is likely that at borderline flow rates 
between 30-45 l/min, inspiratory duration plays a more important role in drug 
delivery. Further studies at inhalation durations less than or equal to 1 second 
are required to further evaluate any possible relationship. 
A number of studies have reported that very high inhalation flow rates through 
the DiskusTM inhaler may be detrimental to airway drug delivery, arguing that 
throat deposition is increased and that particles less than 1 micron in size are 
more likely to be exhaled immediately after inhalation.(94, 164) In contrast, our 
study found that even though MMAD decreases as flow rate increases, the 
lowest MMAD achieved for the salmeterol/fluticasone DiskusTM was 3.47 mm 
with a GSD of 2.22, which means that a significant proportion of particles
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would still be in the range of 2-5 microns to be active on the small airways. It 
is worth mentioning that the MMAD values for salbutamol were lower than the 
salmeterol/ fluticasone formulation. Hence, for this formulation, PIFRs >60 l/
min from a salbutamol DiskusTM may lead to lower pulmonary deposition due 
to exhalation of particles < 1 micron. 
One of the limitations of cascade impactor studies is that they require multiple 
dose actuations in order to enhance detection of very low drug levels in the 
lower Stages. This increases the chances of particle re-entrainment with each 
subsequent inhalation and hence, the drug recovered in each stage is likely to 
be higher than that expected if only one actuation were performed. 
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4.5. Correlation of inhalation acoustics from a DiskusTM Dry Powder 
Inhaler with in vivo drug delivery  
4.5.1. Results 
Baseline demographics for the ten subjects recruited in this study are shown in 
Table 4.15. Figure 4.30 shows that there was a significant difference between 
peak salbutamol concentration (measured at 20 min) achieved when PIFR 
was above 60 l/min compared to when PIFR was below 60 l/min for each 
individual. A t-test for difference in means of groups above and below 60 l/min 
gave a p value < 0.0001 with a mean difference of 0.786 (95% CI: 0.472 – 
1.100).  
Table 4.15: Demographics of ten healthy volunteers recruited for 
pharmacokinetic study. 
Demographic All subjects 
Age (years), mean (SD) 31.1 (9.6) 
Sex, M:F (%) 70:30 
Body mass index (kg/m2), mean (SD) 23.1 (2.7) 
Height (cm), mean (SD) 173.7 (10.0) 
Weight (kg), mean (SD) 69.5 (9.8) 
Race, n (%) 
 White – White/ Caucasian/ European 8 (80) 
 Asian – Central/ South Asian 2 (20) 
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Figure 4.30: Line and dot plot of peak serum concentration of salbutamol 
versus flow rate category (less than or greater than 60 l/min) for ten healthy 
subjects. Each line represents a separate individual and points represent 
actual values of concentration and calculated PIFR. The dotted line represents 
the overall regression line for all the data points. P- value for difference in 
means between high flow rate and low flow rate groups is less than 0.0001. 
Duration of inhalation, and by extension, inspiratory volume did not 
significantly contribute to the multi-level regression model. The R2 for the 
clustered regression model was 0.563 (p < 0.0001), with standard error 
adjusted for 10 clusters of subjects. A large proportion of the variance in peak 
salbutamol concentration could not be explained by inhalation flow rate and 
duration. 
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4.5.2. Discussion 
The relationship between PIFR and duration of inhalation on drug delivery, in 
vivo, was tested in ten healthy subjects. There was a significant difference in 
the serum concentrations of salbutamol when PIFR was low (≤ 60 l/min) 
compared to when the PIFR was > 60 l/min. Together these data confirm that 
the acoustics of inhalation from a DiskusTM DPI can be used to objectively 
quantify pulmonary drug delivery. 
A salbutamol DiskusTM was used because salbutamol has the shortest half-life 
of the drugs studied in vitro in section 4.4. and it reaches relatively high 
concentrations in the blood after inhalation with a short time to maximum 
concentration. It was straightforward to measure serum plasma concentrations 
using a commercially available ELISA. In preliminary experiments there was 
an initial peak at 20 minutes that was distinct from the peak at 2-3 hours, 
which is likely secondary to GI absorption. The initial peak was therefore most 
likely related to pulmonary absorption and hence, pulmonary deposition and 
aerodynamic particle size. Results were concordant with the in vitro studies 
using the NGI and confirmed the relationship between PIFR and peak blood 
concentration.  
Each subject served as his or her own control since inter-individual drug 
metabolism is highly variable. Each individual achieved a lower Cmax when his 
or her inhalation flow rate was less than 60 l/min. Furthermore, the equations 
developed to estimate PIFR from acoustics were able to correctly classify all of 
the inhalations as either above or below 60 l/min and acoustically-determined 
PIFR explained more than 50% of the variance in Cmax. The remainder of the 
variance is likely due to differences in drug metabolism between individuals. 
The study was underpowered to detect a relationship between duration of 
inhalation and peak concentration. The existence of such a relationship is 
however, questionable since the results of prior in vitro studies were 
inconclusive (even though the results for salmeterol and fluticasone were 
statistically significant, the magnitude of the effect is minimal).  
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One limitation of this pharmacokinetic study was the use of salbutamol without 
giving charcoal to the subjects to minimize GI absorption. A consensus 
statement from the British Association for Lung Research recommends the 
use of an inhaled drug like fluticasone, which has less than 1% oral 
bioavailability, in pharmacokinetic studies or another drug in combination with 
activated charcoal.(165) However, we based our method on a previous study, 
which showed that mouth-rinsing effectively eliminates GI absorption.(37) Our 
data from three volunteers also shows that the peak due to GI absorption 
happens much later than when we collected our blood samples. While it would 
have been ideal to use an HPLC or LC-MS/MS assay for detection of 
salbutamol, this technology was not available at the time sample analysis was 
performed. Nonetheless, our method validation of the ELISA showed that is 
had an acceptable imprecision and good recovery. 
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CHAPTER 5: Development and validation of an acoustic method to 
detect and quantify the effect of exhalation into a Dry Powder Inhaler 
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5.1. Results 
5.1.1. Dosage Uniformity Analysis 
The dosage uniformity analysis on the DiskusTM DPI demonstrated that the 
dose delivered from the DiskusTM was uniform and repeatable. Nine of 10 test 
results fell between 75% - 125% and 1 of 10 test results was between 65% 
-135% of the delivered dose label claim, which was in accordance with US
Pharmacopoeia standards.  Results for this testing can be found in Table 5.1. 
Table 5.1: Dosage uniformity analysis of salmeterol/ fluticasone DiskusTM
performed for further comparisons. 
Salmeterol 
Delivered Dose 
(mcg)  
Salmeterol 
Delivered Dose 
(% label claim) 
Fluticasone 
Delivered Dose 
(mcg) 
Fluticasone 
Delivered Dose 
(% label claim) 
DUSA 1 37.14 74.28 200.73 80.29 
DUSA 2 43.79 87.58 225.66 90.27 
DUSA 3 40.86 81.73 207.45 82.98 
DUSA 4 47.55 95.11 231.39 92.56 
DUSA 5 47.43 94.87 238.31 95.32 
DUSA 6 47.07 94.14 239.23 95.69 
DUSA 7 46.56 93.13 238.56 95.42 
DUSA 8 46.46 92.93 218.92 87.57 
DUSA 9 48.37 96.75 245.06 98.02 
DUSA 10 47.95 95.90 242.10 96.84 
Average 45.32 90.64 228.74 91.50 
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5.1.2. Impact of exhalation on delivered dose 
The impact of four distinct exhalation factors (exhalation flow rate, distance to 
inhaler mouthpiece, exhalation duration and relative air humidity level) on drug 
delivery was investigated.  It was found from multivariate regression analysis 
that all four factors had a statistically significant effect on both salmeterol and 
fluticasone drug delivery (p<0.05, significance level α=0.05). From the 
multivariate regression model, the adjusted R-squared values were 62.7% for 
salmeterol and 63.4% for fluticasone. The multivariate regression equations 
derived can be found below: 
𝑺𝒂𝒍𝒎𝒆𝒕𝒆𝒓𝒐𝒍 𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒆𝒅 𝑫𝒐𝒔𝒆 (𝑢𝑔) =
 −0.153 ∗ 𝐸𝑥ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 (𝐿/𝑚𝑖𝑛) + 2.146 ∗
 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑖𝑛ℎ𝑎𝑙𝑒𝑟 (𝑐𝑚) − 1.840 ∗ 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑒𝑥ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 (𝑠) −
10.372 ∗ 𝐴𝑖𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 (𝑑𝑟𝑦 = 0/ ℎ𝑢𝑚𝑖𝑑 = 1) + 43.310  (5.1) 
𝑭𝒍𝒖𝒕𝒊𝒄𝒂𝒔𝒐𝒏𝒆 𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒆𝒅 𝑫𝒐𝒔𝒆 (𝑢𝑔) =
 −0.728 ∗ 𝐸𝑥ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 (𝐿/𝑚𝑖𝑛) + 10.715 ∗
 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑖𝑛ℎ𝑎𝑙𝑒𝑟 (𝑐𝑚) − 9.008 ∗ 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑒𝑥ℎ𝑎𝑙𝑎𝑡𝑖𝑜𝑛 (𝑠) −
50.634 ∗ 𝐴𝑖𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 (𝑑𝑟𝑦 = 0/ ℎ𝑢𝑚𝑖𝑑 = 1) + 214.997  (5.2) 
Figure 5.1 details the total percentage of salmeterol and fluticasone 
delivered as a percentage of the DiskusTM inhaler manufacturer's claims. 
Scatterplot matrices are also shown to illustrate the differences due by 
relative air humidity level.    
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Figure 5.1: Effect of exhalations on delivered dose as percentage of label 
claim: (A) salmeterol delivered dose after exhalation with dry air, (B) 
fluticasone delivered dose after exhalation with dry air, (C) salmeterol 
delivered dose after exhalation with humid air, (D) fluticasone delivered dose 
after exhalation with humid air, (E) interaction plot detailing differences 
between salmeterol delivered dose for different factors and (F) scatterplot 
matrices detailing differences between fluticasone delivered dose for different 
factors. Experiments were performed in triplicate (n=3) at each study 
condition. 
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Exhalations were found to have an overall negative effect on drug delivery. At 
a distance of 0 cm from the inhaler mouthpiece, less than 50% of drug 
available was delivered on average for all flow rates using humid air (relative 
air humidity = 80%). In a worst-case scenario, an average of 2.44% of drug 
was delivered at an expiratory flow rate of 120 l/Min, at a distance of 0 cm 
from the inhaler mouthpiece (Figure 5.1 C & D). Delivered dose was more 
consistent when dry air was used and more variable and unpredictable when 
humid air was used. Less drug was delivered on average when humid air was 
used in comparison to dry air (Figure 5.1 E & F).  
To investigate the effects of each of the four factors on drug delivery, 
measures of effect size (η2 and partial η2) were obtained from the multivariate 
regression model for each independent variable. Results established that 
distance from the inhaler mouthpiece was the single most influential factor in 
reducing the percentage of drug delivery from a DPI. Exhalation flow rate and 
air humidity level were the next most influential factors with similar effect 
sizes. Lastly, although its overall effect was significant, exhalation duration 
was the least influential factor in determining drug delivery for the multivariate 
regression model. Results for this analysis are presented in Tables 5.2 and 
5.3 respectively.   
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Table 5.2: Effect size for each of the four factors on drug delivery for 
salmeterol. 
Variable P > |t| η2 % Change in 
η2
Partial η2
Exhalation 
flow rate 
0.000 0.122 18.890 0.258 
Distance 0.000 0.358 55.255 0.504 
Duration 0.006 0.042 6.498 0.107 
Air Humidity 0.000 0.125 19.356 0.262 
Table 5.3: Effect size for each of the four factors on drug delivery for 
fluticasone. 
Variable P > |t| η2 % Change in 
η2
Partial η2
Exhalation 
flow rate 
0.000 0.116 17.723 0.251 
Distance 0.000 0.372 56.819 0.519 
Duration 0.006 0.042 6.426 0.109 
Air Humidity 0.000 0.125 19.032 0.265 
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5.1.3. Particle size distribution of emitted dose 
An NGI cascade impactor was employed to investigate the effect of 
exhalations versus no exhalations on the particle distribution from a DiskusTM
DPI. There were no differences in the total emitted doses but the fine particle 
fraction (FPF) was significantly reduced for inhaler devices subjected to an 
exhalation, see Figure 5.2. Detailed results for particle size distribution can be 
found in Table 5.4. 
Figure 5.2: Analysis of particle size distribution of salmeterol and fluticasone 
from DiskusTM DPI as obtained from NGI. (A) Total drug recovered from all 
sections of the NGI and (B) Fine Particle Fraction (FPF) drug recovered 
demonstrating a reduction due to exhalations. Experiments were performed 
in duplicate (n=2) at each study condition. 
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Table 5.4: Particle size distribution from NGI for salmeterol and fluticasone 
with and without an exhalation. 
Active 
ingredient Salmeterol Fluticasone 
Study 
Condition Standard Dose 
Post 
humidified-air 
exhalation Standard Dose 
Post 
humidified-air 
exhalation 
Throat (µg) 5.60 11.90 27.35 16.92 
PSa (µg) 26.40 25.68 123.50 190.17 
S1 (µg) 2.03 1.03 9.45 5.63 
S2 (µg) 3.35 1.19 13.42 5.63 
S3 (µg) 3.42 1.43 17.97 7.45 
S4 (µg) 2.68 1.37 13.08 7.20 
S5 (µg) 1.52 0.93 8.35 5.03 
S6 (µg) BLOQ 1.13 1.72 6.05 
S7 (µg) BLOQ BLOQ 1.51 BLOQ 
MOCb (µg) BLOQ BLOQ 1.52 BLOQ 
TEDc (µg) 45.82 45.06 217.87 245.92 
FPDd (µg) 11.53 6.63 57.01 33.87 
UADe (µg) 34.29 38.42 160.86 212.05 
MMADf (µm) 3.85 2.92 3.39 2.86 
GSDg 1.97 2.40 1.95 2.39 
a PS – Pre-separator, b MOC – Micro-orifice Collector, c TED – Total Emitted Dose, d FPD – 
Fine Particle Dose, e MMAD – Mass Median Aerodynamic  Diameter, f GSD – Geometric 
Standard Deviation, BLOQ – Below Limit of Quantification
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5.1.4. Relationship between exhalations and acoustic features 
A strong correlation was observed between the exhalation flow rate and the 
acoustic features obtained from the exhalation audio signal. As the expiratory 
flow rate increased, a corresponding increase was seen in both Pave in the 
300-600 Hz frequency band and in the MAD amplitude. Distance between the
inhaler and the artificial mouthpiece was also related to both power and 
amplitude of the exhalation signal. The smaller this distance, the greater the 
power and amplitude of the signal. Results for the correlations between 
acoustic features with both flow rate and distance are illustrated in Figure 5.3.    
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Figure 5.3: Correlations between flow and distance from inhaler mouthpiece 
with acoustic features for humid air in vitro. (A) Mean Absolute Deviation 
(MAD) of the exhalation signal plotted versus exhalation flow rate and distance 
form inhaler mouthpiece. (B) Average power in the 300-600 Hz frequency 
band of the exhalation signal plotted versus exhalation flow rate and distance 
form inhaler mouthpiece. 
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5.1.5. Acoustic method of automatically detecting exhalations 
Cohen’s kappa statistic (K) was calculated to measure the level of agreement 
between the two respiratory clinicians who manually classified each audio file 
in the validation dataset. K was found to be 1, indicating perfect agreement 
between the two human raters. Using the algorithm described to automatically 
detect exhalations, an evaluation test was performed on the 120 audio files 
from 22 patients, which made up the validation dataset. The overall detection 
rate (accuracy) on the 22 patients in the validation dataset was found to be 
89.1% compared to the gold standard method of classification. Sensitivity 
(detecting exhalations as exhalations) was found to be 82.2%, and specificity 
(detecting noise as noise) was found to be 91.6% compared to the gold 
standard method. These results demonstrated that the algorithm developed 
may be used as a tool to detect exhalations in real world unsupervised inhaler 
audio signals. K was also calculated to compare the level of agreement 
between the proposed algorithm and the gold standard method of 
classification. Taking the classification of the algorithm as one output and the 
classification of respiratory clinicians as the gold standard output, K was found 
to be 0.664, indicating substantial agreement between the two classification 
methods.  
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5.1.6. Acoustic method of assessing exhalations during inhaler use 
In addition to being able to detect exhalations, it would also be beneficial to 
know if exhalations have the potential to effect drug delivery in a DPI. For this 
experiment, exhalations occurring at a distance of 5 cm or less, into the DPI 
mouthpiece or directly at the INCATM device were classified as significant. It 
was found that the equation developed to classify a significant exhalation had 
a sensitivity of 72.22% and a specificity of 85.71% when tested on the 
validation dataset. Results of this test, in addition to positive predictive value 
(PPV) and negative predictive value (NPV) are presented in Table 5.5.  
In terms of classifying exhalations that occur specifically at 0 cm from the 
inhaler mouthpiece or with lips sealed around the inhaler mouthpiece, the 
equation developed had a sensitivity of 88.89% and specificity of 70.73%. 
For classifying exhalations that occur at 5 cm from the inhaler mouthpiece, 
the equations developed had a sensitivity of 81.25% and specificity of 
88.24%. PPV and NPV for these tests are displayed in Table 5.5. Detailed 
results can be found in Tables 5.6 – 5.8.   
Table 5.5: Assessing significance and location of exhalations during inhaler 
use. 
Test Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Significant 
Exhalation 
72.22 85.71 92.86 54.55 
Exhalation at 0 
cm/mouthseal 
88.89 70.73 40.00 96.67 
Exhalation at 5 
cm 
81.25 88.24 76.47 90.91 
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Table 5.6: Confusion matrix for a significant exhalation 
Significant 
Exhalation 
Reference 
POSITIVE 
Reference 
NEGATIVE 
Total Sensitivity 72.22 
Test 
POSITIVE 
26 2 28 Specificity 85.71 
Test 
NEGATIVE 
10 12 22 PPV 92.86 
Total 36 14 NPV 54.55 
Table 5.7: Confusion matrix for an exhalation at 0 cm from the inhaler or with 
a mouthseal 
Exhalation 
at 0 cm/ MS 
Reference 
POSITIVE 
Reference 
NEGATIVE 
Total Sensitivity 88.89 
Test 
POSITIVE 
8 12 20 Specificity 70.73 
Test 
NEGATIVE 
1 29 30 PPV 40.00 
Total 9 41 NPV 96.67 
Table 5.8: Confusion matrix for an exhalation at 5 cm from the inhaler 
Exhalation 
at 5 cm 
Reference 
POSITIVE 
Reference 
NEGATIVE 
Total Sensitivity 81.25 
Test 
POSITIVE 
13 4 17 Specificity 88.24 
Test 
NEGATIVE 
3 30 33 PPV 76.47 
Total 16 34 NPV 90.91 
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5.2. Discussion 
Several commentators have argued that exhaling into a DPI prior to inhalation 
has a detrimental impact on the dose available for pulmonary delivery.(71, 76, 
81-83) There are very few studies that have been done to clearly define the
significance of this effect; nonetheless, exhalation into a DPI has been widely 
reported as a critical error in the assessment of inhaler technique. In this 
study, we aimed to show the relationship between factors related to an 
exhalation and the amount of drug lost or unavailable for delivery during the 
subsequent inhalation using established in vitro methods. 
The DUSA apparatus was used to show the delivered dosage uniformity of ten 
standard doses from a DiskusTM DPI. The results fell within the US 
Pharmacopoeial specifications: approximately 90% of both salmeterol and 
fluticasone were recovered from the DiskusTM. Our results showed that 
exhalation into the DiskusTM DPI had a significant effect on the subsequent 
delivered dose and that the main determining factors were distance of the 
exhalation from the DPI mouthpiece, flow rate of exhalation and humidity of 
exhaled air. The most important of these was distance of the exhalation from 
the mouthpiece. The duration of the exhalation had a negligible effect on drug 
dispersal, even though it was a statistically significant variable in our 
regression model. On average, more than 50% of salmeterol and fluticasone 
were dispersed from the DPI after exhalation from a distance of 0 cm using 
humid air. At 10 cm, less than 25% of drug was lost. 
Experts in the field of inhalers have theorized that the exhalation of humidified 
air into a DPI causes agglomeration or clumping of the preparation inside the 
inhaler, subsequently affecting fine particle dose and overall deposition. 
However this theory has never been proven. We have shown that the 
relationship between flow rate, distance and duration of exhalation using 
humidified air is less predictable than that using dry air. Drug agglomeration 
provides a plausible explanation for our results. Particles that have clumped 
together may either remain inside the DPI or be emitted as a large mass; this 
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accounts for the greater variability in total delivered dose seen with humidified 
air.  
To clarify the effect of air humidity, we performed experiments using the Next 
Generation Cascade Impactor. Our results showed that even though total 
recovery may remain constant after an exhalation with humid air, the fine 
particle fraction is almost halved, meaning that most of the dose emitted is 
deposited in the upper airways.  
Clearly, exhalation into a DPI has a significant and measurable negative effect 
on drug available for delivery during a subsequent inhalation. Our results 
confirm that this observed patient behaviour is a critical error in inhaler user 
technique and methods to monitor and address this error are needed. Our 
group has devised a novel acoustic monitoring device for long term monitoring 
of inhaler user adherence and technique. In the second part of this study we 
tested the ability of this acoustic recording device to detect exhalations prior to 
inhalations and the sensitivity and specificity of our algorithms for estimating 
the distance of the exhalation from the inhaler mouthpiece.  
Our detection algorithm was very accurate at detecting exhalations in 
unsupervised real world inhaler audio signals in comparison to two expert 
respiratory clinicians. Its overall accuracy was demonstrated to be 89.2% in 
detecting exhalations events from non-exhalation events, while its 
corresponding sensitivity and specificity values were also high. These results 
are encouraging if such an algorithm is to be used to automatically detect the 
critical error of exhaling into a DPI.    
Furthermore, our calculations based on acoustic power in various frequency 
bands and mean absolute deviation of the amplitude of the exhalation signal 
was very sensitive and specific for detecting a significant exhalations and for 
differentiation of an exhalation at 0 cm from one at 5 cm. Our in vitro studies 
clearly showed that distance was the single most important factor accounting 
for drug dispersal or loss from the DPI. Our acoustic device is therefore a 
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suitable means of not only automatically detecting exhalations but of 
objectively quantifying the impact exhalations on drug delivery. 
The major shortcoming of our study is that it was limited to in vitro techniques; 
the individual variability in inhaler technique and the confounding factors of 
biological variation in metabolism, inhalation flow rate, volume and additional 
errors meant that the impact of exhalations would be difficult to measure 
accurately in an in vivo pharmacokinetic study. The detection of exhalations 
and the effect quantification is also limited by the fact that exhalations directed 
at the INCATM acoustic device were included in our classification of a 
significant exhalation. It was impossible to differentiate between an exhalation 
directly at the mouthpiece and one directed at the INCATM device because of 
the location of the device on the inhaler. Further improvements in the device, 
such as the addition of a second microphone below the inhaler may allow us 
to filter out exhalations aimed at the device itself. 
The current gold standard in assessing inhaler technique is the checklist 
method. This method is fraught with limitations; it is very subjective and it 
cannot be used to monitor patients longitudinally. There is also a significant 
Hawthorne effect where patients change their behaviour because they know 
they are being assessed. We need to strive towards more objective methods 
for the assessment of inhaler technique and methods that allow patients’ 
inhaler technique to be monitored continuously. Recent advances in acoustic 
analysis and signal processing mean that it is now possible to use the sound 
profile of an exhalation detected during inhaler use as a surrogate measure of 
the amount of drug unavailable for subsequent delivery. This provides a way 
for monitoring patterns of use in a rolling fashion and making necessary 
adjustments to technique. 
190 
CHAPTER 6: Does orientation of the DiskusTM inhaler affect available 
dose for delivery? 
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6.1. Results 
Actuating a dose or a blister while the DiskusTM was held still at 0°, 45° or 90° 
did not remove detectable amounts of active drug from the inhaler (Table 6.1). 
When the device was held at 0°, a dose actuated and the device subsequently 
tilted to the 90° or vertical position, approximately 5 mcg of salbutamol or 2.5% 
of the available dose was removed from the DiskusTM.  Tapping the inhaler 
after actuating a dose in the 90° position similarly did not significantly affect 
the amount of drug removed (average of 4.8% of available dose and maximum 
of 8.4%). 
Only when the DiskusTM was held at the 90° position after dose actuation and 
shaken was significant amount of drug removed (54% of available dose 
removed with a range of 39.4% to 62.3%). Experimental results are shown in 
Figure 6.1. 
Table 6.1: Amount of drug (mcg) removed from the DiskusTM inhaler when held 
different positions. 
Drug removed (mcg) 
DiskusTM 
position 
0° Still 45° Still 90° Still 90°  Tilt 90° 
Shaken 
90° 
Tapped 
Run 1 <0.5 <0.5 <0.5 <0.5 123.8 4.0 
Run 2 <0.5 <0.5 <0.5 11.0 123.2 4.6 
Run 3 <0.5 <0.5 <0.5 5.1 124.6 12.5 
Run 4 <0.5 <0.5 <0.5 8.9 92.7 9.6 
Run 5 <0.5 <0.5 <0.5 <0.5 78.8 16.7 
Mean <0.5 <0.5 <0.5 5.1 108.6 9.5 
Standard 
Deviation 
- - - 4.9 21.5 5.4 
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6.2. Discussion 
The DiskusTM manufacturer and all checklists reviewed for correct DiskusTM
technique recommend holding the DiskusTM either horizontal or upward after 
dose actuation or blistering and holding the DiskusTM in the horizontal position 
during inhalation. There are no in vitro or in vivo studies available that show 
the impact of DiskusTM position on available dose, although it is likely that the 
manufacturer did testing of this kind during device development and validation. 
This study showed that holding the DiskusTM at a 45° angle to the horizontal 
position or in a vertical position with the mouthpiece facing down after 
blistering had an insignificant effect on the amount of drug removed from the 
device. This evidence contradicts current thinking on correct DiskusTM inhaler 
technique and manufacturer’s recommendations. Shaking the device while it 
was held in the downward position was, however, clearly effective at removing 
over half the available drug from the inhaler and this manouvre is not 
uncommon among DiskusTM users, who are used to shaking their pMDI inhaler 
prior to dosing and inhalation. Figure 3.8 shows a visual example of a patient 
shaking his/ her inhaler after blistering a dose. 
While acoustic monitoring is not able to detect the DiskusTM position in space, 
it can detect when the device is shaken or tapped. From the above 
experiments, it is clear that these are the only two scenarios where significant 
amounts of active drug are removed from the inhaler. Consideration was given 
to incorporating a digital inclinometer with or without an accelerometer into the 
INCATM device to better assess DiskusTM position in space and movement, 
based on the above results, the likely benefits do not outweight the cost of this 
technology. 
The method used for estimating drug removed although effective, is a crude 
surrogate measure. Further studies on the effect of DiskusTM position on drug 
delivery should include cascade impactor studies to determine whether angle 
changes the flow dynamics and pharmacokinetic studies, which will better 
approximate real world scenarios. Use of a clamp stand in this study is unlikely 
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to capture the variability in position and movement during DiskusTM use in a 
patient cohort. 
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CHAPTER 7: Impact of breath holding on drug delivery 
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7.1. Results 
All subjects recruited were healthy with no underlying respiratory conditions. 
The mean age was 25.3 ± 4.8 years and five of the seven subjects were male 
(71%). 
Table 7.1 shows the average serum salbutamol concentration at different 
dosing time-points. Dose 1 Time 0 represents baseline concentration and all 
subjects had salbutamol levels below the lower limit of quantification of the 
assay prior to starting the study. After taking the first dose, there was a trend 
towards a smaller increaser in serum salbutamol concentration when breath 
hold duration was 4 seconds compared to 10 seconds; however, this 
difference was not statistically significant. 
There was a statistically significant 29% reduction in trough salbutamol 
concentration when subjects had only a 4 second breath hold duration 
compared to correct inhaler technique with a 10 second breath hold. There 
was also a 22% lower rise in salbutamol concentration from the dose 6 trough 
level when using a 4 second breath hold. These trends are highlighted in 
Figure 7.1. 
All subjects except for subject 3 had a lower pre-dose 6 trough concentration 
with a 4 second breath hold and all except subjects 1 and 2 had a smaller 
absolute rise from pre-dose 6 trough levels with a 4 second breath hold (Table 
7.2). 
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Table 7.1: Average serum salbutamol concentration at different dosing time-
points and different breath hold durations, with absolute and relative 
differences and p-values calculated from a one-sided t-test. 
Mean salbutamol 
concentration 
(ng/ml) at: 
Breath hold 
duration 
Absolute 
difference 
Relative 
difference 
(%) 
p-value
(1-
sided) 10 
seconds 
4 
seconds 
Dose 1 Time 0 < 0.04 < 0.04 0.00 0.0 0.500 
Dose 1 Time 25 0.50 0.46 - 0.04 - 8.0 0.232 
Dose 6 Time 0 0.86 0.61 - 0.25 - 29.0 0.024 
Dose 6 Time 25 1.39 1.09 - 0.30 - 21.6 0.049 
Figure 7.1: Boxplot showing mean salbutamol concentrations (n=7) at 
different time points and at two different breath hold durations (10 s and 4 s). 
There was a significant lower Dose 6 Time 0 trough level and the Dose 6 
Time 25 peak level when breath-hold duration was 4s. 
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Table 7.2: Salbutamol concentration levels at different time points for subjects 
1 to 7 at two different breath hold durations (10s and 4s). 
ID Age Sex Dose 1 
Time 0 
Dose 1 
Time 
25 
Dose 1 
Peak - 
Trough 
Dose 6 
Time 0 
Dose 6 
Time 
25 
Dose 6 
Peak - 
Trough 
Breath 
hold 
duration 
(s) 
Salbutamol concentration (ng/ml) 
1 30 M 0 0.5 0.5 0.69 1 0.31 10 
1 30 M 0 0.42 0.42 0.58 1.01 0.43 4 
2 20 M 0 0.49 0.49 0.82 1.2 0.38 10 
2 20 M 0 0.67 0.67 0.29 0.84 0.55 4 
3 22 F 0 0.54 0.54 0.86 1.78 0.92 10 
3 22 F 0 0.55 0.55 1.05 1.83 0.78 4 
4 20 M 0 0.56 0.56 0.78 1.24 0.46 10 
4 20 M 0 0.45 0.45 0.33 0.65 0.32 4 
5 27 M 0 0.46 0.46 0.98 1.65 0.67 10 
5 27 M 0 0.34 0.34 0.72 1.21 0.59 4 
6 26 F 0 0.38 0.38 0.79 1.34 0.55 10 
6 26 F 0 0.3 0.3 0.52 0.98 0.38 4 
7 32 M 0 0.59 0.55 1.08 1.54 0.46 10 
7 32 M 0 0.5 0.46 0.75 1.13 0.38 4 
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7.2. Discussion 
Breath holding after inhalation enables particles delivered to the smaller 
airways to be deposited in that region, instead of being exhaled.(96) Most 
studies on the effect of breath holding on DPI drug delivery have used in silico 
methods. This is the first pharmacokinetic study on the impact of breath 
holding duration when using a DiskusTM DPI. Again, salbutamol was chosen as 
the active drug due to its short half-life and thus, short washout period, its 
safety profile and the relatively high serum concentrations after inhalation. 
The results above show that reducing the breath hold duration from 10 
seconds to 4 seconds causes an almost 30% reduction in steady state trough 
concentrations and an approximate 20% reduction in peak levels when a dose 
is taken at steady state. However, it is noteworthy that this pattern was not 
observed in all patients. A possible explanation for this is the inter- and intra-
individual variability in bioavailability and features of inhaler technique from 
dose to dose that cannot be detected by the INCATM device. 
Compared to the effect of low PIFR on drug delivery, the effect of low breath 
hold duration is less significant. Since this study did not look at any 
pharmacodynamic measures, the possible downstream effect of a 20-30% 
reduction in serum concentration levels remains to be determined. This 20-
30% change is likely to be more clinically significant when short breath hold 
duration is combined with other technique errors, such as low peak flow rate. 
The INCATM device readily allows determination of multiple inhalations and 
coughing during inhaler use (see Figures 3.4 and 3.5), which are both 
associated with a subsequent shortening of breath hold duration. One 
limitation of the INCATM device in monitoring breath hold duration is that some 
patients close their inhaler prior to exhalation after inhaling a dose. Thus, 
breath hold duration in this circumstance can only be measured from the time 
of inhalation to the time the device is closed. This iteration of the INCATM 
device focuses mainly on detecting multiple inhalations and coughing and for 
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patients with an audible exhalation after inhaling a dose, the INCATM device 
can also be used to accurately quantify breath hold duration. 
Ideally, this study should be repeated at breath hold durations of 1 second and 
2 second to establish whether such short durations have an even greater 
effect on drug delivery. This study focused on only two durations since each 
breath-hold duration studied added four venipunctures per subject; further 
repetitions were limited by subject willingness to participate.  
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CHAPTER 8: Impact of missed doses on steady state trough and peak 
levels 
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8.1. Results 
Based on first-order kinetics and a half-life of salbutamol of 6 hours, 
pharmacokinetic curves were generated to mimic regular 6 hourly dosing for 6 
doses (Figure 8.1) and when doses 3 and 4 are missed (Figure 8.2). Based on 
these curves, pre-dose trough levels were calculated. The expected mean 
trough level when doses 3 and 4 are missed should theoretically be 64% of 
the mean trough level when all doses are taken as specified (Figure 8.3). 
Figure 8.1: Simulated pharmacokinetic profile when all doses are taken at 6 
hourly intervals. 
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Figure 8.2: Simulated pharmacokinetic profile when doses are taken at 6 
hourly intervals with the exception of doses 3 and 4. 
Figure 8.3: Bar graph showing mean trough concentration expected when all 
doses are taken and when doses 3 and 4 are missed. 
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Four healthy volunteers were enrolled with a mean age of 20.3 years. The 
salbutamol concentrations during the control and missed dose phases are 
shown in Table 8.1 and Figure 8.4.  
Table 8.1: Salbutamol concentrations at different time points in the control 
phase (all doses taken) and the missed doses phase (doses 3 and 4 missed). 
Control Missed doses 
ID Age Sex Dose 1 
Time 0 
Dose 1 
Time 
25 
Dose 6 
Time 0 
Dose 6 
Time 
25 
Dose 1 
Time 0 
Dose 1 
Time 
25 
Dose 6 
Time 0 
Dose 6 
Time 
25 
1 19 M <0.04 0.62 0.68 1.03 <0.04 0.51 0.53 1.26 
2 24 F <0.04 0.82 0.86 1.7 <0.04 0.49 0.66 1.68 
3 19 M <0.04 0.35 0.84 0.72 <0.04 0.34 0.48 0.75 
4 19 M <0.04 0.58 1.03 0.67 <0.04 0.31 0.54 0.98 
Mean 20.3 3:1 <0.04 0.59 0.85 1.03 <0.04 0.41 0.55 1.17 
Figure 8.4: Connected dotplots of salbutamol concentration by subject for 
control phase and missed doses phase at time points: (a) Dose 1 time 0, (b) 
Dose 1 time 25, (c) Dose 6 time 0, and (d) Dose 6 time 25. 
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There was no significant difference in concentration levels pre- and post-dose 
1 but there was a statistically significant 64% difference in pre-dose 6 trough 
concentration (control: 0.85 ng/ml and missed doses: 0.55 ng/ml, p<0.001). 
There was no significant difference between post-dose 6 peak levels.  
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8.2. Discussion 
Based on the theoretical pharmacokinetic models, the pre-dose 6 trough 
concentration when doses 3 and 4 are missed should be approximately 80% 
of the level when all 6 doses are taken with the same technique, that is, a 20% 
absolute reduction. The results from the in vivo study showed that the two 
missed doses caused a significant 35% absolute reduction in trough 
concentration. Even with a small sample size, this effect was statistically 
significant. As expected, there was no difference in the peak level achieved 
after dose 1 since this is dependent solely on inhaler technique. There was a 
trend towards a higher post-dose 6 peak level but this was not statistically 
significant and could possibly be explained by variations in inhaler technique 
when taking dose 6. 
Importantly, our theoretical pharmacokinetic model predicted a 36% reduction 
in mean trough concentration when doses 3 and 4 are missed. There was also 
a greater variability in trough concentrations over time with missed doses. 
From the in vivo studies, the effect size of missed doses appears to be less 
than that of low PIFR but greater than that of breath hold duration. Again, 
since pharmacodynamic parameters were not recorded, it is difficult to draw 
conclusions about the clinical relevance of a 35% reduction in trough 
concentrations. However, it is noteworthy that while most investigators focus 
on temporal adherence in clinical studies, technique factors potentially have a 
greater impact on drug delivery since the same technique errors are 
performed with most doses leading to a cumulative effect. 
The small sample size of this study limits the generalizability of the results but 
does highlight similar trends to those predicted. This study only looked at the 
effect of missing doses 3 and 4; it is likely that other combinations of missed 
doses may have more significant effects on pre-dose 6 trough levels but the 
effects will average out when measuring mean trough concentrations. 
This study used a salbutamol half-life of 6 hours. The mean elimination half-life 
of salbutamol after oral administration is approximately 5.7 ± 1.4 hours and 
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after inhalation is 6.1 ± 2.1 hours.(35) The wide range of half-lives reflects 
inter-individual variability in metabolism as well as technique; inhalation 
technique appears to be significant since the standard deviation for inhalation 
is wider than that for oral administration. Due to this wide range of half-lives, 
the generalizability of our theoretical pharmacokinetic model is also 
questionable. Future pharmacokinetic studies should obtain a complete 
pharmacokinetic profile to allow calculation of the drug half-life for every 
subject. These values can then be used in individualized models of salbutamol 
dosing.
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CHAPTER 9: Development and validation of an algorithm for combining 
time and technique of inhaler use into a single metric 
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9.1. Results 
9.1.1. Algorithm development 
Based on the evidence in prior chapters, DiskusTM inhaler technique errors 
were classified as either critical or non-critical (Table 9.1).  
A first-order pharmacokinetic model was used with a functional half-life of 12 
hours (to mimic twice-daily dosing of the salmeterol/ fluticasone inhaler). Bolus 
doses were assigned using the date- and time- stamped data from the INCATM 
device. The fine particle fraction assigned to each bolus was based on the 
estimated peak inspiratory flow rate and the presence or absence of technique 
errors (Table 9.2). Where multiple errors occurred on the same dose, the 
assigned dose fraction attached to the errors were multiplied to arrive at the 
final FPF assigned to that dose. The concentrations used represent small 
airways concentration of the active drug. 
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Table 9.1: Classification of DiskusTM technique errors as critical or non-critical. 
All errors can be detected by the INCATM device unless stated otherwise. 
Step Correct step Possible technique errors Is error critical? 
1 Push the outer cover as far 
as possible before the 
inhalation 
Failure to open the outer cover 
Incomplete opening of outer cover 
Yes 
2 Slide the lever until the ”click” 
sound to actuate dose 
Failure to slide the lever until the 
“click” sound 
Yes 
3 Keep the mouthpiece 
horizontal or in upward 
position 
Holding the DiskusTM inhaler with 
the mouthpiece facing downward 
No – not 
assessed by 
INCA 
4 Exhale into the room and 
away from the mouthpiece 
after loading 
Exhalation into the device 
mouthpiece 
Yes 
5 Slowly and completely exhale 
out to residual volume (to 
empty the lungs) 
(1) No exhalation or insufficient
exhalation
(2) Forced and fast exhalation
Probable – not 
assessed 
6 Tilt head back (hyperextend) 
slightly and keep the device 
horizontal during inhalation 
Lowering one’s head or holding the 
mouthpiece upward during 
inhalation 
Probable – not 
assessed by 
INCA 
7 Place teeth over the 
mouthpiece with lips 
positioned around it deeply 
(over tongue) and securely 
(sealing lip) 
(1) Lips surround the mouthpiece
shallowly against teeth or tongue
(2) Lips are not sealed around the
mouthpiece during inhalation
Probable – not 
assessed by 
INCA 
8 Inhale forcefully from the 
beginning, slowly (for > 2–3 
sec), deeply, uniformly, and 
continuously inhale during 
the inspiratory phase until the 
lungs are full 
(1) Gradual increase in the speed
of inhalation
(2) Fast and extremely forceful
inhalation
(3) Prematurely stop inhaling (not
inhaling to total lung capacity) or
inhaling twice or more during the
inspiratory phase of the breathing
cycle
Yes 
9 At the end of inhalation 
remove the inhaler from the 
mouth and close the lips 
Not removing the inhaler from the 
mouth at the end of inhalation 
No - not 
assessed by 
INCA 
10 Hold breath for > 5 sec 
(optimally for 10 sec) after 
inhalation (an objective 
measurement performed 
using a stopwatch) 
Not holding breath or holding 
breath for < 5 sec 
Yes 
11 Exhale slowly through the 
nose and away from 
mouthpiece 
(1) Breathing out rapidly from the
mouth after holding breath
(2) Exhaling into the mouthpiece
Unlikely – not 
assessed 
12 Recover the lever and the 
outer cover 
Not closing the lever and the outer 
cover 
No 
13 Rinse one’s mouth out after 
inhaling and do not swallow 
the rinsing water 
(1) Failure to rinse one’s mouth
(2) Swallowing the rinsing water
Significant for 
adverse events 
– not assessed
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Table 9.2: Breakdown of factors that were included in algorithm to generate 
the fine particle fraction assigned to every dose. 
Technique step Error Dose assigned 
Open inhaler N 
Y 
100% 
0% 
Actuate dose lever N 
Y 
100% 
0% 
Exhale away from the mouthpiece N 
Y 
100% 
50% 
Inhaler shaking/ tapping after 
dose actuation 
N 
Y 
100% 
50% 
Inhale deeply and forcefully Salmeterol_FPF (%)=0.176*PIFR 
+ 0.627*InhaleDuration + 5.915
Fluticasone_FPF (%)=0.178*PIFR 
Breath holding duration > 10 
seconds  
N 
Y 
+ 0.640*InhaleDuration + 5.538
100%
75% 
Multiple inhalations or coughing 
after inhalation (<10 second 
breath hold) 
N 
Y 
100% 
75% 
The Stata algorithm code developed is shown in Box 9.1. The trough 
concentrations were calculated using the following equations: 
𝑆𝐴𝐿𝑀𝑡𝑟𝑜𝑢𝑔ℎ = 𝑆𝐴𝐿𝑀𝑡𝑟𝑜𝑢𝑔ℎ[𝑛 − 1] + 𝑆𝐴𝐿𝑀𝐹𝑃𝐹[𝑛] ∗ e
−0.693∗
𝑇𝑖𝑚𝑒 𝛥
12  (9.1)   
𝐹𝐿𝑈𝑇𝑡𝑟𝑜𝑢𝑔ℎ = 𝐹𝐿𝑈𝑇𝑡𝑟𝑜𝑢𝑔ℎ[𝑛 − 1] + 𝐹𝐿𝑈𝑇𝐹𝑃𝐹[𝑛] ∗ e
−0.693∗
𝑇𝑖𝑚𝑒 𝛥
12  (9.2)  
Figure 9.1 represents the dosing profile simulated by the algorithm when 
doses are taken every 12 hours with correct technique. This contrasts with the 
dosing profile simulated with missed doses (absence of a blue bolus dots at 12 
hour intervals in Figure 9.2), overdoses (spike in trough concentration green 
line in Figure 9.2) or when technique errors are made and doses are missed 
211 
(FPF% assigned to a blue dot and absence of blue dots at 12 hour intervals in 
Figure 9.3). The trough concentration is significantly different between the two 
simulated patient profiles.      
Figure 9.1: Pharmacokinetic dosing profile expected with 12 hourly dosing 
interval and correct inhaler technique. The green line represents the expected 
pre-dose trough small airway concentration, the yellow line represents the 
minimum toxic concentration predicted from over-dosing, the red line 
represents the minimum effective concentration using a peak inspiratory flow 
rate of 30 l/min, the blue dots represent bolus doses and the red dashed lines 
represent change in concentration over time. The area above is calculated by 
integrating the area between the green trough curve and the yellow line. The 
area below is calculated by integrating the area between the green trough 
curve and red line. “Mean” represents the average pre-dose trough 
concentration. 
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Figure 9.2: Pharmacokinetic dosing profile expected with 12 hourly dosing 
interval and correct inhaler technique when doses are missed (absence of 
blue dots) or extra doses are taken (green line above yellow line). The green 
line represents the expected pre-dose trough small airway concentration, the 
yellow line represents the minimum toxic concentration predicted from over-
dosing, the red line represents the minimum effective concentration using a 
peak inspiratory flow rate of 30 l/min, the blue dots represent bolus doses and 
the red dashed lines represent change in concentration over time. The area 
above is calculated by integrating the area between the green trough curve 
and the yellow line. The area below is calculated by integrating the area 
between the green trough curve and red line. “Mean” represents the average 
pre-dose trough concentration. 
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Figure 9.3: Pharmacokinetic dosing profile expected with 12 hourly dosing 
interval and technique errors (variation in delivered dose %) when doses are 
missed (absence of blue dots). The green line represents the expected pre-
dose trough small airway concentration, the yellow line represents the 
minimum toxic concentration predicted from over-dosing, the red line 
represents the minimum effective concentration using a peak inspiratory flow 
rate of 30 l/min, the blue dots represent bolus doses and the red dashed lines 
represent change in concentration over time. The area above is calculated by 
integrating the area between the green trough curve and the yellow line. The 
area below is calculated by integrating the area between the green trough 
curve and red line. “Mean” represents the average pre-dose trough 
concentration. 
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Box 9.1: Stata code for dosing algorithm
qui foreach y in 1 2 3 {  
clear all 
scalar indir= "/Users/~/Desktop/" 
scalar outdir= "/Users/~/Desktop/" 
cd "`=indir'" 
import excel `y'.xlsx, sheet("MS") firstrow clear 
gen date2=. 
capture confirm string variable Date 
 if !_rc { 
replace date2=date(Date, "DM20Y") 
} 
else { 
replace date2=Date 
} 
format date2 %td 
format Time %tcHH:MM:SS 
gen InhaleDuration=InhaleStartTime 
gen timed_doses=ORClass>0 
gen combined_doses=ORClass==1 
gen technique_errors=(ORClass==2)*-1 
gen SALM_FPF=0.1755314*PIFR + 0.6265714*InhaleDuration + 5.915075 
gen FLUT_FPF=0.1778574*PIFR + 0.6396681*InhaleDuration + 5.538353 
gen SALM_UAD= 0.1044824*PIFR + 64.04375 
gen FLUT_UAD=0.0460495*PIFR + 63.44969 
capture confirm string variable ORError 
 if !_rc { 
replace SALM_FPF = SALM_FPF*0.5 if strpos(ORError, "2") 
replace FLUT_FPF = FLUT_FPF*0.5 if strpos(ORError, "2") 
replace SALM_FPF = SALM_FPF*0.5 if strpos(ORError, "3") 
replace FLUT_FPF = FLUT_FPF*0.5 if strpos(ORError, "3") 
replace SALM_FPF = SALM_FPF*0.75 if strpos(ORError, "4") 
replace FLUT_FPF = FLUT_FPF*0.75 if strpos(ORError, "4") 
replace SALM_FPF = SALM_FPF*0.75 if strpos(ORError, "5") 
replace FLUT_FPF = FLUT_FPF*0.75 if strpos(ORError, "5") 
replace SALM_FPF = SALM_FPF*0 if ORClass == 0 
replace FLUT_FPF = SALM_FPF*0 if ORClass == 0 
replace SALM_UAD = SALM_UAD*0 if ORClass == 0 
replace FLUT_UAD = SALM_UAD*0 if ORClass == 0 
 } 
 else { 
replace SALM_FPF = SALM_FPF*0.25 if ORError == 2 
replace FLUT_FPF = FLUT_FPF*0.25 if ORError == 2 
replace SALM_FPF = SALM_FPF*0.25 if ORError == 3 
replace FLUT_FPF = FLUT_FPF*0.25 if ORError == 3 
replace SALM_FPF = SALM_FPF*0.5 if ORError == 4 
replace FLUT_FPF = FLUT_FPF*0.5 if ORError == 4 
replace SALM_FPF = SALM_FPF*0.75 if ORError == 5 
replace FLUT_FPF = FLUT_FPF*0.75 if ORError == 5 
replace SALM_FPF = SALM_FPF*0 if ORClass == 0 
replace FLUT_FPF = SALM_FPF*0 if ORClass == 0 
replace SALM_UAD = SALM_UAD*0 if ORClass == 0 
replace FLUT_UAD = SALM_UAD*0 if ORClass == 0 
      } 
keep date2 Time VisitNo SALM_FPF FLUT_FPF SALM_UAD FLUT_UAD 
order date2, before(Time) 
drop if SALM_FPF==. 
drop if date2==. 
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replace Time = clock("31dec1899 14:00:00", "DMYhms") if Time==. & date2!=date2[_n-1] & 
date2!=[_n+1] 
replace Time = clock("31dec1899 08:00:00", "DMYhms") if Time==. & date2!=date2[_n-1] & 
date2==date2[_n+1] 
replace Time = clock("31dec1899 20:00:00", "DMYhms") if Time==. & date2==date2[_n-1] & 
date2!=date2[_n+1] 
replace Time = clock("31dec1899 14:00:00", "DMYhms") if Time==. & date2==date2[_n-1] & 
date2==date2[_n+1] 
gen datetime=date2*24*60*60*1000 +60*365*24*60*60*1000 + 15*24*60*60*1000 + Time 
format datetime %tcDD/NN/CCYY_HH:MM:SS 
gen deltatime=. 
gen SALMtrough=. 
by VisitNo, sort: gene id=_n 
summarize VisitNo 
levelsof VisitNo, local(levels) 
qui foreach i of local levels { 
replace deltatime=(datetime[_n+1]-datetime)/1000/60/60 if VisitNo==`i' 
summarize VisitNo if VisitNo==`i' 
replace deltatime=. if id==`r(N)' & VisitNo==`i' 
replace SALMtrough=(SALM_FPF)*exp(-0.693*deltatime/12) if id==1 
forval x=2/`r(N)' { 
replace SALMtrough=(SALMtrough[_n-1]+SALM_FPF)*exp(-0.693*deltatime/12) if id==`x' 
} 
} 
gen SALMtrough2=SALMtrough/23.5*100 
replace SALMtrough2=100 - (SALMtrough2-100) if SALMtrough2>100 
replace SALMtrough2=0 if SALMtrough2<0 
gen Avgtrough=. 
gen SDtrough=. 
gen mintrough=. 
gen maxtrough=. 
summarize VisitNo 
levelsof VisitNo, local(levels) 
qui foreach i of local levels { 
summarize SALMtrough2 if VisitNo==`i' 
replace Avgtrough=`r(mean)' if VisitNo==`i' 
replace SDtrough=`r(sd)' if VisitNo==`i' 
replace mintrough=`r(min)' if VisitNo==`i' 
replace maxtrough=`r(max)' if VisitNo==`i' 
} 
cd "`=outdir'" 
export excel using `y'.xlsx, sheetreplace sheet("Trough_Data_Act_SALM") firstrow(variables) 
collapse Avgtrough SDtrough mintrough maxtrough, by(VisitNo) 
export excel using `y'.xlsx, sheetreplace sheet("Trough_Data_Summary_Act_SALM") 
firstrow(variables) 
*outsheet date2 Time SALM_FPF using "`y'SALM_Trough_Data_Actual_Overall.txt", replace
import excel `y'.xlsx, sheet("MS") firstrow clear 
gen date2=. 
capture confirm string variable Date 
 if !_rc { 
replace date2=date(Date, "DM20Y") 
} 
else { 
replace date2=Date 
} 
format date2 %td 
format Time %tcHH:MM:SS 
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gen InhaleDuration=InhaleStartTime  
gen timed_doses=ORClass>0 
gen combined_doses=ORClass==1 
gen technique_errors=(ORClass==2)*-1 
gen SALM_FPF=23.5 if ORClass>0 
gen FLUT_FPF=23.5 if ORClass>0 
keep date2 Time VisitNo SALM_FPF FLUT_FPF 
order date2, before(Time) 
drop if SALM_FPF==. 
drop if date2==. 
replace Time = clock("31dec1899 14:00:00", "DMYhms") if Time==. & date2!=date2[_n-1] & 
date2!=[_n+1] 
replace Time = clock("31dec1899 08:00:00", "DMYhms") if Time==. & date2!=date2[_n-1] & 
date2==date2[_n+1] 
replace Time = clock("31dec1899 20:00:00", "DMYhms") if Time==. & date2==date2[_n-1] & 
date2!=date2[_n+1] 
replace Time = clock("31dec1899 14:00:00", "DMYhms") if Time==. & date2==date2[_n-1] & 
date2==date2[_n+1] 
gen datetime=date2*24*60*60*1000 +60*365*24*60*60*1000 + 15*24*60*60*1000 + Time 
format datetime %tcDD/NN/CCYY_HH:MM:SS 
gen deltatime=. 
gen SALMtrough=. 
by VisitNo, sort: gene id=_n 
summarize VisitNo 
levelsof VisitNo, local(levels) 
qui foreach i of local levels { 
replace deltatime=(datetime[_n+1]-datetime)/1000/60/60 if VisitNo==`i' 
summarize VisitNo if VisitNo==`i' 
replace deltatime=. if id==`r(N)' & VisitNo==`i' 
replace SALMtrough=(SALM_FPF)*exp(-0.693*deltatime/12) if id==1 
forval x=2/`r(N)' { 
replace SALMtrough=(SALMtrough[_n-1]+SALM_FPF)*exp(-0.693*deltatime/12) if id==`x' 
} 
} 
gen SALMtrough2=SALMtrough/23.5*100 
replace SALMtrough2=100 - (SALMtrough2-100) if SALMtrough2>100 
replace SALMtrough2=0 if SALMtrough2<0 
gen Avgtrough=. 
gen SDtrough=. 
gen mintrough=. 
gen maxtrough=. 
summarize VisitNo 
levelsof VisitNo, local(levels) 
qui foreach i of local levels { 
summarize SALMtrough2 if VisitNo==`i' 
replace Avgtrough=`r(mean)' if VisitNo==`i' 
replace SDtrough=`r(sd)' if VisitNo==`i' 
replace mintrough=`r(min)' if VisitNo==`i' 
replace maxtrough=`r(max)' if VisitNo==`i' 
} 
cd "`=outdir'" 
export excel using `y'.xlsx, sheetreplace sheet("Trough_Data_Att_SALM") firstrow(variables) 
collapse Avgtrough SDtrough mintrough maxtrough, by(VisitNo) 
export excel using `y'.xlsx, sheetreplace sheet("Trough_Data_Summary_Att_SALM") 
firstrow(variables) 
*outsheet date2 Time SALM_FPF using "`y'SALM_Trough_Data_Actual_Overall.txt", replace
}
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9.1.2. Algorithm performance in a patient cohort. 
The characteristics and demographics of the 20 patients studied are 
presented in Table 9.3. Half of the study population were asthmatics and half 
had an underlying diagnosis of COPD. 
Table 9.3: Demographics, primary respiratory diagnosis and smoking status of 
patient cohort. 
Demographic Mean (SD) or count (%) 
Age 54.8 (19.5) years 
Gender Male 
Female 
8 (40) 
12 (60) 
Diagnosis Asthma 
COPD 
10 (50) 
10 (50) 
Smoking status Non-smoker 
Ex-smoker 
Current smoker 
5 (25) 
7 (35) 
8 (40) 
Table 9.4 and Figures 9.1 through 9.20 show tabular and graphical 
representations of the temporal and technique adherence of all 20 subjects 
over the month of monitoring. There was significant variation in both temporal 
and technique adherence. Some patients had very erratic dosing with both 
over dosing and under dosing, others had predominantly under dosing and 
others had significant numbers of technique errors (three patients had all or 
almost all doses with technique errors). 
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Table 9.4: Breakdown of different adherence rates generated by algorithm. 
Timing only Timing and technique 
Subject 
ID 
Dose 
counter 
rate (%) 
INCATM 
dose 
Rate (%) 
AATR 
(au) 
AUTR 
(au) 
Mean 
delivered 
dose (% 
available 
dose) 
Delivered 
dose CV 
(%) 
Attempte
d Rate 
(%) 
AATR 
(au) 
AUTR 
(au) 
Mean 
delivered 
dose (% 
available 
dose) 
Delivered 
dose CV 
(%) 
Actual 
Rate (%) 
1 88.2 92.1 0.9 8.6 18.9 32.2 80.3 0.0 14.8 13.9 38.1 59.2 
2 178.6 82.1 2.2 6.6 20.5 30.6 87.3 0.0 14.6 13.8 31.3 58.7 
3 137.5 92.5 0.1 4.6 20.8 24.1 88.5 0.0 11.3 16.8 25.5 71.3 
4 135.3 91.2 3.2 6.9 21.1 38.6 89.7 0.0 23.5 8.5 43.5 36.2 
5 94.8 96.6 1.6 2.8 22.7 14.5 96.8 0.0 11.1 17.3 16.9 73.8 
6 88.9 88.9 1.0 6.2 20.3 25.0 86.5 0.0 19.3 12.1 25.5 51.7 
7 81.3 82.8 1.1 6.6 20.1 28.2 85.3 0.0 20.3 11.0 29.8 47.0 
8 81.3 81.3 0.6 8.1 18.6 28.5 79.1 0.0 19.7 9.2 39.5 39.3 
9 90.3 96.8 2.4 5.9 21.4 31.5 90.9 0.1 18.4 12.7 29.9 54.1 
10 93.8 85.9 1.7 4.5 21.8 23.5 92.8 0.0 30.5 5.5 58.0 23.5 
11 92.9 85.7 1.0 6.8 19.9 26.6 84.6 0.0 17.3 12.9 26.1 54.8 
12 90.9 90.9 2.4 5.9 21.5 31.1 91.3 0.2 19.5 11.9 35.5 50.8 
13 80.6 80.6 0.7 8.3 18.8 28.5 79.8 0.0 18.1 12.3 29.3 52.4 
14 103.8 100.0 8.8 4.7 25.4 37.9 107.9 0.3 19.2 12.2 43.7 51.9 
15 84.5 86.2 5.4 8.1 21.8 44.2 92.8 0.1 17.3 12.8 48.0 54.4 
16 98.1 98.1 2.6 2.8 23.3 16.6 99.1 0.0 21.4 12.1 24.3 51.4 
17 89.3 89.3 2.6 6.8 21.1 31.1 89.6 0.0 20.2 12.1 29.8 51.6 
18 70.4 70.4 0.7 9.2 16.8 35.5 71.6 0.0 16.3 11.0 36.9 47.0 
19 89.3 89.3 1.3 4.8 21.4 21.5 91.1 0.0 21.3 11.0 24.1 46.9 
20 60.7 60.7 0.1 13.8 13.4 49.4 56.8 0.0 22.7 6.6 48.1 27.9 
AATR: Area between dosing curve and upper limit of therapeutic range; AUTR: Area between dosing curve and lower limit of therapeutic rang; au: arbitrary 
units.
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Figure 9.4: Patient 1- Scatterplot showing time of date and time of use. Green 
dots represent correct technique and red dots represent a technique error. Bar 
graph shows number of doses taken per day with a target of 2 doses per day 
(red line). Green bars represent correct technique and red bars represent 
technique errors. This patient has periods of over-dosing and missed 
doses with only one technique error (Class 1). 
Figure 9.5: Patient 2- Scatterplot showing time of date and time of use. Green 
dots represent correct technique and red dots represent a technique error. Bar 
graph shows number of doses taken per day with a target of 2 doses per day 
(red line). Green bars represent correct technique and red bars represent 
technique errors. This patient has no technique errors but erratic dosing 
with both overdosing and underdosing (Class 1). 
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Figure 9.6: Patient 3- Scatterplot showing time of date and time of use. Green 
dots represent correct technique and red dots represent a technique error. Bar 
graph shows number of doses taken per day with a target of 2 doses per day 
(red line). Green bars represent correct technique and red bars represent 
technique errors. This patient has good temporal and technique 
adherence (Class 2). 
Figure 9.7: Patient 4- Scatterplot showing time of date and time of use. Green 
dots represent correct technique and red dots represent a technique error. Bar 
graph shows number of doses taken per day with a target of 2 doses per day 
(red line). Green bars represent correct technique and red bars represent 
technique errors. This patient has poor temporal and technique adherence 
(Class 0). 
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Figure 9.8: Patient 5- Scatterplot showing time of date and time of use. Green 
dots represent correct technique and red dots represent a technique error. Bar 
graph shows number of doses taken per day with a target of 2 doses per day 
(red line). Green bars represent correct technique and red bars represent 
technique errors. This patient has good temporal and technique 
adherence (Class 2). 
Figure 9.9: Patient 6- Scatterplot showing time of date and time of use. Green 
dots represent correct technique and red dots represent a technique error. Bar 
graph shows number of doses taken per day with a target of 2 doses per day 
(red line). Green bars represent correct technique and red bars represent 
technique errors. This patient has relatively good temporal and good 
technique adherence (Class 1). 
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Figure 9.10: Patient 7- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has regular missed doses and 
technique errors (Class 0). 
Figure 9.11: Patient 8- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has regular missed doses and a 
cluster of doses with technique errors (Class 0). 
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Figure 9.12: Patient 9- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has moderate temporal and good 
technique adherence (Class 1). 
Figure 9.13: Patient 10- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has poor technique adherence and 
good temporal adherence with only a few missed doses (Class 0). 
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Figure 9.14: Patient 11- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has regular missed doses but 
good technique (Class 1). 
Figure 9.15: Patient 12- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has relatively good temporal and 
technique adherence with a few missed doses (Class 1). 
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Figure 9.16: Patient 13- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has moderate temporal adherence 
with regular missed doses and good technique adherence (Class 1). 
Figure 9.17: Patient 14- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has poor temporal and technique 
adherence and both overdosing and underdosing. All events have 
technique errors (Class 0). 
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Figure 9.18: Patient 15- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has poor temporal adherence with 
both overdosing and underdosing, as well as sporadic dose timing 
(Class 0). 
Figure 9.19: Patient 16- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has good temporal adherence but 
poor technique adherence with a cluster of technique errors (Class 1). 
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Figure 9.20: Patient 17- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has moderate temporal and 
moderate technique adherence (Class 1). 
Figure 9.21: Patient 18- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has poor temporal adherence with 
mainly missed doses (Class 0). 
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Figure 9.22: Patient 19- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has good temporal adherence but 
almost all events have technique errors (Class 0). 
Figure 9.23: Patient 20- Scatterplot showing time of date and time of use. 
Green dots represent correct technique and red dots represent a technique 
error. Bar graph shows number of doses taken per day with a target of 2 
doses per day (red line). Green bars represent correct technique and red bars 
represent technique errors. This patient has poor temporal and technique 
adherence with mainly missed doses and almost all events having 
technique errors (Class 0). 
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A summary of the patient overall adherence classification and different 
adherence rates are presented in Table 9.5. The actual rate was significantly 
lower that all other rates (Figure 9.24) but showed the strongest correlation 
with overall technique classification by the raters. Based on the dose counter 
rate or INCATM dose rate alone, all but two patients (patients 18 and 20) were 
classified as good adherence (≥80%). These patients had numerous missed 
doses during the month of monitoring. The attempted rate would have 
classified both of these patients as poor adherence, as well as two others 
(patients 8 and 13). These additional patients also had a relatively large 
number of missed doses. 
There was disagreement between the dose counter rate and the INCATM dose 
or attempted rate for patients 2, 3 and 4. These patients had episodes of 
multiple doses taken at the same time or dose dumping (patient 2) prior to 
returning the inhaler. 
Table 9.5: Summary of overall rater classification, dose counter rate from 
DiskusTM inhaler and three adherence rates calculated from INCATM device. 
Subject 
ID 
Combined 
temporal/ technique 
class 
Dose 
counter 
rate 
INCATM 
dose 
rate 
Attempted 
rate 
Actual 
rate 
1 1 88.2 92.1 80.3 59.2 
2 1 178.6 82.1 87.3 58.7 
3 2 137.5 92.5 88.5 71.3 
4 0 135.3 91.2 89.7 36.2 
5 2 94.8 96.6 96.8 73.8 
6 1 88.9 88.9 86.5 51.7 
7 0 81.3 82.8 85.3 47.0 
8 0 81.3 81.3 79.1 39.3 
9 1 90.3 96.8 90.9 54.1 
10 0 93.8 85.9 92.8 23.5 
11 1 92.9 85.7 84.6 54.8 
12 1 90.9 90.9 91.3 50.8 
13 1 80.6 80.6 79.8 52.4 
14 0 103.8 100.0 107.9 51.9 
15 0 84.5 86.2 92.8 54.4 
16 1 98.1 98.1 99.1 51.4 
17 1 89.3 89.3 89.6 51.6 
18 0 70.4 70.4 71.6 47.0 
19 0 89.3 89.3 91.1 46.9 
20 0 60.7 60.7 56.8 27.9 
Class 0 – poor overall adherence, class 1 – moderate overall adherence, class 2 – 
good overall adherence. 
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Figure 9.24 shows relatively good agreement between the three temporal 
adherence rates and highlights the outliers mentioned before with dose 
counter rates. All three temporal rates were poor at classifying overall 
adherence. There was good separation of the actual rate values according to 
overall classification. 
Figure 9.24: Boxplots of dose counter rate from DiskusTM inhaler and three 
adherence rates calculated from INCATM device grouped by overall rater 
classification of adherence (n=20). 
The scatterplot matrix in Figure 9.25 also highlights the lack of correlation 
between the three temporal adherence rates and the actual rate, thus 
confirming the lack of relationship between temporal dosing errors and 
technique errors. For example, patient 18 had poor temporal adherence and 
good technique adherence, patient 19 had good temporal adherence and poor 
technique adherence and patient 20 had poor temporal and technique 
adherence. The dose counter rate would have classified patients 18 and 20 as 
having poor adherence and would have missed the significant technique 
errors in patient 19’s profile. 
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Figure 9.25: Scatterplot matrix comparing dose counter rate from DiskusTM
inhaler and three adherence rates calculated from INCATM device. 
Spearman’s rho and Pearson’s correlation coefficients for two-way 
comparisons of the four adherence rates (Tables 9.6 and 9.7) demonstrate 
that the dose counter rate correlates poorly with the INCATM device derived 
rates, most likely because of the significant outliers due to dose dumping and 
multiple dosing. The INCATM rate and attempted rate were moderately 
correlated. The actual rate correlated poorly with all temporal rates. 
Table 9.6: Spearman’s rho for two-way comparisons of different adherence 
rates. 
Rate (%) Dose counter INCA Attempted Actual 
Dose counter 1.0000 
INCA 0.6601 
(0.0015) 
1.0000 
Attempted 0.5028 
(0.0238) 
0.7524 
(0.0001) 
1.0000 
Actual 0.4392 
(0.0527) 
0.3755 
(0.1028) 
0.1347 
(0.5713) 
1.0000 
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Table 9.7: Pearson’s correlation coefficients for two-way comparisons of 
different adherence rates. 
Rate (%) Dose counter INCA Attempted Actual 
Dose counter 1.0000 
INCA 0.3645 
(0.1141) 
1.0000 
Attempted 0.3006 
(0.1978) 
0.8980 
(0.0000) 
1.0000 
Actual 0.3757 
(0.1026) 
0.5031 
(0.0238) 
0.3622 
(0.1165) 
1.0000 
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9.2. Discussion 
This chapter sought to unify the previous experimental data and the data 
derived from the INCATM device into a comprehensive measure of adherence 
that incorporates both date and time of inhaler use and the presence or 
absence of technique errors and the significance of these errors. Technique 
errors were weighted according the experimental data presented in prior 
chapters.  
A first-order elimination profile was used to generate trough dose levels. The 
mean overall trough over the study period was compared to the expected 
trough level if the inhaler was used as instructed to determine the attempted 
and actual rates (actual rates also incorporated technique errors). The benefit 
of a pharmacokinetic model is that it also takes into account the concept of 
interval adherence or the gap between doses. Even though an inhaler is used 
twice a day, the time of use affects the trough doses achieved. The interval 
adherence is not considered in the dose counter rate since data on the date 
and time of use is not captured. This is clearly evident for the three patients 
who had significant dose dumping; the dosing profiles from the INCATM device 
showed a marked discrepancy with the dose counter rate. In an effort to not 
disappoint clinicians, some patients engage in this activity of dose dumping 
prior to their visit to show that they have used their inhaler. Failure to capture 
information about actual day-to-day use would therefore be detrimental to the 
patient’s disease control. 
As expected, there was a poor relationship between the actual adherence and 
the temporal adherence rates. Interestingly, most patients had good temporal 
adherence but poor actual adherence due to the high incidence of technique 
errors. No patient achieved an actual rate greater than 80%, highlighting that 
these cutoffs may need to be adjusted to mirror real-world inhaler use where 
both temporal and technique errors are made. 
Clinical trials on inhaler efficacy can significantly benefit from electronic 
monitors like the INCATM device. Results can be interpreted in the context of 
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actual inhaler use instead of averaged surrogate measures. Ease of use can 
also be determined based on the number of technique errors made. In the 
clinical care setting, use of the INCATM device can generate more personalized 
feedback to address temporal adherence, technique adherence or both. 
However, while this technology and method of calculating combined 
adherence rates seems promising, it cannot be recommended at present 
without further outcome studies, which can look at the clinical significance or 
providing feedback and training based on the dose counter and checklist 
(standard of care) versus the INCATM device. These trials are currently under 
way for various patient cohorts. (166) Larger sample sizes are also required to 
validate the algorithm developed in this study.  
The results of this study highlight the need for a device that can monitor 
inhaler adherence, both temporal and technique, longitudinally since there is 
significant variation between patients and within a patient over time. 
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CHAPTER 10: General Discussion 
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10.1. Overview 
Inhaled medications are the mainstay of therapy in the treatment of chronic 
respiratory diseases like asthma and COPD because they allow delivery of the 
active ingredient directly to the site of action. There has been a steady 
increase in the use of dry powder inhalers (DPIs) because they do not use 
chlorofluorocarbon-containing propellants of most of the older metered-dose 
inhalers and they have fewer coordination problems compared to metered 
dose inhalers (MDIs). In fact, the global market for nebulizers, inhalers and 
respirators was worth $12.4 billion in 2014 and is expected to grow at an 
annual rate of 8.9% to reach $19.0 billion by 2019.(167)  
However, DPI devices are not without their problems. Good adherence to 
inhaled medications includes several dimensions: intensity and timing of use 
according to prescription (temporal adherence), continuous use (persistence) 
and correct use (technique adherence).(82, 168)  
Problems with temporal adherence are common among all inhaler types and 
also other medications used to treat chronic diseases. Patient self-reporting 
questionnaires have shown that adherence to inhaled therapy in patients with 
COPD is less than 60% and the most common reason reported for poor 
adherence was the dosing frequency required.(169) Studies evaluating 
prescription filling have found that up to 20% of patients with asthma 
prescribed controller medications for the first time did not fill their prescriptions 
and the mean proportion of days covered varied from 19% to 30% over a 12 
month period.(98) A similar study in Northern Ireland found that one third of 
patients filled fewer than half of their inhaler prescriptions and 88% admitted to 
poor adherence.(170) Patients with COPD generally display poorer adherence 
rates compared to asthmatics with up to a 60% non-adherence rate.(171-173) 
Poor adherence to inhaled controller medications has been estimated to 
account for up to 60% of asthma-related hospitalizations and increased rates 
of 30- and 60- day hospital readmissions in patients with COPD.(174, 175) 
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There are three recognized types of temporal non-adherence: underuse, 
overuse and haphazard use. Underuse is by far the most common type. One 
study found that only 15% of patients took their prescribed inhaler more than 
80% of the days; on the other hand, overdosing occurred on less than 10% of 
days.(173)  
Numerous electronic monitoring devices have been developed over the last 
four decades to monitor temporal non-adherence; however, many of these 
devices do not monitor all or most aspects of inhaler technique. Inhaler 
technique or competence is a very important component of overall adherence. 
Badder et al found that 85% of patients with poor inhaler technique 
demonstrated poor asthma control.(176) Many features specific to inhaler 
design contribute to technique adherence; errors are more common with the 
TurbuhalerTM (32%) and pMDI (28%) compared to the DiskusTM, Autohaler and 
Aerolizer (11-12%).(177) In some studies, up to 90% of patients make at least 
one inhaler technique error.(178) The most common error types are also 
device-specific: low breath-hold duration and exhalation prior to inhalation are 
most common with the DiskusTM, TurbuhalerTM and Aerolizer, whereas errors 
with inhalation are most common with the Autohaler or pMDI.(177) 
Currently used methods for monitoring inhaler technique are suboptimal. 
Checklists are very subjective and other methods such as the Clement-Clarke 
In-Check DialTM assess only one or a few components of technique, such as 
inhalation flow rate.(61, 62, 132, 133) Most methods are a once-off 
assessment in the clinic setting unless the clinician relies on the patient to 
document readings at home, in a similar fashion to peak expiratory flow rate 
readings. The data on the effect of certain errors on drug delivery and efficacy 
is also lacking. The strongest level of evidence exists for the effect of errors in 
inhalation or breath hold duration, although most of the studies have used in 
vitro or in silico methodologies.(75, 85, 86, 89, 94, 96) 
There was a need to study the frequency of temporal and technique non-
adherence in the Irish population and to investigate the impact of dosing and 
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technique errors on drug delivery. Moreover, a comprehensive system of 
tracking the date and time of inhaler use, as well as, the presence or absence 
of technique errors on a daily basis was essential to not only an 
epidemiological understanding of inhaler use but to tailoring of inhaler training 
and clinical care plans to individual patients. 
A collaborative effort by physicians and engineers has allowed the 
development of an acoustic monitor, the INCATM device, which can be 
attached to the DiskusTM inhaler, in order to monitor both how and when the 
inhaler is used. While the accuracy of the device for monitoring date and time 
of use has been studied by the group, the ability to accurately assess inhaler 
technique and the correlation between these errors and drug delivery have 
not.  
This thesis aimed to describe features of temporal and technique adherence 
to a common DPI in a community care Irish population and to study the effects 
of DiskusTM inhaler technique errors on drug delivery. These observations 
were utilized to develop and validate an algorithm to incorporate data on 
temporal and technique adherence obtained from the INCATM device into a 
single overall adherence metric. 
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10.2. Main findings 
10.2.1. How common are DiskusTM inhaler temporal and technique errors in a 
community care setting? 
The dose counter over-estimated the number of doses taken (55 per patient 
versus 49 per patient with INCATM device). Only 20% of patients took their 
inhaler in the correct manner at the correct interval and missed doses were 
more common than extra doses. Three-quarters of the acoustic profiles 
demonstrated good inhaler technique. The most common inhaler technique 
errors identified were poor peak inspiratory flow rate (27% of inhalations), 
multiple inhalations (25%), dose blistering without an inhalation (19%) and 
exhalation into the inhaler after blistering but before inhalation (18%). The 
mean number of errors per person was 12 per 60-dose inhaler. Overall 
adherence changed during the month of observation in two groups of patients; 
adherence improved in one group and worsened in another. 
10.2.2. The effect of inhalation parameters on delivered dose and an acoustic 
method to quantify this effect 
The mean DiskusTM PIFR was lower in patients with COPD and 
Neuromuscular disease compared to asthmatics and healthy individuals. 
DiskusTM PIFR was also lower in older patients (>50 years). There was a 
moderate correlation between DiskusTM PIFR and spirometric PIFR. 
Spirometric PIFR may be used as a surrogate measure of PIFR through the 
DiskusTM inhaler. 
In a study of healthy volunteers, there was a strong correlation between the 
amplitude of inhalation, in particular the mean absolute deviation of amplitude 
and the average power in the 300-600 Hz band, with the PIFR generated 
through the DiskusTM inhaler. Volume of inhalation through the DiskusTM could 
be calculated using the DiskusTM PIFR and duration of inhalation. 
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In a respiratory disease cohort, MAD amplitude had the strongest correlation 
with DiskusTM PIFR (r=0.884). The equations for calculating DiskusTM PIFR 
generated from data collected from healthy individuals demonstrated greater 
than 90% sensitivity and specificity for classifying an inhalation (correctly 
classified 95% of inhalations > 30 l/min, 91% > 45 l/min, 93% > 60 l/min and 
92% > 90 l/min). Estimated DiskusTM PIFR and duration of inhalation 
accounted for greater than 95% of the variation observed in fine particle 
fraction emitted from the salmeterol/ fluticasone inhaler and DiskusTM PIFR 
accounted for more than 70% of the variation observed in FPF from the 
salbutamol inhaler. The FPF from the salbutamol inhaler was more than 
double the FPF from the salmeterol/ fluticasone inhaler and the mean mass 
aerodynamic diameter (MMAD) was lower for the salbutamol inhaler. 
Pharmacokinetic studies on 10 healthy volunteers demonstrated that there 
was a significant two-fold increase in peak salbutamol concentration 
(measured at 20 min post-dose) achieved when DiskusTM PIFR was above 60 
l/min compared to when DiskusTM PIFR was below 60 l/min for each individual. 
DiskusTM PIFR explained more than 50% of the variation observed in peak 
salbutamol concentration. 
10.2.3. Development and validation of an acoustic method to detect and 
quantify the effect of exhalation into a Dry Powder Inhaler 
Exhalation directed at the inhaler mouthpiece after dose blistering was found 
to have an overall negative effect on drug delivery. At an exhalation distance 
of 0 cm from the inhaler mouthpiece, less than 50% of drug available is 
delivered on average for all flow rates using humid air. In a worst-case 
scenario, an average of 2.44% of drug is delivered after an expiratory flow rate 
of 120 L/Min, at a distance of 0 cm from the inhaler mouthpiece. The fine 
particle fraction (FPF) was significantly reduced for inhaler devices subjected 
to an exhalation. 
A strong correlation was observed between the exhalation flow rate, the 
distance of the exhalation from the mouthpiece and the direction of the 
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exhalation with the acoustic features obtained from the exhalation audio 
signal. An algorithm was developed to classify an exhalation as significant 
(exhalations occurring at a distance of 5 cm or less, into the DPI mouthpiece 
or directly at the INCATM device). The algorithm had a sensitivity of 72.22% 
and a specificity of 85.71%. 
10.2.4. Does orientation of the DiskusTM inhaler affect available dose for 
delivery? 
Only when the DiskusTM was held at the 90° position after dose actuation and 
shaken was significant amount of drug removed (54% of available dose 
removed with a range of 39.4% to 62.3%). Tapping the DiskusTM at a position 
of 90° removed approximately 10% of the available dose. Holding the 
DiskusTM in a steady position at 45° or 90° had no appreciable effect on the 
amount of drug available for delivery. 
10.2.5. Impact of breath holding on drug delivery 
There was a statistically significant 29% reduction in trough salbutamol 
concentration when subjects had only a 4 second breath hold duration 
compared to correct inhaler technique with a 10 second breath hold. There 
was also a 22% lower rise in salbutamol concentration from the dose 6 trough 
level when using a 4 second breath hold. 
10.2.6. Impact of missed doses on steady state trough and peak levels 
A theoretical model based on first-order kinetics and a salmeterol/ fluticasone 
functional half-life of 12 hours was used to estimate the impact of missing 
doses 3 and 4 in a 6-dose regimen. The expected mean pre-dose 6 trough 
level when doses 3 and 4 was 36% lower than when all 6 doses are taken. 
Pharacokinetic studies on 7 healthy volunteers demonstrated a statistically 
significant 64% difference in pre-dose 6 trough concentration between the 
control group and the group that missed doses 3 and 4 (control: 0.85 ng/ml 
and missed doses: 0.55ng/ml, p<0.001). 
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10.2.7. Development and validation of an algorithm for combining time and 
technique of inhaler use into a single metric 
A pharmacokinetic algorithm was developed to combine date and time of 
inhaler use with the presence or absence of technique errors into a single 
measure called the actual rate. The algorithm was tested in a cohort of twenty 
patients followed for one month with the INCATM device. There was significant 
variation in both temporal and technique adherence. Some patients had very 
erratic dosing with both over dosing and under dosing, others had 
predominantly under dosing and others had significant numbers of technique 
errors (three patients had all or almost all doses with technique errors). The 
actual rate was significantly lower that all other rates but showed the strongest 
correlation with overall technique classification by the raters. The dose counter 
rate correlated poorly with the INCATM device derived rates, most likely 
because of the significant outliers due to dose dumping and multiple dosing, 
as well as the failure to detect technique errors. 
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10.3. Contextual discussion 
This body of work highlights the utility of the INCATM device in not only logging 
and monitoring the date and time when a DiskusTM inhaler is used but also in 
detecting the presence or absence of critical technique errors, which may be 
detrimental to drug delivery and efficacy. The DiskusTM is one of the two most 
commonly prescribed DPIs in developed countries.(65) The INCATM device 
was designed to be attached to the DiskusTM and to monitor inhaler use over a 
one-month period.  
Chapter 3 showed that temporal and technique adherence was relatively poor 
in an Irish community care setting, with only 20% of patients using their 
DiskusTM DPI as prescribed. The most common technique errors identified 
were poor peak inspiratory flow rate, multiple inhalations, exhalation prior to 
inhalation and dose blistering without a subsequent inhalation.  
Studies normally highlight exhalation errors as the most common DiskusTM
technique error.(81) The rate of inhalation errors is comparatively low in the 
literature.(177) The reason for this discrepancy is likely the lack of an objective 
universal method of assessing peak inspiratory flow rate and the variability in 
flow rate from day to day. Although the Clement-Clarke In-Check DialTM and 
the Vitalograph AIM are available to estimate the PIFR achieved from various 
devices, these devices are not universally used by clinicians in evaluating 
inhaler technique and thus, assessment of inhalation is quite subjective. The 
mouthpiece dimensions of the In-Check Dial and AIM are also quite different 
and may have an effect on the mouthseal achieved by the patient or the 
general way the patient handles the peak flow meter versus the DiskusTM
inhaler. 
The evidence presented in Chapter 4 highlights that peak inspiratory flow rate 
generated through the DiskusTM inhaler has a significant effect on drug 
delivery both in vitro and in vivo, mirroring the evidence in the literature. The 
INCATM device had excellent sensitivity and specificity for classifying an 
inhalation as adequate (>60 l/min), suboptimal (30-60 l/min) or inadequate 
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(<30 l/min). The advantage of the INCATM device compared to other peak flow 
meters is that it can be used to monitor PIFR longitudinally. We have seen that 
patients in a community care setting do not necessarily make the same inhaler 
error on every dose; likewise, there is significant variability in PIFRs generated 
within an individual over time. These findings may be related to acute 
exacerbations or other psycho-social factors, such as the patient’s 
assessment of disease control. It is therefore, more beneficial to look at 
patterns of inhaler use rather than a once-off evaluation of inhaler technique. 
“Multiple inhalations” was the second most frequent error type. Many patients 
with asthma are either current or former users of spacer devices with pMDIs. 
Spacers allow increased drug delivery by decoupling the need to coordinate 
dose actuation with inhalation.(179) The user takes multiple deep breaths in 
and out through the device. Many patients have either used this “multiple 
inhalation” technique or seen it being used and this may explain why one-
quarter of patients demonstrated a similar technique when using the DiskusTM
inhaler. Unfortunately, “multiple inhalations” with a DPI usually shortens the 
breath hold duration. Chapter 7 highlights that a shorter breath hold duration 
leads to reduced drug delivery and this effect is similarly seen in numerous in 
silico models of breath holding in the literature.(75, 86) Coughing immediately 
after inhalation is also a significant problem. ICSs can lead to bronchospasm 
and cough after inhalation and cough is a recognized feature of COPD and 
asthma.(180) Coughing also shortens the breath hold duration, thus impacting 
drug delivery. The INCATM device is able to detect both multiple inhalations 
and episodes of coughing after inhalation and can accurately quantify the 
breath hold duration if these events occur. 
Exhalation into the inhaler mouthpiece after blistering but before inhalation is 
another common technique error in our patient cohort. In vivo studies in 
Chapter 5 showed that exhalation of humidified air directed towards the 
DiskusTM mouthpiece had a significant effect on the amount of drug available 
for delivery and the subsequent fine particle fraction when inhaled. While 
studies on DiskusTM technique have highlighted that this error is very common, 
there is no evidence in the literature quantifying the effect of exhalation on 
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drug delivery. The mechanism underlying the finding of reduced FPF is most 
likely clumping of the active drug and carrier inside the dose blister, limiting the 
subsequent de-aggregation usually observed with inhalation. 
DiskusTM orientation or position during use is frequently assessed in checklists 
of inhaler technique.(76, 181) The rationale for inclusion of this error is the fact 
that after dose blistering, the drug is now exposed and can be displaced from 
the inhaler if not held in a horizontal or upright position. The effect of DiskusTM
position has either never been studied formally or has been studied by the 
manufacturer but not published. The results of Chapter 6 show that DiskusTM
position has a minimal impact on the amount of drug removed from the inhaler 
unless the inhaler is held with the mouthpiece facing down and the inhaler is 
tapped or shaken. While the INCATM device cannot detect DiskusTM orientation 
in space, it can detect when the device is shaken vigorously (another common 
error since patients usually shake their pMDI prior to use) or tapped. 
Published estimates of temporal adherence in the literature have been based 
on pharmacy records of filled prescriptions and on subject patient reports; 
these estimates are either inherently biased in the case of patient reported 
adherence or only give averages of adherence over a period of time.(98, 169) 
New electronic monitors, which log the date and time of inhaler use have 
allowed better estimates of patient adherence. The INCATM device allows 
accurate logging of the date and time of inhaler use allowing the physician to 
recognize patterns of inhaler use and relate these patterns to patient-centric 
factors. The results presented in Chapter 8 show that missed doses can have 
a significant impact on drug delivery, using serum concentrations as a 
surrogate measure. The theoretical pharmacokinetic model shows that the 
number of missed doses and which dose is missed in relation to the time of 
trough concentration measurement can also impact measured serum 
concentrations. It is recognized that many patients, who are enrolled in clinical 
trials of inhaled drugs, demonstrate the Hawthorne effect, that is, adherence 
rates are good at the beginning of the trial and subsequently worsen when 
clinician contact is reduced. Chapter 3 shows similar findings, in that a group 
of patients monitored over a month demonstrated good temporal adherence 
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on enrollment and had a gradual decline in adherence over the month of 
observation. The data highlights the need to be able to track temporal 
adherence and patterns of temporal adherence over time. 
Based on the available evidence in the literature and the results of studies 
reported in Chapters 3 – 8, DiskusTM inhaler errors were classified as either 
critical or non-critical. An algorithm was developed to predict effect small 
airways concentrations of active drugs based on the half-life of the drug (12 
hours), the date and time the inhaler was used, and the predicted fine particle 
fraction delivered, which was affected by the presence of technique errors. 
This is the first study of its kind attempting to combine features of temporal 
and technique adherence in a single metric called actual adherence. The 
results of Chapter 9 show that there was a discrepancy between the INCATM 
dose rate and the dose counter rate, especially when patients engaged in 
dose dumping. Dose dumping has been recognized in prior trials using 
electronic monitoring devices such as the Nebulizer Chronologs, where the 
authors concluded that deception among noncompliers occurs frequently in 
clinical trials, is often not revealed by the usual methods of monitoring, and 
cannot be predicted by data readily available in clinical trials.(182) The INCATM 
device allows another layer of detection of this phenomenon. Not only can the 
number of dose actuations in a short period of time be detected but the 
INCATM device can highlight whether these actuations were associated with 
subsequent inhalations (representing over-dosing) or not (representing dose 
dumping). 
Finally, Chapter 10 highlighted again the frequency of technique errors since 
the actual adherence rate was significantly lower than measures of only 
temporal adherence derived from either the dose counter or the INCATM 
device. There was also very little correlation between actual adherence and 
temporal adherence, meaning that patients with good temporal adherence did 
not necessarily make fewer technique errors. The single metric of actual 
adherence also has a pharmacologic basis and is likely to better predict drug 
efficacy and simple temporal adherence rates. 
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10.4. Limitations 
This thesis did not report on all DiskusTM inhaler technique errors; only errors 
that could potentially be detected by the INCATM device were studied, which 
still accounted for the large majority of DiskusTM technique errors in the 
literature. For example, the failure to exhale to residual lung volume prior to 
inhalation and its effect on subsequent fine particle fraction delivered was not 
studied here and has been reported in the literature to be a common technique 
error in DiskusTM users.(177) The effect of neck extension on fine particle 
fraction or upper airways dose was also not investigated. Some errors, such 
as failure to open the device or failure to actuate or blister a dose, were 
considered to lead to 0% dose availability due simply to the design of the 
DiskusTM and hence, did not require further study. Other errors, such as mouth 
rinsing after inhalation, while important from the point of view of side effects, 
were not important for drug delivery or efficacy and were omitted from this 
thesis.  
One major shortcoming of the INCATM device is its inability to detect the breath 
hold duration if an exhalation is not audible after the dose inhalation or if the 
device is closed prior to this exhalation. Some patients do make audible 
exhalations so that the breath hold duration can be quantified and the duration 
can also be quantified in the case of multiple inhalations or coughing after 
inhalation. 
The acoustic method developed for estimating inspiratory flow rate is also not 
flawless and a few patients with adequate or suboptimal flow rates were 
misclassified into either suboptimal or inadequate categories, respectively. 
The correlation between DiskusTM PIFR and peak serum salbutamol 
concentrations was only moderate and PIFR could not explain a large 
proportion of the variation in peak concentrations, likely reflecting that other 
inhaler technique factors or biological factors, such as drug absorption, were 
not accounted for. This highlights a major flaw in using serum drug 
concentrations to predict local accumulation of the drug at the site of action 
(the small airways). The assumption is made that the two are correlated but 
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there is likely intra- and inter-individual biological variation in drug absorption. 
The ideal method of monitoring drug accumulation or residence time in the 
small airways is the use of radionucleotide tags but this is substantially less 
safe than blood sampling, especially with repeated doses. 
Further limitations of the in vivo studies reported in this thesis are the small 
sample sizes and the use of healthy volunteers only. Most pharmacokinetic 
studies of inhaled medications have been limited to a sample size of 10 
historically due to the extensive blood sampling required. Since the studies 
reported here utilized a repeated measures design with a washout period, the 
number of recruits available was rather small. The physiology and anatomy of 
the lungs in healthy individuals is also significantly different to that of patients 
with chronic airways diseases and this may affect drug delivery and serum 
concentrations achieved. It is therefore difficult to generalize findings in a small 
group of healthy volunteers to larger asthma and COPD populations. 
This body of work also suffers from a lack of data on pharmacodynamics and 
a lack of outcome data. While the trough concentration may be correlated with 
clinical effect, no drug specific effects such as bronchodilation or change in 
FEV1 were studied. Similarly, the longitudinal studies did not investigate the 
relationship between the INCATM device measures of temporal and technique 
adherence with rates of exacerbation, use of reliever medications or overall 
disease control. Collection of these outcome measures would require a longer 
study period and a randomized controlled design. 
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10.5. Future research and applications 
Studies are in progress to evaluate whether patient feedback based on the 
INCATM device is superior to the standard of care in the treatment of 
asthma.(166) These studies are monitoring outcome data such as quality of 
life scores (Asthma Quality of Life Questionnaire), disease control scores 
(Asthma Control Test) and objective measures of control such as peak 
expiratory flow rates, exacerbation rates and use of reliever inhalers. Similar 
studies are being conducted in COPD cohorts. 
The INCATM device is also being adapted to the MDI inhaler, allowing accurate 
monitoring of reliever inhaler use in future clinical trials and patient care.(183) 
The aim is to extend the patented technology to other DPIs, including the 
TurbuhalerTM and the new ELLIPTATM. The ELLIPTATM is Glaxo-Smith Kleine’s 
new inhaler, which is touted to be more user-friendly than the DiskusTM and 
allows once daily dosing.(184) However, the device has its unique technique 
error profile than can affect drug delivery and would still benefit from an 
adherence monitor. 
Further studies are necessary to advance the work conducted here into the 
effect of technique errors in asthma and COPD cohorts. These large trials will 
be able to correlate the measures of drug delivery predicted by the INCATM 
algorithms with actual drug delivery, either from surrogate trough 
concentrations or pharmacodynamic data including FEV1, PEFR or fraction of 
exhaled nitric oxide (FENO). There is increasing interest in the correlation 
between FENO measurements, which are simple and non-invasive, and non-
adherence or asthma disease control.(185) 
The two main areas where the INCATM technology can be applied are in 
clinical trials of new inhaled therapies, where accurate data on adherence is 
necessary to adjust for the effect of this major confounder, and in routine 
patient care, where data from the device can allow the physician or nurse 
practitioner to tailor educational training and feedback. 
250 
References 
1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic 
obstructive pulmonary disease surveillance--United States, 1971-2000. MMWR 
Surveill Summ. 2002;51(6):1-16. 
2. Braman SS. The global burden of asthma. Chest. 2006;130(1 
Suppl):4S-12S. 
3. Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback B. 
Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, 
GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, 
and smoking habits. Respiration. 2005;72(5):471-9. 
4. Rosenberg SR, Kalhan R, Mannino DM. Epidemiology of Chronic 
Obstructive Pulmonary Disease: Prevalence, Morbidity, Mortality, and Risk 
Factors. Semin Respir Crit Care Med. 2015;36(4):457-69. 
5. Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and 
risk factors. CMAJ. 2009;181(9):E181-90. 
6. Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. 
Asthma: prevalence and cost of illness. Eur Respir J. 2005;25(1):47-53. 
7. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years 
lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet. 2012;380(9859):2163-96. 
8. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global 
strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 
2007;176(6):532-55. 
9. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and 
state-specific medical and absenteeism costs of COPD among adults aged >/= 18 
years in the United States for 2010 and projections through 2020. Chest. 
2015;147(1):31-45. 
10. Chrystyn H, Niederlaender C. The Genuair(R) inhaler: a novel, multidose 
dry powder inhaler. Int J Clin Pract. 2012;66(3):309-17. 
251 
11. Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc. 
2003;24(2):79-83. 
12. Leuppi JD. Bronchoprovocation tests in asthma: direct versus indirect 
challenges. Curr Opin Pulm Med. 2014;20(1):31-6. 
13. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 
2015;16(1):45-56. 
14. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. 
Nat Rev Immunol. 2015;15(1):57-65. 
15. Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodeling in 
asthma. Curr Opin Pulm Med. 2000;6(1):15-20. 
16. Boulet LP, Chakir J, Dube J, Laprise C, Boutet M, Laviolette M. Airway 
inflammation and structural changes in airway hyper-responsiveness and asthma: 
an overview. Can Respir J. 1998;5(1):16-21. 
17. National Asthma E, Prevention P. Expert Panel Report 3 (EPR-3): 
Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J 
Allergy Clin Immunol. 2007;120(5 Suppl):S94-138. 
18. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary 
disease. Lancet. 2012;379(9823):1341-51. 
19. Turato G, Zuin R, Saetta M. Pathogenesis and pathology of COPD. 
Respiration. 2001;68(2):117-28. 
20. Enright PL, Kaminsky DA. Strategies for screening for chronic obstructive 
pulmonary disease. Respir Care. 2003;48(12):1194-201; discussion 201-3. 
21. D'Urzo AD, Tamari I, Bouchard J, Jhirad R, Jugovic P. New spirometry 
interpretation algorithm: Primary Care Respiratory Alliance of Canada approach. 
Can Fam Physician. 2011;57(10):1148-52. 
22. Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does 
the 2013 GOLD classification improve the ability to predict lung function decline, 
exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC 
Pulm Med. 2014;14:163. 
23. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, et al. 
Bronchodilator responsiveness in patients with COPD. Eur Respir J. 
2008;31(4):742-50. 
252 
24. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A 
summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 
2015;46(3):622-39. 
25. FitzGerald JM, Poureslami I. The need for humanomics in the era of 
genomics and the challenge of chronic disease management. Chest. 
2014;146(1):10-2. 
26. Global Initiative for Asthma (GINA). Global Strategy for Asthma 
Management and Prevention. 2015. 
27. National Institute for Health and Clinical Excellence (NICE). National 
Clinical Guideline Centre for Acute and Chronic Conditions: Chronic obstructive 
pulmonary disease. Management of chronic obstructive pulmonary disease in 
adults in primary and secondary care. 2010. p. 61 p. (Clinical guideline; no. 101). 
28. Jenkins C. COPD management. Part I. Strategies for managing the burden 
of established COPD. Int J Tuberc Lung Dis. 2008;12(6):586-94. 
29. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Jr., et 
al. A 6-month, placebo-controlled study comparing lung function and health 
status changes in COPD patients treated with tiotropium or salmeterol. Chest. 
2002;122(1):47-55. 
30. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in 
COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95-109. 
31. Rodriguez-Roisin R. Toward a consensus definition for COPD 
exacerbations. Chest. 2000;117(5 Suppl 2):398S-401S. 
32. Ojoo JC, Moon T, McGlone S, Martin K, Gardiner ED, Greenstone MA, et al. 
Patients' and carers' preferences in two models of care for acute exacerbations of 
COPD: results of a randomised controlled trial. Thorax. 2002;57(2):167-9. 
33. Donohue JF, Ohar JA. Bronchodilator therapy of airway disease. In: Chung 
KF, Barnes PJ, editors. Pharmacology and Therapeutics of Airway Disease. New 
York, NY: Informa Healthcare USA; 2009. p. 198–225. 
34. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic 
efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 
2002;165(10):1353-8. 
253 
35. Hindle M, Chrystyn H. Determination of the relative bioavailability of
salbutamol to the lung following inhalation. Br J Clin Pharmacol. 
1992;34(4):311-5. 
36. Elers J, Pedersen L, Henninge J, Lund TK, Hemmersbach P, Dalhoff K, et al.
Blood and urinary concentrations of salbutamol in asthmatic subjects. Med Sci 
Sports Exerc. 2010;42(2):244-9. 
37. Du XL, Zhu Z, Fu Q, Li DK, Xu WB. Pharmacokinetics and relative
bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Acta 
Pharmacol Sin. 2002;23(7):663-6. 
38. Lin C, Magat J, Calesnick B, Symchowicz S. Absorption, excretion and
urinary metabolic pattern of 3 H-albuterol aerosol in man. Xenobiotica. 
1972;2(6):507-15. 
39. Evans ME, Walker SR, Brittain RT, Paterson JW. The metabolism of
salbutamol in man. Xenobiotica. 1973;3(2):113-20. 
40. Walker SR, Evans ME, Richards AJ, Paterson JW. The clinical pharmacology
of oral and inhaled salbutamol. Clin Pharmacol Ther. 1972;13(6):861-7. 
41. Velayati A, Hosseini SA, Sari AA, Mohtasham F, Ghanei M, Yaghoubi M, et al.
Comparison of the effectiveness and safety of formoterol versus salmeterol in the 
treatment of patients with asthma: A systematic review and meta-analysis. J Res 
Med Sci. 2015;20(5):483-90. 
42. Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol.
Clin Pharmacokinet. 2002;41(1):19-30. 
43. Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta 2
adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. 
Thorax. 1988;43(9):674-8. 
44. Soulele K, Macheras P, Silvestro L, Rizea Savu S, Karalis V. Population
pharmacokinetics of fluticasone propionate/salmeterol using two different dry 
powder inhalers. Eur J Pharm Sci. 2015;80:33-42. 
45. Zafar MA, Droege C, Foertsch M, Panos RJ. Update on ultra-long-acting beta
agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 
2014;23(12):1687-701. 
46. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway
obstruction due to emphysema. N Engl J Med. 1984;311(7):421-5. 
254 
47. Roffel AF, Elzinga CR, Zaagsma J. Cholinergic contraction of the guinea pig 
lung strip is mediated by muscarinic M2-like receptors. Eur J Pharmacol. 
1993;250(2):267-79. 
48. Mann KV, Leon AL, Tietze KJ. Use of ipratropium bromide in obstructive 
lung disease. Clin Pharm. 1988;7(9):670-80. 
49. Ensing K, de Zeeuw RA, Nossent GD, Koeter GH, Cornelissen PJ. 
Pharmacokinetics of ipratropium bromide after single dose inhalation and oral 
and intravenous administration. Eur J Clin Pharmacol. 1989;36(2):189-94. 
50. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer 
R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci.
1993;52(5-6):537-44. 
51. Haddad EB, Mak JC, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly 
dissociating muscarinic antagonist, in human lung: radioligand binding and 
autoradiographic mapping. Mol Pharmacol. 1994;45(5):899-907. 
52. Price D, Sharma A, Cerasoli F. Biochemical properties, pharmacokinetics 
and pharmacological response of tiotropium in chronic obstructive pulmonary 
disease patients. Expert Opin Drug Metab Toxicol. 2009;5(4):417-24. 
53. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, 
et al. Improved health outcomes in patients with COPD during 1 yr's treatment 
with tiotropium. Eur Respir J. 2002;19(2):209-16. 
54. Georgitis JW. The 1997 Asthma Management Guidelines and therapeutic 
issues relating to the treatment of asthma. National Heart, Lung, and Blood 
Institute. Chest. 1999;115(1):210-7. 
55. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern 
Med. 2003;139(5 Pt 1):359-70. 
56. Yudt MR, Cidlowski JA. The glucocorticoid receptor: coding a diversity of 
proteins and responses through a single gene. Mol Endocrinol. 
2002;16(8):1719-26. 
57. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am 
Rev Respir Dis. 1990;141(2 Pt 2):S70-6. 
58. Kelly HW, Nelson HS. Potential adverse effects of the inhaled 
corticosteroids. J Allergy Clin Immunol. 2003;112(3):469-78; quiz 79. 
255 
59. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of 
pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. 
Eur Respir J. 2006;28(5):1042-50. 
60. Derendorf H. Pharmacokinetic and pharmacodynamic properties of 
inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91 
Suppl A:22-8. 
61. Khassawneh BY, Al-Ali MK, Alzoubi KH, Batarseh MZ, Al-Safi SA, Sharara 
AM, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose 
inhaler versus dry powder inhalers. Respir Care. 2008;53(3):324-8. 
62. Dal Negro RW. Dry powder inhalers and the right things to remember: a 
concept review. Multidiscip Respir Med. 2015;10(1):13. 
63. Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, et 
al. Retail sales of inhalation devices in European countries: so much for a global 
policy. Respir Med. 2011;105(7):1099-103. 
64. Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative 
assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for 
delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 
2013;13:72. 
65. Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol 
Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small 
airway impairment and airway inflammation in patients with asthma. Pulm 
Pharmacol Ther. 2011;24(5):571-6. 
66. Chrystyn H. The Diskus: a review of its position among dry powder inhaler 
devices. Int J Clin Pract. 2007;61(6):1022-36. 
67. Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug 
delivery to the lung. AAPS PharmSciTech. 2015;16(3):479-90. 
68. IMS Health. National Prescription Audit Plus 2012 [cited 2015 Jul 15]. 
Available from: http://www.imshealth.com. 
69. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med.
2005;353(5):487-97. 
70. Bender BG. Nonadherence in chronic obstructive pulmonary disease 
patients: what do we know and what should we do next? Curr Opin Pulm Med. 
2014;20(2):132-7. 
256 
71. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. 
Effect of incorrect use of dry powder inhalers on management of patients with 
asthma and COPD. Respir Med. 2008;102(4):593-604. 
72. Foster JA, Yawn BP, Maziar A, Jenkins T, Rennard SI, Casebeer L. Enhancing 
COPD management in primary care settings. MedGenMed. 
2007;9(3):24. 
73. Yawn BP, Wollan PC. Knowledge and attitudes of family physicians coming 
to COPD continuing medical education. Int J Chron Obstruct Pulmon Dis. 
2008;3(2):311-7. 
74. Pritchard JN, Nicholls C. Emerging technologies for electronic monitoring 
of adherence, inhaler competence, and true adherence. J Aerosol Med Pulm Drug 
Deliv. 2015;28(2):69-81. 
75. Katz IM, Schroeter JD, Martonen TB. Factors affecting the deposition of 
aerosolized insulin. Diabetes Technol Ther. 2001;3(3):387-97. 
76. Basheti IA, Bosnic-Anticevich SZ, Armour CL, Reddel HK. Checklists for 
powder inhaler technique: a review and recommendations. Respir Care. 
2014;59(7):1140-54. 
77. Cain WT, Cable G, Oppenheimer JJ. The ability of the community 
pharmacist to learn the proper actuation techniques of inhaler devices. J Allergy 
Clin Immunol. 2001;108(6):918-20. 
78. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's 
knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing 
chambers, and breath-actuated dry powder inhalers. Chest. 1994;105(1):111-6. 
79. Serra-Batlles J, Plaza V, Badiola C, Morejon E, Inhalation Devices Study G. 
Patient perception and acceptability of multidose dry powder inhalers: a 
randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. J 
Aerosol Med. 2002;15(1):59-64. 
80. Schulte M, Osseiran K, Betz R, Wencker M, Brand P, Meyer T, et al. 
Handling of and preferences for available dry powder inhaler systems by patients 
with asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2008;21(4):321-8. 
81. Basheti IA, Qunaibi E, Bosnic-Anticevich SZ, Armour CL, Khater S, Omar M, 
et al. User error with Diskus and Turbuhaler by asthma patients and pharmacists 
in Jordan and Australia. Respir Care. 2011;56(12):1916-23. 
257 
82. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler
mishandling remains common in real life and is associated with reduced disease 
control. Respir Med. 2011;105(6):930-8. 
83. Engel T, Scharling B, Skovsted B, Heinig JH. Effects, side effects and plasma
concentrations of terbutaline in adult asthmatics after inhaling from a dry 
powder inhaler device at different inhalation flows and volumes. British journal 
of clinical pharmacology. 1992;33(4):439-44. 
84. Self TH, Pinner NA, Sowell RS, Headley AS. Does it really matter what
volume to exhale before using asthma inhalation devices? J Asthma. 
2009;46(3):212-6. 
85. Sumby B, Cooper S, Smith I. A comparison of the inspiratory effort
required to operate the Diskhaler inhaler and Turbohaler inhaler in the 
administration of powder drug formulations. Br J Clin Res. 1992;3:117-23. 
86. Martonen TB, Katz IM. Deposition patterns of aerosolized drugs within
human lungs: effects of ventilatory parameters. Pharm Res. 1993;10(6):871-8. 
87. Dunbar CA, Hickey AJ, Holder P. Dispersion and characterization of
pharmaceutical dry powder aerosols. KONA Powder and Particle. 1998;16:45. 88.
French DL, Edwards DA, Niven RW. The influence of formulation on emission, 
deaggregation and deposition of dry powders for inhalation. Journal of Aerosol 
Science. 1996;27:769-83. 
89. Voss A, Finlay WH. Deagglomeration of dry powder pharmaceutical
aerosols. Int J Pharm. 2002;248(1-2):39-50. 
90. Burnell PK, Small T, Doig S, Johal B, Jenkins R, Gibson GJ. Ex-vivo product
performance of Diskus and Turbuhaler inhalers using inhalation profiles from 
patients with severe chronic obstructive pulmonary disease. Respir Med. 
2001;95(5):324-30. 
91. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug
delivery. Expert Opin Drug Deliv. 2004;1(1):67-86. 
92. Ganderton D. General factors influencing drug delivery to the lung. Respir
Med. 1997;91 Suppl A:13-6. 
93. Palander A. In vitro comparison of three salbutamol-containing multidose
dry powder inhalers. Clin Drug Invest. 2000;20:25-33. 
258 
94. Rottier BL, Rubin BK. Asthma medication delivery: mists and myths.
Paediatr Respir Rev. 2013;14(2):112-8; quiz 8, 37-8. 
95. Behara SR, Longest PW, Farkas DR, Hindle M. Development and
comparison of new high-efficiency dry powder inhalers for carrier-free 
formulations. J Pharm Sci. 2014;103(2):465-77. 
96. Dolovich M, Ruffin RE, Roberts R, Newhouse MT. Optimal delivery of
aerosols from metered dose inhalers. Chest. 1981;80(6 Suppl):911-5. 
97. Feehan M, Ranker L, Durante R, Cooper DK, Jones GJ, Young DC, et al.
Adherence to controller asthma medications: 6-month prevalence across a US 
community pharmacy chain. J Clin Pharm Ther. 2015;[Epub ahead of print]. 
98. Wu AC, Butler MG, Li L, Fung V, Kharbanda EO, Larkin EK, et al. Primary
adherence to controller medications for asthma is poor. Ann Am Thorac Soc. 
2015;12(2):161-6. 
99. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM.
Adherence to prescribed treatment for asthma: evidence from pharmacy benefits 
data. J Asthma. 2003;40(1):93-101. 
100. Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Stanford R, Su Z, et al.
Impact of adherence to treatment with fluticasone propionate/salmeterol in 
asthma patients. Curr Med Res Opin. 2014;30(7):1417-25. 
101. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and
medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811. 
102. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al.
Effects of smoking intervention and the use of an inhaled anticholinergic 
bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 
1994;272(19):1497-505. 
103. Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated
outcomes in elderly patients with moderate to severe chronic pulmonary disease. 
Clin Ther. 2000;22(4):452-69. 
104. Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R,
et al. The need to improve inhalation technique in Europe: a report from the 
Aerosol Drug Management Improvement Team. Respir Med. 2006;100(9):1479-
94.
259 
105. Crompton GK. Inhaler technique blind spot. Eur Respir J.
2006;27(5):1070-1; author reply 1. 
106. Nikander K, Turpeinen M, Pelkonen AS, Bengtsson T, Selroos O, Haahtela T.
True adherence with the Turbuhaler in young children with asthma. Arch Dis
Child. 2011;96(2):168-73. 
107. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled
corticosteroids for asthma therapy: patient compliance, devices, and inhalation 
technique. Chest. 2000;117(2):542-50. 
108. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT.
Determinants of an incorrect inhalation technique in patients with asthma or 
COPD. Scand J Prim Health Care. 2001;19(4):255-60. 
109. Li H, Chen Y, Zhang Z, Dong X, Zhang G, Zhang H. Handling of Diskus dry
powder inhaler in Chinese chronic obstructive pulmonary disease patients. J 
Aerosol Med Pulm Drug Deliv. 2014;27(3):219-27. 
110. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N.
Assessment of handling of inhaler devices in real life: an observational study in 
3811 patients in primary care. J Aerosol Med. 2003;16(3):249-54. 
111. van der Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose
powder inhaler (Diskus/Accuhaler) and the Turbuhaler regarding preference and 
ease of use. J Asthma. 1998;35(2):147-52. 
112. Girodet PO, Raherison C, Abouelfath A, Lignot S, Depont F, Moore N, et al.
Real-life use of inhaler devices for chronic obstructive pulmonary disease in 
primary care. Therapie. 2003;58(6):499-504. 
113. De Angelis G DA, Donati G, et al. GEINA Project. Survey on the modalities of
use of Diskuss in Italy. Rass Patol Apparato Respir 2003;18:450–4. 
114. Farmer KC. Methods for measuring and monitoring medication regimen
adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-90. 
115. Patel M, Pilcher J, Travers J, Perrin K, Shaw D, Black P, et al. Use of
metered-dose inhaler electronic monitoring in a real-world asthma randomized 
controlled trial. J Allergy Clin Immunol Pract. 2013;1(1):83-91. 
116. O'Connor SL, Bender BG, Gavin-Devitt LA, Wamboldt MZ, Milgrom H,
Szefler S, et al. Measuring adherence with the Doser CT in children with asthma. J 
Asthma. 2004;41(6):663-70. 
260 
117. Julius SM, Sherman JM, Hendeles L. Accuracy of three electronic monitors
for metered-dose inhalers. Chest. 2002;121(3):871-6. 
118. Foster JM, Smith L, Usherwood T, Sawyer SM, Rand CS, Reddel HK. The
reliability and patient acceptability of the SmartTrack device: a new electronic 
monitor and reminder device for metered dose inhalers. J Asthma. 
2012;49(6):657-62. 
119. Bogen D, Apter AJ. Adherence logger for a dry powder inhaler: a new
device for medical adherence research. J Allergy Clin Immunol. 
2004;114(4):863-8. 
120. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, et al. Efficacy
and safety of maintenance and reliever combination budesonide-formoterol 
inhaler in patients with asthma at risk of severe exacerbations: a randomised 
controlled trial. Lancet Respir Med. 2013;1(1):32-42. 
121. Perrin K, Williams M, Wijesinghe M, James K, Weatherall M, Beasley R.
Randomized controlled trial of adherence with single or combination inhaled 
corticosteroid/long-acting beta-agonist inhaler therapy in asthma. J Allergy Clin 
Immunol. 2010;126(3):505-10. 
122. Foster JM, Usherwood T, Smith L, Sawyer SM, Xuan W, Rand CS, et al.
Inhaler reminders improve adherence with controller treatment in primary care 
patients with asthma. J Allergy Clin Immunol. 2014;134(6):1260-8 e3. 
123. Capanoglu M, Dibek Misirlioglu E, Toyran M, Civelek E, Kocabas CN.
Evaluation of inhaler technique, adherence to therapy and their effect on disease 
control among children with asthma using metered dose or dry powder inhalers. 
J Asthma. 2015;52(8):838-45. 
124. Al-Jahdali H, Ahmed A, Al-Harbi A, Khan M, Baharoon S, Bin Salih S, et al.
Improper inhaler technique is associated with poor asthma control and frequent 
emergency department visits. Allergy Asthma Clin Immunol. 2013;9(1):8. 
125. Press VG, Arora VM, Shah LM, Lewis SL, Ivy K, Charbeneau J, et al. Misuse
of respiratory inhalers in hospitalized patients with asthma or COPD. J Gen Intern 
Med. 2011;26(6):635-42. 
126. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors
determine the frequency of handling errors? Respiration. 2008;75(1):18-25. 
261 
127. Apter AJ, Tor M, Feldman HI. Testing the reliability of old and new features
of a new electronic monitor for metered dose inhalers. Ann Allergy Asthma 
Immunol. 2001;86(4):421-4. 
128. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human
lung following administration from a microprocessor controlled pressurised 
metered dose inhaler. Thorax. 1995;50(6):639-44. 
129. Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Mode of breathing-
tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system 
affects lung deposition of (99m)Tc-DTPA. J Aerosol Med Pulm Drug Deliv. 
2010;23 Suppl 1:S37-43. 
130. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using
the In-Check Dial to identify these rates. Respir Med. 2003;97(2):181-7. 
131. Broeders ME, Molema J, Vermue NA, Folgering HT. In Check Dial: accuracy
for Diskus and Turbuhaler. Int J Pharm. 2003;252(1-2):275-80. 
132. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for
a suboptimal peak inspiratory flow rate against the simulated resistance of the 
Diskus(R) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174-9. 
133. Melani AS, Bracci LS, Rossi M. Reduced Peak Inspiratory Effort through the
Diskus((R)) and the Turbuhaler((R)) due to Mishandling is Common in Clinical 
Practice. Clin Drug Investig. 2005;25(8):543-9. 
134. Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML.
Technique training does not improve the ability of most patients to use 
pressurised metered-dose inhalers (pMDIs). Prim Care Respir J. 2011;20(1):92-6. 
135. Jolly GP, Mohan A, Guleria R, Poulose R, George J. Evaluation of Metered
Dose Inhaler Use Technique and Response to Educational Training. Indian J Chest 
Dis Allied Sci. 2015;57(1):17-20. 
136. Rahmati H, Ansarfard F, Ghodsbin F, Ghayumi MA, Sayadi M. The Effect of
Training Inhalation Technique with or without Spacer on Maximum Expiratory 
Flow Rate and Inhaler Usage Skills in Asthmatic Patients: A Randomized 
Controlled Trial. Int J Community Based Nurs Midwifery. 2014;2(4):211-9. 
137. Press VG, Arora VM, Shah LM, Lewis SL, Charbeneau J, Naureckas ET, et al.
Teaching the use of respiratory inhalers to hospitalized patients with asthma or 
COPD: a randomized trial. J Gen Intern Med. 2012;27(10):1317-25. 
262 
138. Nides MA, Tashkin DP, Simmons MS, Wise RA, Li VC, Rand CS. Improving
inhaler adherence in a clinical trial through the use of the nebulizer chronolog. 
Chest. 1993;104(2):501-7. 
139. Onyirimba F, Apter A, Reisine S, Litt M, McCusker C, Connors M, et al.
Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on 
adherence. Ann Allergy Asthma Immunol. 2003;90(4):411-5. 
140. Charles T, Quinn D, Weatherall M, Aldington S, Beasley R, Holt S. An
audiovisual reminder function improves adherence with inhaled corticosteroid 
therapy in asthma. J Allergy Clin Immunol. 2007;119(4):811-6. 
141. World Medical Association. Declaration of Helsinki: ethical principles for
medical research involving human subjects. JAMA. 2013;310(20):2191-4. 
142. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, et
al. Peak inspiratory flow through the Genuair inhaler in patients with moderate 
or severe COPD. Respiratory medicine. 2009;103(12):1832-7. 
143. Malmberg LP, Rytilä P, Happonen P, Haahtela T. Inspiratory flows through
dry powder inhaler in chronic obstructive pulmonary disease: age and gender 
rather than severity matters. International journal of chronic obstructive 
pulmonary disease. 2010;5:257. 
144. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.
Standardisation of spirometry. Eur Respir J. 2005;26(2):319-38. 
145. Kiyokawa H, Pasterkamp H. Volume-dependent variations of regional lung
sound, amplitude, and phase. Journal of Applied Physiology. 2002;93(3):1030-8. 
146. Hossain I, Moussavi Z, editors. Finding the lung sound-flow relationship in
normal and asthmatic subjects. Engineering in Medicine and Biology Society, 
2004 IEMBS'04 26th Annual International Conference of the IEEE; 2004: IEEE. 
147. Physical Tests and Determinations- Aerosols NS, Metered-Dose Inhalers
and Dry Powder Inhalers. The United States Pharmacopeial Convention. 2013; 
USP 36: 242-262. . 
148. Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH. Characterisation of
high dose aerosols from dry powder inhalers. Int J Pharm. 2012;437(1-2):242-9. 
149. Hoe S, Young PM, Chan HK, Traini D. Introduction of the electrical next
generation impactor (eNGI) and investigation of its capabilities for the study of 
pressurized metered dose inhalers. Pharm Res. 2009;26(2):431-7. 
263 
150. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use ICH Q2 (R1). Validation of 
Analytical Procedures: Text and Methodology. Federal Register.1997. p. 27463-7. 
151. ISO 27427: 2009 (Nebulizing Systems and Components).
152. Inhalation Report. How do you calculate MMAD 2010 [cited 2013 Nov 10].
Available from: http://www.inhalationreport.com. 
153. Berry E. Relative Humidity of Expired Air. American Physical Education
Review. 1914;19(6):452-4. 
154. Holmes MS, Seheult JN, Geraghty C, D'Arcy S, O'Brien U, Crispino O'Connell
G, et al. A method of estimating inspiratory flow rate and volume from an inhaler 
using acoustic measurements. Physiol Meas. 2013;34(8):903-14. 
155. Hossain I, Moussavi Z. Finding the lung sound-flow relationship in normal
and asthmatic subjects. Conf Proc IEEE Eng Med Biol Soc. 2004;5:3852-5. 
156. Paliwal KK. On the use of filter-bank energies as features for robust speech
recognition. Proceedings of the Fifth International Symposium on Signal 
Processing and Its Applications. 1999;2:641-4. 
157. Paliwal KK. Decorrelated and liftered filter-bank energies for robust
speech recognition. Eurospeech. 1999;99:85-8. 
158. Quatieri TE. Discrete Time Speech Signal Processing Principles and
Practice. Oppenheim AV, editor: Prentice Hall 2002. 
159. Sidler-Moix AL, Mercier T, Decosterd LA, Di Paolo ER, Berger-Gryllaki M,
Cotting J, et al. A highly sensitive LC-tandem MS assay for the measurement in 
plasma and in urine of salbutamol administered by nebulization during 
mechanical ventilation in healthy volunteers. Biomed Chromatogr. 
2012;26(5):672-80. 
160. Kraman S. The relationship between airflow and lung sound amplitude in
normal subjects. Chest. 1984;86(2):225-9. 
161. Gavriely N, Cugell DW. Airflow effects on amplitude and spectral content of
normal breath sounds. Journal of applied physiology. 1996;80(1):5-13. 
162. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T,
Troosters T, et al. Inspiratory flow rates at different levels of resistance in elderly 
COPD patients. European Respiratory Journal. 2008;31(1):78-83. 
264 
163. Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory
flow with in‐check dial device to simulate low‐resistance (Diskus) and high‐
resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatric 
pulmonology. 2005;39(5):447-51. 
164. Palander A, Mattila T, Karhu M, Muttonen E. In vitro Comparison of Three
Salbutamol-Containing Multidose Dry Powder Inhalers. Clin Drug Investig. 
2000;20(1):25-33. 
165. Edwards AM. Assessing lung deposition of inhaled medications. Consensus
statement from a workshop of the British Association for Lung Research, held at 
the Institute of Biology, London, U.K. on 17 April 1998. Snell NJC, Ganderton D. 
eds. Respir Med 1999; 93: 123-133. Respir Med. 2000;94(9):918-9. 
166. Sulaiman I, Mac Hale E, Holmes M, Hughes C, D'Arcy S, Taylor T, et al. A
protocol for a randomised clinical trial of the effect of providing feedback on 
inhaler technique and adherence from an electronic device in patients with poorly 
controlled severe asthma. BMJ Open. 2016;6(1):e009350. 
167. Nebulizers, Inhalers and Respirators for Asthma Treatment: Global
Markets [press release]. March 2015. 
168. World Health Organization. Adherence to long-term therapies—evidence
for action 2003 [cited 2015 Oct 30]. Available from: 
http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf. 
169. Tamura G, Ohta K. Adherence to treatment by patients with asthma or
COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 
2007;101(9):1895-902. 
170. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of
nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180(9):817-22. 
171. Chryssidis E, Frewin DB, Frith PA, Dawes ER. Compliance with aerosol
therapy in chronic obstructive lung disease. N Z Med J. 1981;94(696):375-7. 172.
Haupt D, Krigsman K, Nilsson JL. Medication persistence among patients with 
asthma/COPD drugs. Pharm World Sci. 2008;30(5):509-14. 
173. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled
medication: does combining beta-agonists with corticosteroids improve 
compliance? Eur Respir J. 1994;7(3):504-9. 
265 
174. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the
long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880-4. 
175. Blee J, Roux RK, Gautreaux S, Sherer JT, Garey KW. Dispensing inhalers to
patients with chronic obstructive pulmonary disease on hospital discharge: 
Effects on prescription filling and readmission. Am J Health Syst Pharm. 
2015;72(14):1204-8. 
176. Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of
compliance and inhaler technique assessments. J Asthma. 2014;51(4):429-34. 
177. Molimard M. How to achieve good compliance and adherence with
inhalation therapy. Curr Med Res Opin. 2005;21 Suppl 4:S33-7. 
178. van Beerendonk I, Mesters I, Mudde AN, Tan TD. Assessment of the
inhalation technique in outpatients with asthma or chronic obstructive 
pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma. 
1998;35(3):273-9. 
179. Jat KR, Singhal KK, Guglani V. Autohaler vs. metered-dose inhaler with
spacer in children with asthma. Pediatr Allergy Immunol. 2016;27(2):217-20. 
180. Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled
corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin 
Drug Saf. 2015;14(4):533-41. 
181. De Tratto K, Gomez C, Ryan CJ, Bracken N, Steffen A, Corbridge SJ. Nurses'
knowledge of inhaler technique in the inpatient hospital setting. Clin Nurse Spec. 
2014;28(3):156-60. 
182. Simmons MS, Nides MA, Rand CS, Wise RA, Tashkin DP. Unpredictability of
deception in compliance with physician-prescribed bronchodilator inhaler use in 
a clinical trial. Chest. 2000;118(2):290-5. 
183. Taylor TE, Holmes MS, Sulaiman I, D'Arcy S, Costello RW, Reilly RB. An
acoustic method to automatically detect pressurized metered dose inhaler 
actuations. Conf Proc IEEE Eng Med Biol Soc. 2014;2014:4611-4. 
184. Yun Kirby S, Zhu CQ, Kerwin EM, Stanford RH, Georges G. A Preference
Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA(R) Dry 
Powder Inhaler (DPI) versus DISKUS(R) DPI. COPD. 2015:1-9. 
266 
185. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of
fractional exhaled nitric oxide suppression in the identification of nonadherence 
in difficult asthma. Am J Respir Crit Care Med. 2012;186(11):1102-8. 
267 
APPENDICES
268 
APPENDIX 1: Ethics approvals and patient information leaflet. 
Consent and Patient Information 
Version	  3	  Salbutamol	   Date	  16/12/2013	   Page	  1	  
Patient	  Information	  Leaflet	  
(Assessing	  inhaled	  drug	  delivery	  through	  sound	  analysis)
Study	  title:	  Dosing	  algorithm	  for	  inhalational	  therapy	  using	  acoustics	  
Principal	  investigator’s	  name:	   Professor	  Richard	  W.	  Costello	  
Telephone	  number	  of	  principal	  investigator:	   00353-­‐1-­‐809-­‐3762	  
You	  are	  being	  invited	  to	  take	  part	  in	  a	  clinical	  research	  study	  to	  be	  carried	  out	  at	  Beaumont	  
Hospital.	  	  
Before	  you	  decide	  whether	  or	  not	  you	  wish	  to	  take	  part,	  you	  should	  read	  the	  information	  
provided	  below	  carefully.	  	  Take	  time	  to	  ask	  questions	  –	  don’t	  feel	  rushed	  and	  don’t	  feel	  under	  
pressure	  to	  make	  a	  quick	  decision.	  
You	  should	  clearly	  understand	  the	  risks	  and	  benefits	  of	  taking	  part	  in	  this	  study	  so	  that	  you	  can	  
make	  a	  decision	  that	  is	  right	  for	  you.	  This	  process	  is	  known	  as	  ‘Informed	  Consent’.	  	  
You	  don’t	  have	  to	  take	  part	  in	  this	  study	  and	  a	  decision	  not	  to	  take	  part	  will	  have	  no	  effect	  on	  
your	  future	  medical	  care.	  	  
You	  can	  change	  your	  mind	  about	  taking	  part	  in	  the	  study	  any	  time	  you	  like.	  	  Even	  if	  the	  study	  
has	  started,	  you	  can	  still	  opt	  out.	  	  You	  don't	  have	  to	  give	  us	  a	  reason.	  	  If	  you	  do	  opt	  out,	  rest	  
assured	  it	  won't	  affect	  the	  quality	  of	  treatment	  you	  get	  in	  the	  future.	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Why	  is	  this	  study	  being	  done?	  
We	  want	  to	  	  measure	  how	  well	  a	  drug	  gets	  into	  your	  system	  and	  see	  if	  we	  can	  relate	  that	  	  with	  
the	  sounds	  of	  breathing	  through	  an	  inhaler.	  
Who	  is	  organising	  and	  funding	  this	  study?	  
Professor	  Richard	  Costello	  and	  his	  research	  team	  are	  organising	  this	  study.	  This	  is	  an	  
investigator-­‐led	  study	  and	  is	  being	  funded	  by	  the	  Health	  Research	  Board	  of	  Ireland.	  The	  results	  
of	  this	  study	  will	  be	  used	  to	  write	  a	  thesis	  for	  one	  of	  Professor	  Costello’s researchers	  with	  the	  
aim	  of	  obtaining	  a	  degree. 
Why	  am	  I	  being	  	  asked	  to	  take	  part?	  
You	  have	  been	  approached	  to	  consider	  taking	  part	  in	  this	  study	  because	  you	  are	  a	  healthy	  
individual	  or	  have	  mild	  obstruction	  from	  asthma	  on	  your	  breathing	  tests.	  
How	  will	  the	  study	  be	  carried	  out?	  
The	  study	  will	  commence	  in	  June	  2013	  and	  	  recruitment	  will	  continue	  until	  April	  2015	  (2	  years).	  
The	  study	  will	  take	  place	  at	  Beaumont	  Hospital	  under	  the	  management	  of	  Professor	  Costello	  
and	  his	  research	  team	  and	  with	  engineers	  in	  TCD.	  For	  you	  there	  is	  only	  one	  set	  of	  tests	  required	  
and	  they	  take	  about	  60	  minutes	  to	  complete.	  
What	  will	  happen	  to	  me	  if	  I	  agree	  to	  take	  part?	  
If	  you	  take	  part	  we	  will	  ask	  you	  to	  have	  basic	  lung	  function	  tests	  done.	  We	  will	  also	  instruct	  you	  
on	  how	  to	  use	  a	  Diskus	  inhaler.	  You	  will	  be	  enrolled	  in	  this	  study	  for	  a	  period	  of	  three	  (3)	  weeks.	  
On	  week	  one,	  you	  will	  take	  a	  Salbutamol	  Diskus	  inhaler	  regularly	  for	  one	  week.	  You	  will	  have	  
blood	  samples	  taken,	  lung	  function	  tests	  and	  Blood	  Pressure/	  Heart	  Rate	  monitoring	  done	  
during	  this	  period.	  This	  will	  be	  followed	  by	  a	  week	  where	  no	  drug	  is	  taken.	  In	  the	  final	  week,	  
the	  above	  will	  be	  repeated	  with	  a	  change	  to	  the	  dosing	  frequency	  or	  how	  the	  inhaler	  is	  used.	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What	  are	  the	  benefits?	  
There	  are	  no	  immediate	  benefits	  to	  your	  participation	  in	  this	  study.	  
What	  are	  the	  risks?	  
The	  needle	  into	  the	  arm	  can	  be	  sore	  and	  there	  is	  a	  small	  risk	  of	  infection,	  although	  by	  using	  the	  
best	  sterile	  techniques	  we	  will	  keep	  this	  risk	  to	  a	  minimum.	  
The	  medicine,	  salbutamol	  can	  cause	  shaking	  or	  fast	  beating	  of	  the	  heart	  although	  this	  is	  
unlikely	  when	  a	  person	  takes	  a	  single	  dose.	  
Is	  the	  study	  confidential?	  
Your	  GP	  will	  not	  be	  informed	  of	  your	  participation	  unless	  this	  is	  specifically	  requested	  by	  you,	  as	  
there	  is	  no	  new	  treatment	  or	  change	  in	  therapy.	  	  
All	  your	  information	  will	  be	  viewed	  only	  by	  members	  of	  Professor	  Costello’s	  team	  and	  be	  stored	  
on	  encrypted,	  password	  protected	  computer	  systems.	  The	  sounds	  of	  your	  breathing	  tests	  will	  
be	  analysed	  by	  engineers	  in	  Trinity	  College	  Dublin,	  although	  they	  will	  not	  know	  your	  name	  or	  
identity.	  	  The	  blood	  samples	  will	  not	  be	  kept	  after	  they	  have	  been	  analysed.	  
All	  your	  results	  and	  your	  personal	  information	  from	  the	  study	  will	  be	  stored	  for	  a	  period	  not	  
exceeding	  ten	  years	  after	  which	  they	  will	  be	  destroyed	  as	  per	  hospital	  protocol,	  i.e.	  shredding	  
and	  deletion.	  
All	  data	  we	  collect	  through	  this	  research	  study	  will	  be	  ‘coded’.	  This	  means	  that	  only	  members	  of	  
Professor	  Costello’s	  research	  team	  will	  be	  aware	  of	  the	  code	  and	  therefore	  your	  identity	  when	  
looking	  at	  the	  data.	  	  
The	  results	  obtained	  from	  this	  study	  will	  be	  published	  in	  a	  scientific	  journal,	  no	  patient	  
information	  will	  be	  published. 
Where	  can	  I	  get	  further	  information?	  
If	  you	  have	  any	  further	  questions	  about	  the	  study	  or	  if	  you	  want	  to	  opt	  out	  of	  the	  study,	  you	  
can	  rest	  assured	  it	  won't	  affect	  the	  quality	  of	  treatment	  you	  get	  in	  the	  future.  	  
If	  you	  need	  any	  further	  information	  now	  or	  at	  any	  time	  in	  the	  future,	  please	  contact:	  	  
Name:	  	  	  	  	  	  	  	  Prof.	  Richard	  W.	  Costello	  
Address:	  	  	  	  Department	  of	  Medicine,	  Education	  &	  Research	  Centre,	  
Consent and Patient Information 
Version	  3	  Salbutamol	   Date	  16/12/2013	   Page	  4	  
Beaumont	  Hospital,	  Dublin	  9	  	  
Phone	  No:	  	  (353)	  01-­‐8093762	  (office	  hours	  only)	  
Beaumont Hospital 
Ethics (Medical Research) Committee 
Chairperson:  Professor Gerry McElvaney Administrator:  Gillian Vale 
Convenor:   Professor Alice Stanton 
21st
REC reference:  13/ 36 
 June 2013 
Prof. Richard Costello 
Consultant Physician 
Department of Medicine 
Smurfit Building 
Dear Prof. Costello 
RE: 13/36 – Prof. R. Costello – Monitoring Lung Function through Sound Analysis 
Please find enclosed ethics approval documentation for the above study, and both Parts thereof – 
Part 1A – which records breathing sounds of patients undergoing breathing tests; and Part 1B – 
which records breathing sounds of patients undergoing a Histamine Challenge. 
Please ensure that the Patient Information Leaflet for Part 1B is footnoted V2, 4 June 2013 prior to 
recruitment. 
With best regards 
Yours sincerely 
Ms. Gillian Vale 
Administrator 
Ethics (Medical Research) Committee 
c.c.
Dr. Jansen Seheult 
c/o Prof. Richard Costello 
Department of Medicine 
Smurfit Building 
_____________________________________________________________________________________________ 
Ethics (Medical Research) Committee      Beaumont Hospital   Dublin 9 
Tel: 353-1-809 2680       Email:  gvale@rcsi.ie    www.beaumontethics.ie 
Ethics (Medical Research) Committee - Beaumont Hospital 
Notification of ERC/IRB Approval 
Principal Investigator:  Prof. R. Costello 
REC reference:  13/36 
Protocol Title:  Monitoring Lung Function through Sound Analysis 
Part 1A = Recording breath sounds during breathing tests 
Part 1B = Recording breath sounds during a histamine challenge test 
Ethics Committee Meeting Date: 12th April 2013 
Final Approval Date:  21st June 2013 
From: Ethics (Medical Research) Committee - Beaumont Hospital, Beaumont, Dublin 9 
Documents Reviewed 
Document and Date Date Reviewed Approved 
Application, 
V2, 25/5/13 21/6/13 Yes 
Patient Information Leaflet, 
(Part 1A) 
V2, 4/6/13 21/6/13 Yes 
Patient Information Leaflet, 
(Part 1 B) 
V2, 4/6/13 21/6/13 Yes 
Patient Consent Form 
 (Part 1A & 1B) 
V1, 1/3/13 21/6/13 Yes 
CV:  R. Costello On File On File 
Cert of Insurance, RCSI On File On File 
____________________________________________ 
Prof. Alice Stanton 
ERC/IRB Convenor’s Signature 
Approval # 1, dated 21st June 2013 
Terms of Approval 
• The protocol and research must comply with all relevant Irish legislative requirements
and the researchers must abide by the ethical principles outlined in the Declaration of
Helsinki and Good Clinical Practice.
• Prior approval from the Ethics Committee must be sought for any proposed
changes/amendments to this protocol and research.
• Annual Progress Reports and a Final report must be supplied to the Ethics Committee.
FIRST REPORT DUE:  JUNE 2014 
FINAL REPORT DUE:  JUNE 2015 
• All relevant information about serious adverse reactions and new events likely to affect
the safety of the subjects must be reported to the Ethics (Medical Research) Committee
in writing.
.,-. 
81h May 2012 
Prof Richard Costello 
Dept of Medicine 
RCSI Smurfit building 
Beaumont Hospital 
Dublin 9 
Dear Prof Costello, 
Inhaler Adherence In real life General Practice
�",.. ... , .... - -- ,� . , ·' .. . .... :J ..... --· ._!._.,._ ._'_ . ' 
9P� 
The Irish College of 
General Practitioners 
Colaiste Dhochtuiri 
Teaghlaigh Eireann 
I wish to confirm that on review of your amendments I am now happy to approve your study. 
Yours sincerely, 
5 Lincoln Place, Dublin 2 
Tel: (01) 676 3705/06 Fax: (01) 676 5850 
e-mail: info@icgp.ie www.icgp.ie 
llegd. in Ireland at the Irish College of General Practitioners Limited 
Registration Number 100456 
ICieran Ryan 
Chief Executive OHicer 
1 '
I 
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APPENDIX 2: Journal publications. 
See RCSI Institutional Repository
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